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ABSTRACT 
SO2 is widely recognized as an air pollutant and is a known cause of acid rain.  At a 
sufficiently high level, it also causes respiratory diseases. There is mounting evidence that SO2 is 
produced during normal cellular metabolism and may possibly function as a signaling molecule 
in normal physiology. One difficulty in studying the biological and pharmacological roles of SO2 
is the lack of adequate tools for its controllable and precise delivery. Traditional methods of 
using SO2 gas or mixed sulfite salts do not meet research need for several reasons. Therefore, 
there has been increasing attention on the need of developing SO2 donors or prodrugs that can be 
used as tools for the elucidation of SO2’s physiological roles, pharmacological effects, and 
possible mechanism(s) of action. In the first chapter, we provided two strategies to deliver SO2 in 
its molecule form to allow SO2 release with tunable release rate. Such SO2 donors and prodrugs 
would serve as useful tools for researchers to probe the mystery of SO2 as a gasotransmitter.  
A decreased level of thiamine-dependent enzyme pyruvate dehydrogenase (PDH) is an 
important characteristic of cancer cells. Pyruvate dehydrogenase kinase (PDK) inhibits the 
activity of PDH which helps cancer cells to gain more energy by converting glucose into lactate. 
Therefore, inhibiting the activity of PDK can be a promising approach for cancer therapy. 
Thiamine at a high concentration was found to have inhibitory effect on cancer cell proliferation 
as a PDK inhibitor. From previous studies, a series of thiamine analogues were designed, 
synthesized, and tested in vitro for anti-proliferative effect. However, all the analogues 
demonstrate low inhibitory effect on cancer cell proliferation. We hypothesize that the low 
inhibitory activity may be due to a lack of phosphorylation inside the cell. A phosphate prodrug 
strategy that can release thiamine monophosphate mimetics inside the cell may overcome this 
problem. In the second chapter, we describe the design, synthesis, and preliminary biological 
evaluation of several prodrugs of thiamine monophosphate mimics. Cancer cell proliferation 
tests suggest significantly increased inhibitory effect of the phosphate prodrugs compared with 
respective thiamine analogues without the phosphate prodrug moiety.  
 
INDEX WORDS: Gasotransmitter, Sulfur dioxide, Prodrugs, PDK inhibitors, Thiamine 
analogues, Phosphate prodrugs.  
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1 DESIGN AND DEVELOPMENT OF SO2 PRODRUGS 
1.1 Introduction 
SO2 has long been recognized as an air pollutant produced by fossil fuel consumption and 
volcano eruptions. Upon oxidation and/or hydration, SO2 can serve as a precursor of acid species 
such as H2SO3 and H2SO4, which cause acidification of rain water, and thus acid pollution. In 
terms of toxicology, overexposure to SO2 may induce respiratory tract irritation and damage to 
many organs.1-4 Besides forming acid which causes mucous irritation, the mechanism of SO2’s 
toxicity is generally thought to involve the oxidation process of its derivatives.5 For example, it 
has been demonstrated that the DNA damage effect of SO2 can be induced by SO3˙
- and SO4˙
- 
radicals produced by autoxidation of sulfite (SO3
2-).6-7 However, as a matter of fact, SO2 and its 
derivatives have a long history of being applied in food industry as preservatives. Moreover, 
endogenous SO2 can be produced enzymatically through the metabolism of sulfur-containing 
amino acids or non-enzymatically through oxidation of H2S in neutrophils under oxidative 
stress.5, 8 A recent review by Huang et al. considered SO2 as the fourth gasotransmitter after 
nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H2S).
9 By the same token, it is 
hard to imagine that O2 and CO2 do not have regulatory roles and should not be considered as 
gasotransmitters as well. Indeed, sensing for O2 and CO2 are essential for their regulatory roles 
and have been extensively studied.10-12 Therefore, one may consider the gasotransmitter family 
having at least 6 members. 
In recent years, accumulating evidence demonstrates that SO2 possesses many 
bioactivities, especially in the cardiovascular system.13-14 Besides the biological effect SO2 
demonstrated under physiological concentration, it has been shown that abnormal levels of SO2 
are related to many pathological conditions such as hypertension and pulmonary hypertension.9 
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Its regulatory effects in the cardiovascular system may have therapeutic potential and thus 
require more detailed studies for its mechanism of activity.15 
1.1.1 SO2 chemistry 
Much of the recent rise in interest for SO2 originates from its possible roles as an 
endogenous signaling molecule. As a gaseous molecule, SO2 has a Henry’s constant of 1.23 mol 
kg-1 bar-1.16 It can readily dissolve in water and form hydrated SO2 complex (SO2H2O), which in 
turn undergoes first and second dissociation to give bisulfite (HOSO2
- or HSO3
-) and sulfite 
(SO3
2-) ions.17-19 The first and second pKas of SO2H2O are 1.81 and 6.97. Accordingly, it can be 
calculated that under physiological pH, the bisulfite and sulfite are formed in a molar ratio of 
about 1: 3. Dimerization of bisulfite would form disulfite (S2O5
-). The interconversion of these 
species is summarized in Figure 1-1. Due to the abundance of water in biological system, all the 
species exist in an equilibrium. Therefore, it will be hard to isolate one species out and study its 
sole effect; and it is important to study SO2 and its derivatives as a whole. Besides hydration, 
another important aspect of SO2 chemistry is its redox chemistry, which is much more complex 
in a biological setting. SO2 and its derivatives are interconnected with many other sulfur species 
through enzymatic or non-enzymatic processes. Generally speaking, SO2 is produced as an 
intermediate of metabolism of sulfur-containing compounds and can be oxidized further to 
generate other sulfur species. For example, SO2 can be produced from L-cysteine through 
sequential catalysis of cysteine dioxygenase and aspartate aminotransferase (AAT); oxidation of 
sulfite through sulfite oxidase can produce sulfate; H2S can be generated from L-cysteine by 
cystathionine β-synthase, and further oxidation by NADPH oxidase would generate SO2; under 
ambient conditions, more reactive species such as SO3˙
- and SO4˙
-can be produced through 
autoxidation of sulfite.7, 9, 20  
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Figure 1-1 Interconversion of SO2 derivatives 
 
Taken together the chemistry of SO2 and current reports about SO2’s biological activity, 
one may see some contradictory results. On one hand, SO2 and its derivatives seems to be toxic 
intermediates produced in sulfur metabolism. The high oxidation state of endogenous SO2 
produced by oxidation of sulfur species at lower oxidation states (e.g. cysteine, H2S) can pose 
oxidative stress on cells and tissue, causing oxidative damage.4 Moreover, deficiency of sulfite 
oxidase, which catalyzes the oxidation of sulfite to sulfate as the last oxidative step of sulfur 
metabolism, is known to result in fatal neurological symptoms.21-22 On the other hand, the 
potential for further oxidation allows SO2 and its derivatives to function as an antioxidant. 
Indeed, SO2 plays a protective role against oxidative stress under certain circumstances.
23-26 For 
example, Chen et al. have demonstrated that endogenous SO2 offers protection against oleic 
acid-induced acute lung injury by suppressing oxidative stress.26 Also, SO2 preconditioning was 
shown to be effective in preventing ischemia-reperfusion injury in cardiovascular system.23 It is 
nonetheless clear that the chemical reaction to go from SO2 to SO3 is only a 2-electron process. 
Thus, the scavenging capacity of SO2 is far lower than that of H2S, which can give 6 electrons to 
go to the oxidation state of SO2 and 8 electrons to that of SO3.  The dual role of SO2 and its 
“inefficiency” as antioxidant makes us wonder what would be the reason for SO2 to be used as 
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an antioxidant by nature. Does SO2 perform its “antioxidant” role through direct 
reduction/scavenging of an oxidizing species or through regulatory functions that make cells 
more resilient under an oxidizing environment? The interconversion rates among sulfur species 
are also very important in considering the meaning of using SO2 as signaling molecule. 
Enzymatic processes not only provide more precise control of substrate concentration compared 
with non-enzymatic process, but also offer potential targets for regulation. In addition, bisulfite 
and sulfite are strong nucleophiles and such properties may contribute to their biological 
activities. For all these reasons and more, it is very important to understand the chemistry issues 
when studying its biology and developing its donors and prodrugs. However, such relationships 
are very convoluted that makes deciphering the precise role of SO2 very hard, given that the 
enzymes and reaction kinetics involved are not so clear.  
For a signal molecule to function, the existence of relevant biological target(s) is a critical 
question. For small organic molecules, proteins, peptides, lipids and others, binding to a 
macromolecular target is often the mechanism of action. The issue is nevertheless more 
challenging for gasotransmitters. There are well-established mechanism(s) of action at the 
molecular level for NO, H2S
27 and CO.28 Specifically, NO can bind to a heme moiety at the distal 
site of soluble form of guanylyl cyclase, and thus activates guanylyl cyclase, leading to elevated 
levels of cGMP.29 Hydrogen sulfide in its persulfide form is known to be responsible for protein 
persulfidation, which is a well-established regulatory process.30 For CO, there is also strong 
evidence that binding to heme and other metal-containing biomolecules is a critical first step.28, 31 
For example, CO can bind a soluble form of guanylyl cyclase much the same way as NO, except 
with decreased ability to activate the cyclase. CO is also reported to inhibit cytochrome C 
oxidase leading to increased production of ROS, which in turn leads to the production of the 
5 
persulfide form of glutathione (GSSG).32-34 GSSG is known to facilitate protein 
glutathionylation, a known form of protein post-translational modification, and plays a 
regulatory role. With SO2, molecular level studies have been scarce, though various regulation 
effects of SO2 and its derivatives on other biological molecules have been observed, especially in 
the cardiovascular system.9 However, the binding targets of SO2 or its derivatives are not yet 
clear. It is not hard to envision that the equilibrium between SO2 and other sulfur species would 
play an important role in maintaining the intracellular redox balance. Therefore, enzymes 
involved in generating related species may serve as potential binding targets. Moreover, the 
varied concentration of SO2 in different tissue hints that SO2 may have tissue-specific target.
35 
Furthermore, as a strong nucleophile and Lewis base, bisulfite’s interaction with certain metal-
containing proteins (e.g. sulfite oxidase) and reaction with electrophiles could play a role in 
regulating the biological functions of these molecules.36 With such knowledge, SO2 donors and 
prodrugs with desirable properties will help us understand the molecular mechanism of SO2’s 
action. 
1.1.2 Endogenous production and physiological effects of SO2.  
SO2 can be produced endogenously through several pathways (Figure 1-2). In the 
aspartate aminotransferase (AAT) pathway, L-cysteine is first oxidized to L-cysteine sulfinate by 
cysteine dioxygenase (CDO). AAT then catalyzes the transamination between L-cysteine 
sulfinate and α-ketoglutarate to form β-sulfinylpyruvate. The spontaneous decomposition of the 
latter would yield SO2 and pyruvate. 
37 SO2 can also be produced from the oxidation of H2S, 
another metabolite of sulfur-containing amino acids. The oxidation could be directly through 
NADPH oxidase in activated neutrophils, or through oxidation by sulfide oxidase followed by 
thiosulfate sulfurtransferase or glutathione-dependent thiosulfate reductase. 38-40 Zhang et al. 
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have shown that the endogenous production of SO2 is closely related to endogenous H2S. 
Endogenous H2S can inhibit endothelial SO2 production through suppressing AAT activity, 
while impaired H2S production pathway would lead to upregulation of SO2 production. 
41 The 
excretion of SO2 is through hydration and oxidation by sulfite oxidase to sulfate followed by 
renal clearance to urine. 42 
The most profound effect of SO2 under physiological conditions was found in the 
cardiovascular system. Du et al. tested various vascular tissues and found the highest SO2 content 
in the aorta.35 Using a mixture of bisulfite/sulfite salt as an SO2 source, a slight relaxation effect 
was observed on isolated rat aortic rings while a concentration-dependent relaxation was 
observed with higher dosages. The same effect was also observed using SO2 gas and SO2 gas 
solution as later demonstrated by Meng et al.43-44 Such result indicates the role SO2 plays in 
maintaining normal vascular tone and blood pressure. SO2 was also found to have a negative 
inotropic effect as observed on isolated perfused rat heart, which in turn affects the heart rate and 
left ventricular developed pressure.45   Besides in the cardiovascular system, SO2 was also found 
to be involved in lipid metabolism, possibly due to its oxidant effect.46-47 More interestingly, 
aligned with the well-known antimicrobial activity of SO2 and its derivatives, Nojima and 
colleagues have demonstrated that sulfite is a neutrophil mediator of host defense that in vivo 
administration of lipopolysaccharide (LPS) would trigger sulfite release from neutrophil and 
increase serum sulfite concentration in rats.48  
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Figure 1-2 Endogenous production of SO2. 
* Process catalyzed by thiosulfate sulfurtransferase or glutathione-dependent thiosulfate 
reductase. 
 
1.1.3 Pathophysiological effect of SO2 
Many research papers and excellent reviews have been published in recent years 
addressing the pathophysiological effect of SO2. 
9, 14 Here we give a brief summary to provide a 
background for readers to understand the therapeutic potential and future application of SO2. 
 Compared with the SO2’s therapeutic potential, the toxicity of SO2 is more widely 
accepted by the public; and is likely to be attributed to SO2’s oxidative property. Meng has 
suggested that SO2 as an oxidative agent can cause lipid peroxidation and changes anti-oxidation 
status in multiple organs. 4 Chronic exposure to SO2 was also found to promote atherosclerosis.
49 
Controversially, in atherosclerosis rats, a decreased level of plasma and aortic SO2 content, as 
well as AAT activity, was reported by Li et al. 50 Further, treatment of SO2 derivatives could 
diminish the size of atherosclerotic plaques in rat coronary artery. Under certain physiological or 
pathological conditions, the regulation of endogenous SO2 level may vary, resulting from or 
contributing to the formation of the pathological condition.  
8 
The fluctuation of endogenous SO2 level has been observed in several animal disease 
models and human. An elevated level of serum sulfite content was found in patients with chronic 
renal failure and pneumonia. 51-52 Corresponding with afore mentioned LPS stimulated sulfite 
release stimulated by LPS, the serum level of SO2 was found to increase significantly in pediatric 
patients with acute lymphoblastic leukemia with bacteria-induced inflammation, which is likely a 
defensive mechanism indicating SO2’s anti-inflammatory role. 
53  
SO2’s pathophysiological roles have been widely studied in cardiovascular disease 
models. In spontaneous hypertensive rats (SHRs), a significantly lower level of SO2 and AAT 
activity was observed in serum and aorta. 54 In a study conducted on children with congenital 
heart disease (CHD), serum SO2 level showed a negative relationship with pulmonary 
hypertension. For example, in the CHD group with severe pulmonary hypertension, the SO2 
concentration was only half of that of the group without pulmonary hypertension. 55 Similarly, in 
rats under hypoxic conditions, a decreased SO2 level in plasma and lung tissue was observed 
simultaneously with pulmonary hypertension, pulmonary vascular structural remodeling, and 
increased vascular inflammatory response. 56 In rat model with monocrotaline-induced 
pulmonary vascular collagen remodeling, SO2 content and AAT activity were significantly 
increased. 57 Meanwhile, in rats with monocrotaline (MCT) induced pulmonary hypertension, 
higher SO2 level, AAT expression and activity were observed compared to the control group, 
indicating a protective role of endogenous SO2. 
58 Additionally, in rat myocardial ischemia-
reperfusion (I/R) models, AAT1 protein expression showed a significant decrease. 59 In 
isoproterenol induced myocardial injury rat model, the SO2/AAT pathway also showed a down 
regulation. 24 Subjecting such animal models to treatment or pretreatment with SO2 derivatives or 
SO2 gas led to alleviation of the pathology, indicating a strong therapeutic potential of SO2. 
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1.1.4 SO2 donors and prodrugs 
For biological assessment, SO2 gas and mixed sulfite salts (NaHSO3 and Na2SO3 in 1: 3 
molar ratio) have been most widely used as sources of SO2. SO2 gas was used for preparation of 
stock solution or administration to small animals by inhalation. The dosage can be controlled 
through partial pressure. In such applications, using gaseous SO2 requires special laboratory 
equipment and settings as well as prolonged exposure time at low concentration to avoid acute 
toxicity or irritation. Neither does it offer precise dosage control nor future prospect of human 
use. The second method of using mixed sulfite salts to generate SO2 depends on the complex 
kinetics of the dynamic equilibrium between gaseous SO2 and its hydrated derivatives (Figure 1-
1). Using such donors lacking controllable release rate cannot mimic endogenous production of 
SO2 and may lead to transient effect and overdosing. The quick renal clearance rate may also 
limit the efficiency of using mixed salt as SO2, especially when prolonged exposure at low 
dosage is required. Moreover, efficiency of SO2 delivery to cell or tissue can hardly be 
guaranteed and may result in irreproducible experiment results. According to Meng and co-
workers, gaseous SO2 may have much stronger vasorelaxant effect compared with mixed sulfite 
salts.43 Another way of donating SO2 is through overexpression of two isoenzymes of AAT.
60 
AAT is an upstream enzyme in the SO2 generation pathway, which can catalyze the 
transamination of L-cysteine sulfinate to form β-sulfinylpyruvate and generate SO2. Therefore, 
the activity of AAT may directly influence SO2 production.  Vascular smooth muscle cells 
(VSMCs) transfected with AAT1 or AAT2 plasmids showed suppressed serum-induced 
proliferation, while AAT1 or AAT2 knocked-down VSMCs showed exacerbated serum-induced 
proliferation. Such approaches could serve as a powerful research tools in cell-based assays. 
Nevertheless, the same kind of studies at the tissue, organ, or animal level would require much 
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more complicated work.61 The lack of reliable donors that can generate SO2 in a controllable 
manner has hampered the delineation of SO2’s precise biological and regulatory roles. To 
overcome these obstacles, SO2 donors and prodrugs with different triggering mechanisms have 
been developed in recent years. 
1.1.4.1 Thiol-activated SO2 prodrugs 
Chakrapani’s group pioneered in the work of developing SO2 prodrugs. They first 
developed a series of 2,4-dinitrophenylsulfonamide compounds as prodrugs that release SO2 
upon thiol triggering for antimycobacterial purpose (Scheme 1-1).62 2,4-
Dinitrophenylsulfonamide was previously employed in thiol-detection systems, which produces 
SO2 as a byproduct upon decomposition. In their design, mycothiol (MSH), which exists in 
Mycobacterium tuberculosis (Mtb) in millimolar concentrations, would serve as the thiol source 
to trigger the release. Depleting thiols and generating SO2 at the same time would disrupt cellular 
redox equilibrium and damage biomacromolecules, causing Mtb growth inhibition. A first batch 
of 17 compounds were synthesized with varied substitutions on both the amino group and the 
sulfonyl group through simple substitution reactions using the corresponding amines and 
sulfonyl chlorides. The compounds were incubated in pH 7.4 buffer with cysteine and tested of 
SO2 release by a p-rosaniline-based assay. Release rates were measured by ion chromatography 
(IC) with a conductivity detector. Antimycobacterial activity of the compounds against Mtb was 
quantified as minimum inhibitory concentrations (MICs, the minimum concentration required to 
inhibit 99% of bacterial growth). Eleven compounds containing the 2,4-dinitrophenylsulfone 
(DNS) moiety showed SO2 release within 30 min and demonstrated greater antimycobacterial 
activity than the non-releasing compounds, indicating a correlation between SO2 release and Mtb 
inhibition. The release mechanism was proposed to go through Jackson-Meisenheimer complex 
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intermediates to produce SO2, benzylamine, and 2,4-dinitrophenylthioether (Scheme 1-1). N-
Benzyl-2,4-dinitrophenylsulfonamide (1, Scheme 1-1) showed 100% SO2 release within 30 min 
(estimated half-life ~ 2 min) and was found to have the best Mtb inhibitory potency with a MIC 
of 0.15 μM, which is lower than the clinically used agent isoniazid (0.37 μM) tested under the 
same conditions. Moreover, compound 1 showed no cytotoxicity at such concentration towards 
human embryonic kidney 293 cells (HEK293) (IC50 = 7 μM). Further studies of the relationship 
between SO2 release rates and MICs on 6 compounds (t1/2 = 2~63 min) with similar clogP values 
found a good correlation between fast SO2 release rates and inhibitory potency.  
To better understand this relationship as well as the structure-activity relationship (SAR), 
the same group synthesized a total of 19 structural analogues of compound 1 with varied amino 
substitutions and comparable clogP values.63 The results showed only decreased SO2 release 
rates and MICs compared with compound 1, regardless of modifications made. Seven 
compounds with potent MICs (highest MIC = 2.13 μM) were found better than clinically used 
drugs ethambutol and pyrazinamide tested under the same conditions. According to Spearman 
rank correlation analysis, a correlation between MIC and SO2 yield after 5 min was established 
that higher SO2 yield is related to lower MIC.  
This strategy was further tested on methicillin sensitive Staphylococcus aureus (MSSA, 
Gram+), methicillin-resistant Staphylococcus aureus (MRSA, Gram+), Enterococcus faecalis (E. 
faecalis, Gram+), and Escherichia coli (E. coli, Gram-).64 A library of 38 2,4-
dinitrophenylsulfonamides (including compound 1) were synthesized, among which 12 
compounds were in “dimerized” forms. All compounds were shown to be able to release SO2 
under physiological conditions with different rates. Compound 2 (Scheme 1-1) showed good 
MICs of 4 μg/mL (~10 μM) against both strains of S. aureus and 8 μg/mL MIC against E. 
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faecalis. However, no compound was found to be effective against E. coli, possibly due to the 
permeation barrier presented by the outer membrane of Gram-negative bacteria in general. The 
inhibitory mechanism remains to be determined since evidence suggests that the SO2 generating 
ability of these compounds is not the sole reason responsible for the inhibitory effect. The 
capability of the compounds to permeate cells and deplete thiols may as well affect the inhibitory 
effect, since thiols in presence of oxidative stress can be primarily oxidized to disulfide species. 
Indeed, compound 2 showed much better capacity depleting intracellular thiols compared with 
compounds with poor inhibitory activity. Furthermore, compound 2 was also capable of 
inhibiting several patient-derived MRSA strains with MIC values of 2~4 μg/mL. Cytotoxicity 
was also assessed against A549 lung carcinoma cells. A GI50 of 27 μM and a selectivity index 
(GI50/MIC) of 5.2 were determined.  
Besides antibacterial applications, compound 1 has been extensively used as an 
intracellular SO2 source in validation of utility of many SO2 probes in biological settings.
65-69 
Depletion of thiol with thiol scavenger (N-ethylmaleimide, NEM) would easily disable SO2 
release from the prodrug, offering a good method for conducting control experiments. 
 
Scheme 1-1 Thiol-activated SO2 prodrugs. 
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1.1.4.2 Thermally activated SO2 prodrugs 
Another class of SO2 prodrugs developed by Chakrapani’s groups uses the benzosultine 
scaffold (Scheme 1-2).70 By design, such prodrugs would release SO2 through a thermal retro-
Diels-Alder reaction. The substitutions on the 1-position would allow reactivity tuning and thus 
cycloreversion at physiological temperature. As such, benzosultine and 1-substituted (Me, Ph) 
benzosultines were subjected to ab initio calculations. Reaction energies (ΔErxn), Gibbs free 
energies (ΔGrxn), and Gibbs free-energy barriers (ΔG
‡) of different conformations of the 
benzosultines and sulfones to produce dienes and SO2 were calculated to predict the stable 
conformations and favorable reaction paths (Scheme 1-2). Results showed that, compared with 
benzosultine, 1-substituted benzosultines have lower Gibbs energy barriers (ΔG‡) and would be 
expected to have enhanced cycloreversion rates. Besides, phenyl substitution (6) would further 
reduce cycloreversion barrier than methyl substitution, leading to faster reactions at the same 
temperature. All three compounds were synthesized and tested under varied thermal conditions. 
Compound 6 was shown to be an active SO2 donor at physiological pH and 37 °C with a release 
rate constant k of 0.0140 min-1, while the other two compounds were found to be unreactive 
under similar conditions. Moreover, calculations predicted conversion of 1-phenyl-benzosultine 
(3) to form 1-phenyl-benzosulfone (5) as a more stable form (Scheme 2). This prediction was 
confirmed by experiments. When compound 6 was incubated in MeCN solution at 37 °C, it was 
fully converted to 1-phenyl-benzosulfone (7), presumably through a retro-Diels-Alder reaction 
followed by in situ cheletropic addition of SO2. Based on this result, the authors further 
developed UV-light sensitive SO2 donors based on the sulfone structure, which is discussed in 
the next section. The utility of compound 6 as a SO2 prodrug was demonstrated using a DNA 
cleavage assay. Compound 6 showed the same potency as mixed sulfite salts in cleaving plasmid 
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DNA. 1-Aryl-benzosultines with varied substitution groups were prepared to further explore the 
tunability of the reaction rate. These compounds showed release half-lives ranging from 10 to 68 
min at pH 7.4 in 30–40% MeCN/PBS mixture at 37 °C. According to Hammett plot of rate 
constants, the substitution groups were found to have a weak electronic effect on the reaction rate 
that electron-donating group would accelerate the reaction. However, none of these compounds 
showed complete release of SO2, with maximal SO2 yield ranging from 59% to 89%. This 
incomplete conversion was thought to be caused by decomposition of sultine through 
uncharacterized process(es). 
 
Scheme 1-2 Thermally activated retro-Diels-Alder reaction-based SO2 prodrugs. 
 
1.1.4.3 Photochemically activated SO2 prodrugs  
1-Phenyl-benzosulfone (7) was found to be a more stable form of 1-phenyl-benzosultine 
(6).70 To develop UV light-triggered SO2 prodrugs, Chakrapani’s group further exploited the 
stability of benzosulfones.71 Three classes of benzosulfone were designed with varied 
substitution groups on the 1-position and the aryl ring (8, Scheme 1-3). A total of 17 compounds 
were synthesized and subjected to UV irritation in pH 7.4 buffered solution (30–40% MeCN or 
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EtOH in PBS). All tested compounds successfully released SO2 within 10 min with yields 
ranging from 12% to 90%. Fifteen compounds gave yields of more than 93% after 60 min. 
Structure-activity analysis showed that electron-donating groups on the aryl ring and 
substitutions on 1-position both have promoting effect on SO2 release, possibly through 
stabilizing the radical intermediates. No biological applications of these prodrugs have been 
reported so far.  
Sumaru and Uchida’s group later reported another UV light triggered SO2 donor based on 
an dithienylethene structure and demonstrated its application in inducing cell death “on demand” 
(Scheme 1-3).72 Close-ring compound 9c was found to be stable upon heating up to 70 °C. While 
upon visible light (λ > 480 nm) or UV light (300 nm < λ < 365 nm) irradiation, 9c undergoes 
cycloreversion reaction to form open-ring isomer 9o. Further irradiation by UV light (300 nm < λ 
< 365 nm) of 9o would lead to both SO2 gas formation and cyclization reaction to form 9c. 
Therefore, SO2 gas can be stored in the form of 9c as a thermally stable reagent and be released 
upon UV irradiation. Compounds 9c and 9o were then coated on substrates as thin layers and 
tested for cell death-inducing effect. NIH/3T3 and MDCK cells were disseminated on the thin 
layers and light at 365 or 436 nm was used in a striped pattern. It was found that 365 nm light 
would induce cell damage and detachment from the thin layers of both 9c and 9o in the patterned 
area, demonstrating an on-demand feature of killing cells.  
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Scheme 1-3 UV-triggered SO2 prodrugs.  
* Byproducts not fully characterized in original literature 
 
1.1.4.4 Hydrolysis-based SO2 prodrugs 
Xian’s group later reported sodium benzothiazole sulfinate (13, BTS, Scheme 1-4) as a 
water-soluble prodrug features slow-release of SO2.
73 The inspiration came from their previous 
finding that methyl sulfonyl benzothiazole (10, MSBT) selectively blocks protein thiols through 
electrophilic substitution on the C2 position of benzothiazole (14, BT), and produce methyl 
sulfinic acid (12) as a byproduct (Scheme 1-4).74 Therefore, replacing the methyl sulfone group 
with a sulfonate group would allow BTS to undergo self-elimination and to release SO2 and 
benzothiazole upon hydrolysis. This idea was well supported by experimental results. BTS was 
obtained as crystalline solid through basic hydrolysis of benzothiazole methyl sulfinic ester. As a 
salt, it has solubility as high as 100 mM in water. Production of SO2 through decomposition of 
BTS and formation of BT was monitored by HPLC. The release of SO2 was shown to be second-
order that the rate depends on both pH (proton concentration) and concentration of BTS itself. At 
pH 7.4 and 37 °C, 0.4 mM BTS would slowly release SO2 with a half-life of about 13 days.  
Lower pH would promote SO2 release that at pH 4, the same concentration of BTS has a half-life 
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of only 7.5 min. SO2 release was further confirmed using a reported ratiometric fluorescent probe 
(Mito-Ratio-SO2).
75 This prodrug was then applied in a vasorelaxation experiment using rat aorta 
rings. 250 μM to 4 mM of BTS was applied to aorta rings and demonstrated dose-dependent 
relaxation effect. When compared with SO2 gas, the same concentration of BTS (2 mM) showed 
weaker but longer-lasting vasorelaxant effect, while SO2 gas has a stronger but shorter effect. 
Such results are consistent with the slow releasing property of BTS compared with SO2 gas.  
 
Scheme 1-4 Hydrolysis-based SO2 prodrug. 
 
1.1.5 Expected Results  
Despite the remarkable progress in making SO2 donors and the associated beautiful 
chemistry, there are still unresolved issues including the reliance on other sulfur species for SO2 
release, the need for two components in the bimolecular reaction-based prodrugs, and the 
delicate and sometimes difficult balance between stability and rapid release of SO2 from 
unimolecular systems without the use of a trigger. Our group has a long-standing interest in 
studying gasotransmitters.76-81 Herein we aim to provide strategies that allows the release of SO2 
in a controllable fashion.  
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1.2 Click reaction-based SO2 prodrugs 
Previously, we have demonstrated the feasibility of using an extrusion reaction as a way to 
deliver carbon monoxide.77 Herein we describe a strategy to cage SO2 in thiophene dioxide and 
use a strained alkyne to trigger the release of SO2 in a controllable fashion (Scheme 1-5). By 
varying the substituents on the thiophene dioxide scaffold, the release rates can also be tuned.  
1.2.1 Results and discussion 
As early as 1976, Stille already examined the reaction of thiophene dioxide and a terminal 
alkyne under reflux condition in toluene. Though conditions were “harsh”, the cheletropic 
reaction yielded a cyclized product with the release of SO2.
82 We planned to take advantage of 
this reaction to construct caged SO2 for release under near physiological conditions (room 
temperature to 37 C, pH 7.4, and aqueous solution). A key issue in this project was how to 
lower the reaction temperature to ambient temperature for applications under near physiological 
conditions. 2,3,4,5-Tetrachlorothiophene dioxide has been shown to possess high reactivity in 
cycloaddition reactions with a variety of olefines. Specifically, it was shown to react steadily 
with ethylene and to give a cyclohexyldiene product and SO2 at 28 
oC.83 We reasoned that a 
strained alkyne with increased HOMO energy would promote this cycloaddition reaction. The 
formation of a stable phenyl ring should also help to drive the subsequent cheletropic reaction 
with the concomitant release of SO2. Therefore, we synthesized 2,3,4,5-tetrachlorothiophene 
dioxide 3 from commercially available perchlorothiophene 2. Then we first examined the 
reaction of 3 (20 mM in MeOH) with endo-BCN (1, 4 equiv.) at room temperature as a proof-of-
concept test. Indeed, after 5 min, we saw complete conversion of 3 into a new product, which 
was spectroscopically characterized as 4 (Scheme 1-5). 
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Scheme 1-5 Proof-of-concept test of SO2 donor system 
 
We then examined the reaction kinetics. The UV absorption of the product is significantly 
lower than that of the reactants at 328 nm. Therefore, we used UV absorbance decrease to 
monitor the reaction progress.  The second order rate constant was determined by first using a 
large excess of 1 to examine the pseudo-first order reaction followed by plotting the pseudo-first 
order reaction rate constants against different 1 concentration. The second order rate constant 
was determined to be 1.50 M-1 s-1 in MeOH at room temperature, allowing the reaction to be 
finished in about 3 hours at mid-μM levels (Figure 1-8). 
To further confirm the formation of SO2, we performed the DTNB test, which has been 
applied in SO2 measurement in atmosphere and food samples.
84-86 DTNB would react with SO3
2- 
ion to give an reduced product, which can be quantitatively measured by UV absorbance at 412 
nm (Figure 1-3).84 To allow hydration of SO2, we performed this test in 5% DMSO/PBS. A 
reaction mixture was incubated at room temperature or 37 oC for 45 min (about 1 t1/2) and then 
the DTNB probe was added. Afterwards, the test solution was incubated at room temperature for 
another 15 min and subjected to UV absorbance reading at 412 nm. The experimental group 
showed higher absorbance at both room temperature and 37 oC than the negative control groups, 
confirming the formation of SO3
2-. Both experimental groups and positive control groups showed 
lower SO3
2- formation at 37 oC than at room temperature, presumably due to increased SO2 
escape at higher temperature (Figure 1-4).  
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Figure 1-3 DTNB test mechanism 
 
 
Figure 1-4 UV absorption at 412 nm of DTNB test 
After 45 min incubation at room temperature or 37 oC (a) blank (5% DMSO/PBS), (b) 
250 μM of 3 only, (c) 2.5 mM of 1 only, (d) 250 μM of 4 only, (e) 250 μM of 3 +2.5 mM of 1, (f) 
50 μM of Na2SO3, (g) 50 μM of NaHSO3. 
 
Encouraged by the initial success, we went on to synthesize additional analogues to see 
whether we can tune the reaction rates for various applications. Thus, we synthesized compounds 
5 and 6 with electron withdrawing groups at different positions (Figure 1-5). We reasoned that 
by varying the electron density on the thiophene ring, different LUMO energy will result in 
varied reaction rate with BCN. We also tested reaction with a trans-cyclooctene compound (8, 
equatorial isomer), which is known to have high strain energy and high HOMO, to see if the 
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reaction rate can be further enhanced. In all these reactions at room temperature, we successfully 
isolated the cheletropic reaction products. Interestingly, we had initial difficulties in analysing 
the room temperature NMR spectra of the products containing the bicyclo(6.1.0)non-4-ene 
structure. This was due to line broadening caused peak overlap in 1H NMR. Structure elucidation 
by 13C NMR is equally difficult because of missing peak(s) at high field. Given HRMS 
confirmation, we reasoned that this phenomenon is caused by the slow flipping of eight-member 
ring between the “chair” and “boat” conformations. We successfully observed two 
conformations by tracking the -CH2 group next to the -OH group at low temperature (270 K). As 
temperature increases, the exchange rate of the two populations increases, and the two peaks 
observed for the –CH2 group coalesced and then averaged to give a sharp peak. Unfortunately, 
within the temperature range tested, the exchange rate is not fast enough to average the –CH2 and 
–CH groups from the bicyclo(6.1.0)non-4-ene structure, which become broad above 278 K and 
hard to track (Figure 1-7). However, this phenomenon has been observed exclusively with endo-
product. As for product obtained from reaction between 6 and exo-BCN, sharp peaks at high 
field were observed at room temperature. By contrast, with chlorine substitutions, we are able to 
track the carbons at room temperature because of their fast flipping rate. Edited HSQC 
experiment gave clear evidence of geminal protons splitting from the eight-membered ring, 
confirming the structures of cheletropic products. We studied the reaction kinetics for these 
reactions and obtained k2 values ranging from 0.02 to 0.33 M
-1s-1 (Table 1; Figure 1-8). 
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Figure 1-5 SO2 donor pairs 
 
 
Figure 1-6 Fluorescent SO2 donor and product after SO2 release (100 μM in MeOH) 
 
–CH2OH                                   –CH2 and –CH groups 
                                    from the  bicyclo(6.1.0)non-4-ene structure 
                               
Figure 1-7 Coalescence of cheletropic product (6 + 1) observed in 13C NMR (DEPT-135) with 
increasing temperature 
270 K 
278 K 
288 K 
298 K 
308 K 
318 K 
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Currently, several elegant fluorescent probes for SO2 have been developed based on the 
nucleophilicity of SO3
2-/HSO3
-. However, few of them are suitable for real-time monitoring of 
SO2 generation due to delayed response.
87 One alternative strategy for real time monitoring of 
SO2 release is to devise such SO2 prodrugs that would become fluorescent after SO2 release. 
Therefore, we were interested in designing SO2 prodrugs that would lead to the formation of a 
fluorescent reporter, which allows for real-time monitoring of SO2 release. We reasoned that 
attaching an aromatic substituent to the thiophene ring would allow formation of an expanded 
conjugation system after the cheletropic reaction and thus result in pronounced changes in the 
spectroscopic behavior of the aromatic system after the reaction. Therefore, we synthesized 
thiophene dioxide with naphthalene conjugated at the 3,4 positions (7, Figure 1-5). The 
compound itself has weak yellow fluorescence with an excitation wavelength of 299 nm, 
emission wavelength of 556 nm, and a quantum yield of 0.006. After reaction with BCN and SO2 
release, the resulting product shows strong cyan fluorescence with an emission wavelength of 
470 nm, excitation wavelength of 296 nm, and quantum yield of 0.138 (Figure 1-6). We also 
established the kinetics profile of this reaction by monitoring the fluorescence increase at 470 
nm. A k2 of 0.01 M
-1s-1 was obtained (Table 1-1; Figure 1-6; Figure 1-9). 
Table 1-1 Kinetics study of SO2 donor pairs 
SO2 donor pairs 3 + 1 3 + 8 5 + 1 6 + 1 7 + 1 6 +exo-BCN 
k2 (M-1s-1) 1.50a 0.02a 0.33b 0.05a 0.01c 0.04a 
Note: a. Measured in MeOH under room temperature. b. Measured in ACN under room 
temperature. c. Measured in DMSO/PBS 4:1 at 37 ℃. 
 
In summary, we have developed a SO2 donor system, which releases SO2 through a 
Diels-Alder reaction with a strained alkyne/alkene as a trigger. We explored the initial tunability 
of the releasing rate by varying the electron density of thiophene dioxide ring. With a small set of 
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compounds, we were able to tune the reaction rate in the range of 0.01-1.50 M-1s-1, giving a 150-
fold variation in reactivity. This work has been published in Chem. Commun., 2017, 53, 1370–
1373.  
1.2.2 Experimental procedures 
1.2.2.1 Materials and Methods 
All reagents and chemicals were purchased from commercial suppliers as reagent grade 
or higher, and were used without further purification unless otherwise noted. NMR spectra were 
recorded on a Bruker Avance NMR spectrometer at 400 MHz for 1H and 101 MHz for 13C at 
room temperature unless otherwise specified. Solvent peaks were served as internal standard. 
Mass spectral analyses were performed by the GSU Mass Spectrometry Facilities. UV-Vis 
absorption spectra were recorded on a Shimadzu PharmaSpec UV-1700 UV-Visible 
spectrophotometer. Fluorescence spectra were recorded on a Shimadzu RF- 5301PC fluorimeter. 
1.2.2.2 Synthesis of thiophene dioxides 
General method for the oxidation of thiophenes: 
Thiophene S-dioxides were synthesized following a literature procedure using 
peroxytrifluoroacetic acid as the oxidant.88 
 
Tetrachlorothiophene-1,1-dioxide (3)  
Tetrachlorothiophene-1,1-dioxide was synthesized following the general procedure of 
thiophene oxidation. Off-white solid was obtained. Yield: 85% 13C NMR (CDCl3): δ 131.2, 
127.4 ppm. IR: 1598 cm-1, 1337cm-1, 1166 cm-1. 
25 
 
Methyl 3,4,5-trichlorothiophene-2-carboxylate (10) 
500 mg 3,4,5-trichlorothiophene-2-carboxylic acid (9, 2.16 mmol) was dissolved in 10 
mL MeOH. 1 mL concentrated H2SO4 was added dropwise with stirring. The reaction mixture 
was stirred under reflux for 1 day. Then the reaction mixture was cooled down to room 
temperature and stirred for another 2 days. White precipitate was filtered off. Filter cake was 
kept. The filtrate was dried over vacuum, washed with sat. NaHCO3 solution, and extracted with 
EtOAc. The organic phase was dried over Na2SO4 followed by solvent evaporation with rotavap. 
Solid was combined with filter cake and recrystallized in MeOH. 400 mg beige needle crystals 
were obtained. Yield: 75%. 1H NMR (CDCl3): δ 3.91 (s, 3H) ppm. HRMS (ESI): calcd for 
C6H4Cl3O2S [M+H]
+ 244.8992, found 244.9002.  
Methyl 3,4,5-trichlorothiophene-2-carboxylate 1,1-dioxide (5) 
Methyl 3,4,5-trichlorothiophene-2-carboxylate 1,1-dioxide was synthesized following the 
general procedure of thiophene oxidation from methyl 3,4,5-trichlorothiophene-2-carboxylate 
(10). Pale yellow cylinder crystals were obtained. Yield: 60%. 1H NMR (CDCl3): δ 3.99 (s, 3H) 
ppm. 13C NMR (CDCl3): δ 156.3, 145.0, 133.0, 130.7, 127.8, 53.7 ppm. IR : 1727, 1564, 1437, 
1335, 1244, 1196, 1172 cm-1. HRMS (ESI): calcd for C6H3Cl2O4S [M-Cl]
+ 240.9124, found 
240.9134.  
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5-(Ethoxycarbonyl)-3,4-diphenylthiophene-2-carboxylic acid (13) 
1500 mg diethyl 2,2'-thiodiacetate (11, 7.26 mmol) and 1270 mg benzil (12, 6.05 mmol) 
were dissolved in 30 mL dry THF. 850 mg EtONa (12.50 mmol) was then added. The reaction 
mixture was refluxed overnight under argon protection. Then the reaction was quenched by 
pouring onto ice followed by washing with EtOAc. The aqueous phase was acidified using 1N 
HCl. The solid was filtered off and kept. The filtrate was extracted with EtOAc. The organic 
phase was dried over Na2SO4. Solvent was removed by vacuum. The remaining solid was 
combined with filter cake and directly used for the next step as crude (1.42 g). Crude yield: 67%.   
Diethyl 3,4-diphenylthiophene-2,5-dicarboxylate (14) 
1.42 g crude 5-(ethoxycarbonyl)-3,4-diphenylthiophene-2-carboxylic acid (13) was 
dissolved in 50 mL EtOH. 2 mL concentrated H2SO4 was added. The reaction mixture was 
refluxed with stirring for 2 days and then cooled to room temperature. Solid was filtered out and 
kept. The solution was then dried under vacuum. To the residue was added with sat. NaHCO3 
solution. The resulting solution was extracted with EtOAc. Organic phase was dried over 
Na2SO4 followed by solvent evaporation under vacuum. Solid was combined with the filter cake 
and recrystallized in EtOH to give 576 mg product. Combined yield of two steps: 25%. 1H NMR 
(CDCl3): δ 7.23 – 7.11 (m, 6H), 7.02 (dd, J = 6.5, 3.1 Hz, 4H), 4.20 (q, J = 7.1 Hz, 4H), 1.18 (t, J 
= 7.1 Hz, 6H) ppm. 
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Diethyl 3,4-diphenylthiophene-2,5-dicarboxylate 1,1-dioxide (6) 
Diethyl 3,4-diphenylthiophene-2,5-dicarboxylate 1,1-dioxide was synthesized following 
the general procedure of thiophene oxidation from diethyl 3,4-diphenylthiophene-2,5-
dicarboxylate (14). Product was obtained as yellow solid. Yield: 65%. 1H NMR (CDCl3): δ 7.32 
(t, J = 7.5 Hz, 2H), 7.22 (t, J = 7.6 Hz, 4H), 6.93 (d, J = 7.3 Hz, 4H), 4.30 (q, J = 7.1 Hz, 4H), 
1.26 (t, J = 7.1 Hz, 6H) ppm. 13C NMR (CDCl3): δ 157.7, 150.1, 130.0, 129.9, 129.5, 128.9, 
127.8, 62.5, 13.8 ppm. IR: 3061, 1725, 1583, 1311, 1241, 1194 cm-1. HRMS (ESI): calcd for 
C22H21O6S [M+H]
+ 413.1053, found 413.1045. 
 
Diethyl 2,2'-sulfinyldiacetate (15) 
1 g diethyl 2,2'-thiodiacetate (11, 4.84 mmol) and 30 mg SeO2 (0.27 mmol) were 
dissolved in 10 mL MeOH and added with 1.22 mL H2O2 (~27% w/w in water, ~10 mmol) 
slowly. The reaction mixture was stirred under room temperature for 15 min. Then the reaction 
mixture was concentrated over a rotavap. The residue was dissolved in water (10 mL) and 
extracted with DCM (20 mL × 3). The organic phase was combined. Removal of solvent yielded 
1.05 g crude oil, which was used directly in the next step. Crude yield: 98%. 1H NMR (CDCl3): δ 
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4.25 (q, J = 7.2 Hz, 4H), 4.05 (d, J = 14.3 Hz, 2H), 3.83 (d, J = 14.3 Hz, 2H), 1.30 (t, J = 7.1 Hz, 
6H) ppm. 
Diethyl acenaphtho(1,2-c)thiophene-7,9-dicarboxylate 8-oxide (17) 
373 mg acenaphthylene-1,2-dione (16, 2.05 mmol) and 500 mg diethyl 2,2'-
sulfinyldiacetate (15, 2.25 mmol) were dissolved in 2.5 mL ethanol. 456 mg trimethylamine 
(4.51 mmol) was added slowly to the reaction mixture. Then the reaction mixture was stirred at 
room temperature overnight. Then the precipitates were filtered out and recrystallized using 
DCM/hexane. 400 mg yellow crystals were obtained. Yield: 53%. 1H NMR (CDCl3): δ 8.75 (d, J 
= 7.2 Hz, 2H), 8.05 (d, J = 8.2 Hz, 2H), 7.76 (t, J = 7.7 Hz, 2H), 4.54 (m, 4H), 1.50 (t, J = 7.1 
Hz, 6H) ppm. 13C NMR (CDCl3): δ 161.3, 151.2, 147.1, 133.2, 131.1, 130.4, 129.0, 128.6, 128.4, 
62.6, 14.5 ppm.  
Diethyl acenaphtho(1,2-c)thiophene-7,9-dicarboxylate 8,8-dioxide (7) 
Diethyl acenaphtho(1,2-c)thiophene-7,9-dicarboxylate 8,8-dioxide was synthesized 
following the general procedure of thiophene oxidation. 100 mg diethyl acenaphtho(1,2-
c)thiophene-7,9- dicarboxylate 8-oxide (17, 0.27 mmol) was dissolved in 2 mL DCM and added 
with 1 mL freshly prepared peroxytrifluoroacetic acid. The reaction mixture was stirred at room 
temperature for 1 day. Then the reaction mixture was dried under vacuum and redissolved in 
DCM. The drying process was repeated several times till the residue is free of acid. 
Recrystallization from EtOAC/DCM yielded orange solid 46 mg. Yield: 45%. 1H NMR (CDCl3): 
δ 8.90 (d, J = 7.3 Hz, 2H), 8.11 (d, J = 8.2 Hz, 2H), 7.86-7.77 (m, 2H), 4.55 (q, J = 7.1 Hz, 4H), 
1.51 (t, J = 7.1 Hz, 6H) ppm. 13C NMR (CDCl3): δ 158.9, 147.8, 145.2, 131.0, 130.9, 129.1, 
129.1, 128.0, 124.3, 62.7, 14.2 ppm. IR: 1707, 1654, 1581, 1318, 1259, 1231, 1196 cm-1. HRMS 
(ESI): calcd for C20H17O6S [M+H]
+ 385.0740, found 385.0729.  
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General procedure of the reaction between thiophene dioxides and strained alkyne/alkene 
Thiophene dioxide was dissolved in a small amount of MeCN or MeOH to give a final 
concentration of around 50~100 mM. 1~1.5 equiv. of strained alkyne (or trans-alkene) was then 
added to the solution. TLC was used to monitor the procession of the reaction. After completion, 
the reaction mixture was directly dried on a rotavap and purified by column chromatography to 
yield the product after SO2 release. 
((1s,1aR,9aS)-4,5,6,7-tetrachloro-1a,2,3,8,9,9a-hexahydro-1H-
benzo(a)cyclopropa(e)(8)annulen-1-yl)methanol (4)  
Product obtained as white solid. Yield: 53%. 1H NMR (600 MHz, DMSO-d6): δ 4.35 (br, 
1H), 3.52 (br, 2H), 3.26 (br, 2H), 3.00 (br, 2H), 2.18 (br, 2H), 1.78 (br, 2H), 0.82 (br, 1H), 0.32 
(br, 2H) ppm. 13C NMR (CDCl3): δ 140.6, 132.4, 130.5, 59.7, 29.9, 21.1, 16.3 ppm.  
To allow HRMS characterization, compound 4 was acetylated by reacting with acetic 
anhydride (3 equiv.) and triethylamine (3 equiv.) in DCM in the presence of DMAP (0.1 equiv.) 
at room temperature overnight. Reaction mixture was dried over vacuum and purified by column 
chromatography (eluent: EtOAc/Hex 1:2). HRMS of acetyl derivative (ESI): calcd for 
C16H16O2Cl4Na [M+Na]
+ 402.9797, found 402.9814.  
 
1,2,3,4-Tetrachloro-4a,5,6,7,8,9,10,10a-octahydrobenzo(8)annulen-5-ol (18) 
Product obtained as white solid. Yield: 77%.1H NMR (CDCl3): δ 4.29 – 4.15 (m, 1H), 
2.94 – 2.78 (m, 1H), 2.73 – 2.63 (m, 1H), 2.15 (d, J = 2.9 Hz, 1H), 2.09 – 1.73 (m, 6H), 1.73 – 
1.58 (m, 2H), 1.53 – 1.42 (m, 1H), 1.16 – 1.00 (m, 1H) ppm. 13C NMR (CDCl3): δ 133.6, 129.3, 
30 
125.2, 122.7, 74.3, 47.2, 43.0, 36.6, 30.6, 27.9, 26.2, 23.3 ppm. HRMS (ESI): calcd for 
C12H14Cl4NaO [M+Na]
+ 336.9691, found 336.9681.  
 
Methyl (1S,1aS,9aR)-5,6,7-trichloro-1-(hydroxymethyl)-1a,2,3,8,9,9a-hexahydro-1H-
benzo(a) cyclopropa(e)(8)annulene-4-carboxylate and enantiomer (19) 
Product obtained as white solid. Yield: 61%. 1H NMR (CDCl3): δ 3.98 (s, 3H), 3.75 (br, 
2H), 3.28 (br, 1H), 2.96 (br, 2H), 2.80-2.65 (m, 1H), 2.50-2.35 (m, 1H), 2.24 (br, 1H), 1.75 (br, 
1H), 1.38-1.00 (br, 3H), 0.95-0.44 (br, 2H). 13C NMR (CDCl3):
 δ 167.5, 140.8, 138.8, 134.7, 
129.9, 127.5, 59.7, 53.0 30.5, 28.8, 22.3, 21.0, 20.4, 16.9, 15.7. HRMS (ESI): calcd for 
C16H17O3NaCl3 [M+Na]
+ 385.0141, found 385.0128. 
 
Diethyl (1s,1aR,9aS)-1-(hydroxymethyl)-5,6-diphenyl-1a,2,3,8,9,9a-hexahydro-1H-benzo(a) 
cyclopropa(e)(8)annulene-4,7-dicarboxylate (20) 
Product obtained as yellowish solid. Yield: 46%. 1H NMR (CDCl3): δ 7.16 – 7.05 (m, 
6H), 7.02 (br, 4H), 3.94 (q, J = 7.1 Hz, 4H), 3.75 (br, 2H), 2.98 (br, 2H), 2.90 – 2.74 (m, 2H), 
2.31 (br, 2H), 1.87 – 1.64 (br, 1H), 1.55 – 1.29 (br, 2H), 1.21 – 0.98 (br, 3H), 0.89 (t, J = 7.1 Hz, 
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6H) ppm. 13C NMR (CDCl3): δ 169.6, 138.3, 136.5, 130.4, 127.2, 126.8, 61.0, 59.8, 13.7 ppm. 
HRMS (ESI): calcd for C32H35O5 [M+H]
+ 499.2479, found: 499.2479.  
 
Diethyl (9aR,10s,10aS)-10-(hydroxymethyl)-9,9a,10,10a,11,12-hexahydro-8H-
cyclopropa(5,6) cycloocta(1,2-k)fluoranthene-7,13-dicarboxylate (21) 
Product obtained as yellow solid. Yield: 60%. 1H NMR (CDCl3): δ 7.85 (d, J = 8.2 Hz, 
2H), 7.77 (d, J = 7.1 Hz, 2H), 7.65 – 7.55 (m, 2H), 4.60 (q, J = 7.1 Hz, 4H), 3.81 – 3.57 (m, 2H), 
3.17 – 2.95 (m, 2H), 2.95 – 2.78 (m, 2H), 2.33 (br, 2H), 1.83 – 1.52 (m, 2H), 1.51 – 1.37 (m, 
6H), 1.17 – 0.62 (m, 4H) ppm. 13C NMR (CDCl3): δ 169.8, 134.2, 133.7, 132.7, 129.9, 127.9, 
127.4, 121.9, 61.7, 59.8, 14.3 ppm. HRMS (ESI): calcd for C30H30O5Na [M+Na]
+ 493.1991, 
found: 493.1987.  
 
Diethyl (1r,1aR,9aS)-1-(hydroxymethyl)-5,6-diphenyl-1a,2,3,8,9,9a-hexahydro-1H-benzo(a) 
cyclopropa(e)(8)annulene-4,7-dicarboxylate (22) 
Product obtained as yellowish solid. Yield: 58%. 1H NMR (CDCl3) δ 7.08 (s, 6H), 7.01 
(s, 4H), 4.07 – 3.78 (m, 4H), 3.44 (d, J = 6.7 Hz, 2H), 3.03 – 2.88 (m, 2H), 2.88 – 2.68 (m, 2H), 
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2.62 – 2.38 (br, 2H), 1.49 – 1.31 (br, 3H), 0.89 (t, J = 7.1 Hz, 6H), 0.85 – 0.72 (br, 2H) ppm. 13C 
NMR (CDCl3) δ 169.6, 138.5, 138.3, 136.4, 136.3, 130.4, 130.2, 127.2, 126.8, 66.5, 61.0, 30.4, 
29.7, 29.5, 21.6, 13.7 ppm. HRMS (ESI): calcd for C32H35O5 [M+H]
+ 499.2479, found: 
499.2462. 
1.2.2.3 Confirmation of SO2 release by the DTNB test 
3 was prepared as 500 μM stock solution in 5% DMSO/PBS. 1 was prepared as 5 mM 
stock solution in 5% DMSO/PBS. DTNB was prepared as 1.5 mM stock solution in 10% 
EtOH/PBS stock solution. NaHSO3 and Na2SO3 as positive controls were prepared as 500 μM 
stock solution in 5% DMSO/PBS, respectively. 
Room temperature incubation: Each group (2 mL) was prepared in 4 mL glass vial, 
sealed with Parafilm® M, and incubated at room temperature (21 oC) for 45 min. 2 mL DTNB 
stock solution was then added to each group. The solutions were allowed to stand at room 
temperature for another 15 min. Then the solution was filtered through 0.45 μm micron filters 
and its UV-vis absorption measured at 412 nm in a quartz cuvette.  
37 oC incubation: Each group (2 mL) was prepared in 4 mL glass vial, added with 0.3 mL 
silicon fluid (to minimize SO2 escape), and sealed with Parafilm
® M. Then all the groups were 
incubated in a 37 oC water bath for 45 min. Then the solutions were taken out and allowed 15 
min to cool to room temperature. 2 mL DTNB was then added to each group. The solution was 
allowed to stand at room temperature for another 15 min. Then the water phase of each solution 
was taken out by syringe and filtered through 0.45 μm micron filters. The UV-vis absorption of 
the filtrate was measured at 412 nm in a quartz cuvette. 
All DTNB tests were in triplicates. 
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1.2.2.4 Kinetics studies of cycloaddition reactions 
Second order reaction rate constants (k2) were obtained as slopes of pseudo-first reaction 
rate constants (k1) plotted linearly against concentrations of strained alkyne/alkene.  
UV-vis kinetic measurements: Separate stock solutions of thiophene dioxide (3, 5, or 6) 
and BCN (1) or trans-cyclooctene (8) (concentration 10 ~18 times of respective thiophene 
dioxide) were prepared in HPLC-grade solvent (MeOH, MeCN) at room temperature. The 
“click-release” reaction led to significant changes in the UV-vis spectrum of thiophene dioxide. 
Thiophene dioxide stock solution (200 μL), BCN (or trans-alkene) (300, 400, 500, 600 μL), and 
solvent (300, 200, 100, 0 μL) were added into 10 mm quartz cuvettes, thoroughly mixed and 
sealed with a PTFE cap and monitored for time-dependent UV-vis absorption changes. All 
kinetic runs were in triplicates. Curve fitting was operated using the SigmaPlot® 10 software 
(Figure 1-8).  
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Figure 1-8 Kinetics studies of cycloaddition reactions by UV-vis absorbance change 
(A) Example of pseudo-first reaction monitored by UV absorbance decrease. A typical curve 
shows reaction between 125 μM 6 and 5.625 mM 1 in MeOH at room temperature. λ=324 nm. 
(B) Linear plot of k1 at different concentrations of 1 or 8. SO2 donor pairs and solvents: a) 3 + 1, 
MeOH; b) 3 + 8, MeOH; c) 5 + 1, MeCN; d) 6 + 1, MeOH; e) 6 + exo-BCN.  
 
Fluorescence kinetics measurements: Separate solutions of thiophene dioxide (7, 500 μM) 
and 1 (5 mM) were prepared in HPLC-grade solvent (DMSO/PBS 4:1) at room temperature. The 
“click-release” reaction gives a fluorescent product that can be monitored by fluorimeter. The 
solutions containing thiophene dioxide (200 μL), BCN (300, 400, 500, 600 μL), and solvent 
(300, 200, 100, 0 μL) were added into quartz cuvettes, thoroughly mixed and sealed with a PTFE 
cap, kept at 37 oC in water bath, and tested for fluorescence emission change (λex=350 nm, 
λem=470 nm). All kinetics runs were in triplicates. Curve fitting was done using the SigmaPlot
® 
10 software (Figure 1-9). 
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Figure 1-9 Kinetics studies of cycloaddition reaction between 7 and 1 by monitoring 
fluorescence changes 
(A) Time-dependent fluorescence increases. Conditions: 250 μM 7 + 2500 μM 1 in 4:1 
DMSO/PBS at 37 oC. (B) Example of pseudo-first reaction monitored by fluorescence increase. 
Conditions: 125 μM 7 + 3.125 mM 1 in 4:1 DMSO/PBS at 37 oC. λex=350 nm, λem=470 nm; slit 
width: ex 3 nm, em 1.5 nm. (C) Linear plot of k1 at different concentrations of 1. 
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1.2.2.5 Determination of fluorescence quantum yields 
Quinine sulfate (QS) in 0.1M H2SO4 water solution was chosen as the standard (ex: 350 nm, 
em: 400-600 nm). Literature89 quantum yield: 0.54. The quantum yields of compound 7 and 
compound 21 were determined according to the equation: 
Φ𝑋 = Φ𝑆𝑇 (
𝐺𝑟𝑎𝑑𝑋
𝐺𝑟𝑎𝑑𝑆𝑇
)(
𝜂𝑋
2
𝜂𝑆𝑇
2 ) 
Where Φ is the fluorescence quantum yield, the subscripts ST and X denote standard and 
test compounds respectively, Grad is the gradient from the plot of integrated fluorescence 
intensity versus UV-vis absorbance, and η is the refractive index of the solvent (1.3330 for 
water, 1.3284 for methanol). Excitation wavelength were chosen as UV-vis absorbance < 0.1 to 
avoid reabsorption effect. 
Quantum yield determination of 7:  
Solutions of compound 7 at 0, 2, 4, 6, 8, 10 μM in methanol were prepared at room 
temperature. Each solution was tested for absorbance at 345 nm and fluorescence emission at 
380-680 nm under 345 nm excitation (slit width: ex: 5, em: 3; fluorescence cuvette: 10 mm). 
Fluorescence responses were integrated in the same range to obtain AUC readings. Then AUC 
readings were plotted against absorbance readings to obtain 𝐺𝑟𝑎𝑑𝑋 as the slope of linear 
regression equation. 𝐺𝑟𝑎𝑑𝑆𝑇 of QS were determined in the same manner using 0, 0, 1, 1, 2, 2 μM 
solutions instead (Figure 1-10). Calculated quantum yield for 7 was 0.006. 
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                            (C) 
 
Figure 1-10 Quantum yield determination of 7 using QS as the reference 
(A) UV-vis absorbance spectrum. (B) Fluorescence response spectrum (λex: 345 nm; slit width: 
ex: 5 nm, em: 3 nm; fluorescence cuvette: 10 mm). (C) Plot of AUC versus UV-vis absorbance 
(integration range: 380 nm to 680 nm). 
 
Quantum yield determination of 21:  
Solutions of compound 21 at 0, 2, 4, 6, 8, 10, 12 μM in methanol were prepared at room 
temperature. Each solution was tested for absorbance at 364 nm and fluorescence emission at 
380-620 nm under 364 nm excitation (slit width: ex: 3 nm, em: 1.5 nm; fluorescence cuvette: 10 
mm). Fluorescence responses were integrated at the same range to obtain AUC readings. Then 
AUC readings were plotted against absorbance readings to get 𝐺𝑟𝑎𝑑𝑋 as the slope of linear 
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regression equation. 𝐺𝑟𝑎𝑑𝑆𝑇 of QS were determined in the same manner using 0, 5, 10, 15, 20, 
25 μM solution instead (Figure 1-11). Calculated quantum yield for 21 is 0.138. 
 (A)                                                              (B) 
 
                               (D) 
 
Figure 1-11 Quantum yield determination of 21 using QS as the reference 
 (A) UV-vis absorbance spectrum. (B) Fluorescence response spectrum (λex: 364 nm; slit width: 
ex: 3 nm, em: 1.5 nm; fluorescence cuvette: 10 mm). (C) Plot of AUC versus UV-vis absorbance 
(integration range: 380 nm to 620 nm). 
 
1.3 Esterase-sensitive SO2 prodrugs 
Despite the remarkable progress in making SO2 donors and the associated beautiful 
chemistry, there are still unresolved issues including the reliance on other sulfur species for SO2 
release, the need for two components in the bimolecular reaction-based prodrugs, and the 
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delicate and sometimes difficult balance between stability and rapid release of SO2 from 
unimolecular systems without the use of a trigger.  Herein, we describe a series of esterase-
sensitive SO2 prodrugs. Such SO2 prodrugs would release SO2 under physiological conditions 
with a bio-compatible triggering mechanism. We envision that prodrugs with an enzyme-
sensitive release mechanism would simulate the endogenous SO2 generating process and offer 
unique advantages as research tools. We understand that it is unlikely that a single triggering 
mechanism, such as the esterase-sensitive triggering mechanism, would meet the demand of all 
research needs. We further envision that the general method used can be a platform approach that 
allows for the incorporation of other triggering mechanisms to provide research tools applicable 
in different situations. 
1.3.1 Results and discussion 
In our search for the chemistry needed for developing esterase-sensitive SO2 prodrugs, 
we found SO2 is formed as a byproduct in modified Julia olefination (also known as one-pot 
Julia olefination). Modified Julia olefination as well as Julia reaction have been widely applied in 
organic synthesis for fragment connection (Scheme 1-6).90-95 Briefly, benzothiazole sulfone is 
first deprotonated by a base. The carbanion formed then can undergo an aldol condensation-type 
of reaction leading to an alkoxide intermediate (I). Intramolecular addition-elimination followed 
by extrusion of SO2 and 2-hydroxybenzothiazole (2-OHBT) gives the final product with a double 
bond. As to the reaction itself, strongly basic condition is required in the first step to generate the 
carbanion as nucleophile. This need for strongly basic conditions present an obstacle in the 
development of prodrugs that can release SO2 under physiological conditions. However, if we 
could “trap” the β-alkoxysulfone intermediate (I) as the donor molecule, the subsequent 
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intramolecular reaction should readily occur under physiological conditions. As a result, we 
designed the esterase-sensitive prodrug system described in Scheme 1-7. 
 
Scheme 1-6 Modified Julia olefination 
 
As a first step, we were interested in studying the SO2 release chemistry from compound 
1 and its analogues. Thus compound 1 was synthesized from commercially available 2-(2-
benzothiazolylthio)ethanol in one step (Scheme 1-8). It should be noted that besides 
benzothiazole (BT), various heterocycles have been applied in modified Julia olefination.91 We 
reasoned that BT holds certain advantage for the easy accessibility of 2-substituted BT 
derivatives and its strong UV absorption for easy detection.  
 
Scheme 1-7 Design of SO2 prodrug 
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To gain an initial understanding of the SO2 release tendency, we incubated compound 1 
(200 μM) in 10% DMSO/PBS (pH 7.4) at 37 °C and monitored the reaction with HPLC. Over a 
period of 4 days, only a small amount of 2-OHBT was formed, and yet compound 1 was fully 
consumed (Scheme 1-8, data not shown). Mass spectral analysis of the reaction mixture suggest 
the formation of 2-(benzo(d)thiazol-2-yloxy)ethane-1-sulfonic acid (3). This was likely formed 
through oxidation of corresponding sulfinic acid (2), and indicates successful “cyclization” to the 
2-position of BT. Possible issues that hinder the elimination step might include the lack of 
stabilization of the transition state.96 
 
Scheme 1-8 Synthesis and proposed reaction route of compound 1 under physiological 
conditions 
 
 
According to computational studies by Robiette and Pospíšil, introduction of substituents 
on the linker portion (1,2-positions) can offer electronic stabilization to the transition state of the 
elimination step.96 It is also well known that introduction of substituents can significantly affect 
the outcome of cyclization reactions.97-98 Thus, there is a need to study analogues with various 
substitution patterns on the linker portion to facilitate the steps leading to SO2 production. We 
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synthesized a set of compounds (compound 7a-e) with different substituents at the 1- and 2- 
positions (Scheme 1-9). These β-alkoxysulfones were readily prepared through a 3-step synthesis 
route by first condensing 2-thiolbenzothiazole with α-bromoketone (or α-chloroketone) under 
basic conditions. The resulting β-ketosulfides were then reduced with NaBH4 to give the 
respective β-alkoxysulfides. The final product was obtained by S-oxidation using 2.5~3 
equivalents of m-CPBA. The final compounds were incubated in PBS (with 1~10% DMSO to 
solubilize) at 37 °C. Formation of 2- OHBT was monitored with HPLC as an indication of 
reaction progress. Compounds 7a-d successfully yielded 2-OHBT peaks, whereas compound 7e 
with the sulfone group locked in a cis- configuration with the hydroxyl group failed to release 2-
OHBT, suggesting the need for an antiperiplanary relationship for the final elimination step, as 
expected (Figure 1-19).24   
 
Scheme 1-9 Synthesis of sulfone compounds with different substitution groups 
 
Studies of reaction kinetics of 7a-d were conducted at 50 μM in 10% DMSO/PBS at 37 
°C. The overall reaction was treated as single first-order reaction. kobs was calculated 
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accordingly. The resulting half-life (t1/2) of 7a-d ranges from 1.7 to 86.6 min (Table 1-2; Figure 
1-18).  
Table 1-2 SO2 release rate monitored by HPLC 
Compound 7a 7b 7c 7d 
kobsa (min-1) 0.014±0.001 0.397±0.081 0.168±0.028 0.008±0.000 
t1/2 (min) 49.5 1.7 4.1 86.6 
Note: a. Measured at 37 °C with 50 μM compound in 10% DMSO/PBS in triplicates; 
Curve fitted as first-order reaction.  
 
To further confirm the release of SO2, the DTNB test was performed using a modified 
method that has been previously reported (Figure 1-17).86 The positive responses from such tests 
confirmed SO2 formation.  
 
Scheme 1-10 Synthesis of compound 9 and 10 
 
In designing an esterase-sensitive prodrug approach, we masked the hydroxy group as an 
ester. The ester group should be labile to hydrolysis by esterases in the blood and in cell. A 
hydrophobic ester group can also increase the membrane permeability of the prodrug. Therefore, 
compound 9 (BW-SO2-201) was prepared from 6b (Scheme 1-10). We first tested the stability of 
compound 9 in PBS (with 1% DMSO at 37 °C) by HPLC. It was surprising to find that 9 was not 
stable, leading to slow decomposition with elimination of the ester group and neighboring 
hydrogen without 2-OHBT formation (Figure 1-20). Such results can be explained by the good 
leaving ability of the newly attached ester group. We reasoned that we should be able to avoid 
this self-elimination problem by replacing the susceptible hydrogen with a methyl group. We 
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therefore synthesized compound 10 (BW-SO2-202) following the same synthetic route from 6c 
(Scheme 1-10). Compound 10 did not show degradation within the time range (3~4 h) examined 
(Figure 1-21). When incubated with porcine liver esterase (PLE, 5 unit/mL) in 10% DMSO/PBS 
at 37 °C, 2-OHBT formation was readily observed, affirming the validity of our design. The 
observed half-life (t1/2obs, ~1 h) is much slower than 7c, indicating the esterase cleavage step is 
the rate-limiting step in the releasing process (Figure1-13). 
From previous work in our group, it has been shown that esterase-catalyzed hydrolysis is 
tunable by varying the acyl moiety.81 Therefore, we designed and synthesized compounds 11-13 
(BW-SO2-203-205) with different acyl groups in order to tune the SO2 release rate. Indeed, 
significant differences in release rates were observed (Figure 1-13). Compounds 11 and 13 
exhibited the fastest release rates, with t1/2obs being ~10 min and ~9 min respectively. Compound 
12 with a bulky t-butyl group exhibited the slowest release rate with only ~10% release after 2 
hours. Compound 10 falls somewhere in between that showed ~70% release within 2 hours. The 
kinetics were also monitored using a literature reported bisulfite probe 14 (Figure 1-16; Figure 1-
23).99 Results are consistent with that of HPLC studies that compound 10-13 demonstrated 
significantly different release rates. Compound 13 with an α- dimethyl amino group is expected 
to possess much higher water solubility compared with compounds 10-12. Thus, we hope this 
compound will be especially useful as a prodrug for future work. We have further tested the 
stability and esterase-triggered release kinetics of 13 in 1% DMSO/PBS solution at 37 °C using 
HPLC. The results show that the ester group slowly hydrolyzed with t1/2 of about 24 h in the 
absence of PLE. With 1 unit/mL PLE, the release was complete within 90 min (Figures 1-13,1-
14). Therefore, the esterase-triggered release is the dominant pathway for SO2 release.  
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Figure 1-12 Structures of compounds 10-13 
 
Figure 1-13 Kinetics of esterase triggered release monitored by HPLC 
Condition: 50 μM compound in 10% DMSO/PBS at 37 °C with 5 unit/mL PLE, n=3. 
 
Figure 1-14 Stability of compound 13 in 1% DMSO/PBS 
0
10000
20000
30000
40000
50000
60000
70000
80000
90000
0 10 20 30 40 50 60 70 80 90 100 110 120
2
-O
H
B
T
 a
re
a
Time (min)
10 11 12 13
0
50000
100000
150000
200000
250000
300000
0 20 40 60 80 100
P
ea
k
 a
re
a
Time (h)
2-OHBT 13
47 
 
Figure 1-15 Esterase triggered release of compound 13 under different conditions 
 
With these esterase-sensitive SO2 prodrugs in hand, we further tested whether they can be 
applied in biological systems. Using the fast-releasing prodrug 13 as a representative, we used 
probe 14 for cell imaging studies. Briefly, HeLa cells were incubated with 100 μM prodrug at 37 
°C for 2 h. Then the cells were washed with PBS and incubated with 10 μM of probe 14 for 
another 0.5 h (Figure 1-16). The experimental group showed strong fluorescence inside the cells 
while the negative control groups showed no fluorescence or very weak fluorescence. It is worth 
noting that NaHSO3 gives much weaker fluorescence than 13 even at 400 μM. Such results 
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indicate that prodrug 13 has much better capacity to deliver SO2 into the cell than the widely 
used NaHSO3 as a SO2 donor. 
a) cell only; b) 14 only (10 μM); c) 13 only (100 μM); d) 13 (100 μM) + 14 (10 μM); e) NaHSO3 
(400 μM) + 14 (10 μM); f) product (2-OHBT and 2-methyl-1-phenyl-propene, 100 μM each) + 
14 (10 μM) 
 
In summary, a series of SO2 prodrugs inspired by modified Julia olefination was designed 
and synthesized. The release kinetics were determined by HPLC through monitoring the 
formation of 2-OHBT, a byproduct generated simultaneously with SO2. Through manipulating 
the substitution patterns, the release rate has been tuned with t1/2 ranging from ~ 2 min to ~1.5 h. 
More importantly, by attaching an acyl group at the free hydroxyl group of compound 7c, 
esterase-sensitive SO2 prodrugs were prepared. Tunable release rate was also achieved using 
different esterase-sensitive acyl groups. Prodrug 13 exhibited the fastest release and was selected 
for cell imaging studies. It exhibited high efficiency in releasing SO2 in biological environment. 
Other triggering mechanisms are equally possible with proper modification to serve different 
research purposes. Most SO2 donors and prodrugs in this paper were obtained in the solid form, 
and they remain stable under normal storage condition for several months (-20 °C, data not 
Figure 1-16 Cell imaging study of SO2 release from 13 in HeLa cells 
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shown). We feel that these SO2 prodrugs wll be very useful tools in elucidating SO2 biology. 
This work has been published in Chem. Commun., 2017, 53, 10124-10127. 
1.3.2 Experimental procedures 
1.3.2.1 Materials and Methods 
All chemicals, reagents, and solvents were purchased from commercial suppliers as reagent 
grade and were used without further purification. NMR spectra were recorded on a Bruker 
Avance NMR spectrometer at 400 MHz for 1H spectra and 101 MHz for 13C spectra at room 
temperature. Solvent peaks were used as internal standards. Mass spectral analyses were 
performed by the GSU Mass Spectrometry Facilities. HPLC analyses were performed on a 
Shimadzu HPLC equipped with UV detector. Column: Shimadzu C18 3μm 4.6×50 mm column. 
1.3.2.2 Synthesis 
General procedure of the oxidation of sulfide to sulfone: 
Sulfone compounds were synthesized following similar procedure with necessary 
adjustments using 3-chloroperoxybenzoic acid (m-CPBA) as the oxidant. 
Generally, 1 equiv. of sulfide was dissolved in dichloromethane (DCM) at a concentration 
of ~0.5 mmol/10 mL. The resulting solution was treated with 2.5~3 equiv. of m-CPBA in small 
portions under stirring at room temperature (ice bath can be applied for large scale reaction). 
Reaction process was monitored by thin layer chromatography (TLC). Usual reaction time is 
between 1~4 hours. When reaction finished, the reaction was quenched with an equal volume of 
sat. NaHCO3 aqueous solution. For small scale reactions, dilution with DCM was used to 
facilitate separation and washing. The aqueous phase was separated with separatory funnel and 
back-extracted with fresh DCM twice. Combined organic phase was washed with brine and dried 
over Na2SO4. Solvent was then removed under reduced pressure. Column chromatography was 
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used for purification. Further washing with sat. NaHCO3 solution was used to remove residual 
m-CPBA/m-CBA.  
 
2-(Benzo(d)thiazol-2-ylsulfonyl)ethan-1-ol (1) 
Synthesis followed the general procedure of oxidation of sulfide to sulfone. Product was 
obtained as white solid. Yield: 77%. 1H NMR (CDCl3) δ 8.21 (d, J = 7.9 Hz, 1H), 8.04 (d, J = 
7.9 Hz, 1H), 7.72 – 7.56 (m, 2H), 4.21 (s, 2H), 3.81 – 3.73 (m, 2H), 2.97 (s, 1H) ppm. 13C NMR 
(CDCl3) δ 166.2, 152.4, 136.6, 128.3, 127.9, 125.42, 122.4, 57.7, 56.5 ppm. IR: νmax/cm
-1 3388 
(O-H), 2929 (C-H), 1322 (S=O), 1301 (C-O), 1128 (S=O). HRMS (ESI): calcd. for C9H10NO3S2
+ 
[M+H]+ 244.0097, found 244.0089. 
 
2-(Benzo(d)thiazol-2-ylthio)-1-phenylethan-1-one (5a) 
2-Mercaptobenzothiazole (1.0 g, 6.0 mmol) and 2-bromoacetophenone (1.2 g, 6.0 mmol) 
were dissolved in 50 mL acetone and treated with K2CO3 (0.83 g, 6.0 mmol). The reaction 
mixture was heated at reflux temperature for 0.5 h and then cooled down to room temperature. 
Solvent was evaporated under reduced pressure. The residue was re-dissolved in ethyl acetate 
(EA, ~50 mL) and washed with brine (~50 mL). Organic phase was then dried over Na2SO4, and 
concentrated in vacuo. Residue was recrystallized in ethanol to yield 1.4 g of product as yellow 
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needle crystals. Yield: 82%. 1H NMR (CDCl3) δ 8.13 – 8.05 (m, 2H), 7.81 (dd, J = 8.1, 0.4 Hz, 
1H), 7.75 (dd, J = 8.0, 0.6 Hz, 1H), 7.68 – 7.58 (m, 1H), 7.56 – 7.47 (m, 2H), 7.43 – 7.37 (m, 
1H), 7.33 – 7.27 (m, 1H), 4.98 (s, 2H) ppm. 13C NMR (CDCl3) δ 193.0, 165.2, 152.9, 135.6, 
133.9, 128.8, 128.6, 126.1, 124.4, 121.5, 121.1, 41.0 ppm. HRMS (ESI): calcd. for 
C15H11NOS2Na
+ [M+Na]+ 308.0174, found 308.0189. 
2-(Benzo(d)thiazol-2-ylthio)-1-phenylpropan-1-one (5b) 
To a solution of 2-mercaptobenzothiazole (334 mg, 2 mmol) in 4 mL DCM was added 
triethylamine (TEA, 0.39 mL, 2.8 mmol). The 2-bromopropiophenone (0.30 mL, 2 mmol) was 
added dropwise. The reaction mixture was stirred at room temperature for 1 h and then dried 
under vacuum. The residue was re-dissolved in 10 mL EA and washed with water (10 mL  2). 
Water phase was back extracted with 15 mL EA. Combined organic phase was dried over 
Na2SO4, concentrated in vacuo, and purified by column chromatography (EA/Hex 1:20 to 1:10). 
Product (470 mg) was obtained as yellow oil. Yield: 78%. 1H NMR (CDCl3) δ 8.11 (dt, J = 8.5, 
1.7 Hz, 2H), 7.83 (dd, J = 8.1, 0.4 Hz, 1H), 7.75 (dd, J = 8.0, 0.6 Hz, 1H), 7.64 – 7.54 (m, 1H), 
7.53 – 7.45 (m, 2H), 7.42 (ddd, J = 8.3, 7.4, 1.2 Hz, 1H), 7.35 – 7.27 (m, 1H), 5.88 (q, J = 7.1 
Hz, 1H), 1.77 (d, J = 7.1 Hz, 3H) ppm. 13C NMR (CDCl3) δ 197.3, 164.7, 152.9, 135.7, 135.0, 
133.6, 128.9, 128.8, 126.1, 124.5, 121.6, 121.1, 47.1, 18.3 ppm. HRMS (ESI): calcd. for 
C16H13NOS2Na
+ [M+Na]+ 322.0331, found 322.0352. 
2-(Benzo(d)thiazol-2-ylthio)-2-methyl-1-phenylpropan-1-one (5c) 
A solution of 2-mercaptobenzothiazole (167 mg, 1 mmol) in 2 mL DCM was added with 
0.20 mL TEA (1.4 mmol). To the solution was then added 2-bromo-2-methylpropiophenone 
(0.17 mL, 1 mmol) dropwise. The reaction mixture was stirred at room temperature for 0.5 h and 
then heated to 60 oC for 4 h. After cooling to room temperature, solvent was removed by reduced 
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pressure. Residue was re-dissolved in 10 mL EA and washed with water (10 mL  2). Aqueous 
phase was back extracted with 15 mL EA. Combined organic phase was dried over Na2SO4, 
concentrated in vacuo, and purified by column chromatography (EA/Hex 1:20 to 1:10). 175 mg 
product was obtained as yellow oil. Yield: 56%. 1H NMR (CDCl3) δ 8.13 – 8.05 (m, 2H), 7.89 
(d, J = 8.1 Hz, 1H), 7.71 (d, J = 8.0 Hz, 1H), 7.50 – 7.43 (m, 1H), 7.43 – 7.35 (m, 3H), 7.33 – 
7.27 (m, 1H), 1.86 (s, 6H) ppm. 13C NMR (CDCl3) δ 200.6, 161.4, 153.1, 136.7, 136.3, 131.8, 
129.1, 127.9, 126.1, 125.0, 122.5, 121.0, 58.1, 27.4 ppm. HRMS (ESI): calcd. for C17H16NOS2
+ 
[M+H]+ 314.0668, found 314.0655. 
1-(Benzo(d)thiazol-2-ylthio)-3-methylbutan-2-one (5d) 
1-Bromo-3-methyl-2-butanone (0.12 mL, 1 mmol) and 2-mercaptobenzothiazole (167 mg, 1 
mmol) were dissolved in 5 mL acetone. To the solution was added K2CO3 (138 mg, 1 mmol). 
The reaction mixture was stirred at room temperature for 1 h then dried under reduced pressure. 
The residue was re-dissolved in 10 mL EA and washed with water (10 mL  2). The aqueous 
phase was back extracted with EA (15mL  2). Combined organic phase was dried over Na2SO4 
and concentrated over vacuum. The crude product was purified by column chromatography 
(EA/Hex 1:20 to 1:10). 204 mg product was obtained as white solid. Yield: 81%. 1H NMR 
(CDCl3) δ 7.81 (d, J = 8.1 Hz, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.44 – 7.36 (m, 1H), 7.32 – 7.27 (m, 
1H), 4.35 (s, 2H), 2.97 (dt, J = 13.9, 6.9 Hz, 1H), 1.22 (d, J = 6.9 Hz, 6H) ppm. 13C NMR 
(CDCl3) δ 207.3, 165.3, 152.9, 135.6, 126.1, 124.4, 121.4, 121.1, 41.4, 40.1, 18.4 ppm. HRMS 
(ESI): calcd. for C12H14NOS2
+ [M+H]+ 252.0511, found 252.0505. 
2-(Benzo(d)thiazol-2-ylthio)cyclohexan-1-one (5e) 
To a solution of 2-mercaptobenzothiazole (500 mg, 3.0 mmol) and trimethylamine (0.58 
mL, 4.2 mmol) in 6 mL DCM was added 2-chlorocyclohexan-1-one (0.36 mL, 3.1 mmol) 
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slowly. The solution was heated at reflux for 4.5 h, then cooled to room temperature, and stirred 
overnight. The reaction mixture was diluted with DCM to 15 mL and washed with water (10 mL 
 2). The combined aqueous phase was back extracted with DCM (15 mL  2). Combined 
organic phase was dried over Na2SO4, concentrated in vacuo, and purified by column 
chromatography (EA/Hex 1:10 to 1:5) to yield the product (454 mg) as yellow solid. Yield: 57%. 
1H NMR (CDCl3) δ 7.89 (d, J = 8.2 Hz, 1H), 7.77 (dd, J = 8.0, 0.6 Hz, 1H), 7.50 – 7.39 (m, 1H), 
7.38 – 7.30 (m, 1H), 4.93 (dd, J = 10.2, 5.7 Hz, 1H), 2.82 – 2.65 (m, 2H), 2.65 – 2.48 (m, 1H), 
2.25 – 2.09 (m, 1H), 2.05 – 1.74 (m, 4H) ppm. 13C NMR (CDCl3) δ 205.5, 164.8, 153.1, 135.5, 
126.0, 124.4, 121.6, 121.0, 57.4, 41.6, 35.5, 27.6, 25.1 ppm. HRMS (ESI): calcd. for 
C13H13NOS2Na
+ [M+Na]+ 286.0331, found 286.0339. 
General procedure of reducing β-ketosulfides to β-alkoxysulfides: 
Compounds 6a-e were prepared by reducing compounds 5a-e with NaBH4. In general, 1 
equiv. of compounds 5a-e was dissolved in MeOH (10~15 mL/mmol) and cooled to 0 °C in an 
ice bath. NaBH4 (4 equiv.) was added to the solution in small portions. The reaction was then 
allowed to warm up to room temperature. The reaction process was monitored by TLC. After 
completion, the reaction was quenched with sat. NH4Cl aqueous solution. The mixture was then 
extracted with EA and washed with water and brine. The organic phase was dried over Na2SO4 
and concentrated under reduced pressure. Crude product was purified by column 
chromatography.   
2-(Benzo(d)thiazol-2-ylthio)-1-phenylethan-1-ol (6a) 
Synthesis followed the general procedure of reducing β-ketosulfides to β-alkoxysulfides 
from 5a. Product was obtained as yellow solid. Yield: 99%. 1H NMR (CDCl3) δ 7.92 (d, J = 8.1 
Hz, 1H), 7.76 (d, J = 7.9 Hz, 1H), 7.57 – 7.25 (m, 7H), 5.31 – 5.05 (m, 2H), 3.74 (dd, J = 14.3, 
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2.5 Hz, 1H), 3.58 (dd, J = 14.3, 7.9 Hz, 1H) ppm. 13C NMR (CDCl3) δ 167.9, 152.5, 142.9, 
135.5, 128.6, 127.9, 126.3, 125.9, 124.7, 121.4, 121.1, 73.6, 42.8 ppm. HRMS (ESI): calcd. for 
C15H13NOS2Na
+ [M+Na]+ 310.0331, found 310.0340. 
2-(Benzo(d)thiazol-2-ylthio)-1-phenylpropan-1-ol (6b) 
Synthesis followed the general procedure of reducing β-ketosulfides to β-alkoxysulfides 
from 5b. Two isomers were obtained in (Ration of 35:65 between the compounds with a high 
and low Rf) with a total yield of 100 %. Both isomers were obtained as clear oil. Isomer with the 
lower Rf on TLC was characterized as below and used for the next step. 
1H NMR (CDCl3) δ 7.95 
(d, J = 8.1 Hz, 1H), 7.79 (d, J = 7.7 Hz, 1H), 7.51 – 7.29 (m, 7H), 4.88 (d, J = 7.2 Hz, 1H), 4.12 
– 4.02 (m, 1H), 1.45 (d, J = 7.2 Hz, 3H) ppm. 13C NMR (CDCl3) δ 166.9, 152.5, 142.5, 135.6, 
128.4, 127.9, 126.7, 126.3, 124.8, 121.5, 121.1, 78.5, 52.3, 18.3 ppm. HRMS (ESI): calcd. for 
C16H16NOS2
+ [M+H]+ 302.0668, found 302.0661. 
2-(Benzo(d)thiazol-2-ylthio)-2-methyl-1-phenylpropan-1-ol (6c) 
Synthesis followed the general procedure of reducing β-ketosulfides to β-alkoxysulfides 
from 5c. Product obtained as white solid. Yield: 87%. 1H NMR (CDCl3) δ 7.99 (d, J = 8.1 Hz, 
1H), 7.81 (d, J = 7.6 Hz, 1H), 7.56 – 7.44 (m, 1H), 7.44 – 7.35 (m, 3H), 7.35 – 7.27 (m, 3H), 
4.95 (s, 1H), 1.58 (s, 3H), 1.41 (s, 3H) ppm. 13C NMR (CDCl3) δ 165.3, 152.6, 141.0, 136.1, 
128.1, 127.7, 127.7, 126.5, 125.2, 121.9, 121.1, 81.7, 60.1, 27.1, 24.1 ppm. HRMS (ESI): calcd. 
for C17H17NOS2Na
+ [M+Na]+ 338.0644, found 338.0663. 
1-(Benzo(d)thiazol-2-ylthio)-3-methylbutan-2-ol (6d) 
Synthesis followed the general procedure of reducing β-ketosulfides to β-alkoxysulfides 
from 5d. Product was obtained as clear oil. Yield: 90%. 1H NMR (CDCl3) δ 7.84 (d, J = 8.1 Hz, 
1H), 7.74 (d, J = 8.0 Hz, 1H), 7.48 – 7.37 (m, 1H), 7.37 – 7.27 (m, 1H), 4.37 (s, br, 1H), 3.76 
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(ddd, J = 8.2, 6.0, 2.5 Hz, 1H), 3.52 (dd, J = 14.4, 2.5 Hz, 1H), 3.38 (dd, J = 14.4, 7.9 Hz, 1H), 
1.88 (dq, J = 13.4, 6.7 Hz, 1H), 1.05 (d, J = 6.8 Hz, 3H), 1.00 (d, J = 6.8 Hz, 3H) ppm. 13C NMR 
(CDCl3) δ 168.0, 152.5, 135.4, 126.2, 124.6, 121.3, 121.0, 76.6, 38.8, 33.6, 18.7, 17.8 ppm. 
HRMS (ESI): calcd. for C12H16NOS2
+ [M+H]+ 254.0668, found 254.0660. 
cis-2-(benzo(d)thiazol-2-ylthio)cyclohexan-1-ol (6e) 
Synthesis followed the general procedure of reducing β-ketosulfides to β-alkoxysulfides 
from 5e. Both cis- and trans-products were obtained in about 5:4 ratio (according to crude 
NMR). Total yield: 91%. cis-product was characterized as below and used for further synthesis. 
1H NMR (CDCl3) δ 7.84 (d, J = 8.1 Hz, 1H), 7.73 (d, J = 7.9 Hz, 1H), 7.47 – 7.35 (m, 1H), 7.35 
– 7.27 (m, 1H), 4.38 – 4.23 (m, 1H), 4.23 – 4.08 (m, 1H), 2.15 – 2.01 (m, 1H), 1.92 (dtd, J = 
10.3, 6.4, 4.1 Hz, 1H), 1.85 – 1.67 (m, 3H), 1.64 – 1.49 (m, 2H), 1.49 – 1.33 (m, 1H). 13C NMR 
(CDCl3) δ 167.4, 152.7, 135.4, 126.2, 124.5, 121.4, 121.0, 70.2, 53.9, 31.5, 29.2, 23.9, 21.8 ppm. 
HRMS (ESI): calcd. for C13H15NOS2Na
+ [M+Na]+ 288.0487, found 288.0497. 
Trans-product characterization: 1H NMR (CDCl3) δ 7.86 (d, J = 8.1 Hz, 1H), 7.74 (d, J = 
7.9 Hz, 1H), 7.48 – 7.35 (m, 1H), 7.35 – 7.27 (m, 1H), 4.67 (s, 1H), 3.73 – 3.56 (m, 2H), 2.33 – 
2.14 (m, 2H), 1.84 – 1.72 (m, 2H), 1.66 – 1.29 (m, 4H) ppm. 13C NMR (CDCl3) δ 167.4, 152.5, 
135.6, 126.3, 124.7, 121.6, 121.0, 75.0, 55.6, 35.6, 32.2, 26.1, 24.1 ppm. HRMS (ESI): calcd. for 
C13H16NOS2
+ [M+H]+ 266.0668, found 266.0672. 
2-(Benzo(d)thiazol-2-ylsulfonyl)-1-phenylethan-1-ol (7a) 
Synthesis followed the general procedure of the oxidation of sulfide to sulfone from 6a. 
Product was obtained as white solid. Yield: 78%. 1H NMR (CDCl3) δ 8.28 – 8.17 (m, 1H), 8.09 – 
7.97 (m, 1H), 7.75 – 7.54 (m, 2H), 7.42 – 7.27 (m, 5H), 5.51 (dd, J = 9.7, 1.8 Hz, 1H), 3.94 (dd, 
J = 14.9, 9.7 Hz, 1H), 3.82 (dd, J = 14.9, 2.1 Hz, 1H), 3.59 (s, 1H) ppm. 13C NMR (CDCl3) δ 
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166.3, 152.4, 140.3, 136.7, 128. 9, 128.6, 128.3, 127.9, 125.7, 125.5, 122.4, 68.7, 63.0 ppm. IR: 
νmax/cm
-1 3347 (O-H), 2930 (C-H), 1334 (S=O) and 1141 (S=O). HRMS (ESI): calcd. for 
C15H13NO3S2
+ [M+H]+ 320.0410, found 320.0400. 
2-(Benzo(d)thiazol-2-ylsulfonyl)-1-phenylpropan-1-ol (7b) 
Synthesis followed the general procedure of the oxidation of sulfide to sulfone from 6b. 
Product was obtained as white solid. Yield: 23% 1H NMR (CDCl3) δ 8.33 – 8.18 (m, 1H), 
8.09 – 7.95 (m, 1H), 7.73 – 7.63 (m, 1H), 7.63 – 7.57 (m, 1H), 7.40 – 7.28 (m, 5H), 5.18 (d, J = 
9.1 Hz, 1H), 4.08 – 3.94 (m, 1H), 3.59 (d, J = 1.9 Hz, 1H), 1.13 (d, J = 7.2 Hz, 3H) ppm. 13C 
NMR (CDCl3) δ 166.0, 152.7, 139.5, 136.9, 128.9, 128.8, 128.1, 127.7, 127.1, 125.6, 122.3, 
74.0, 66.2, 11.9 ppm. IR: νmax/cm
-1 3484 (O-H), 2851 (C-H), 1313 (S=O), and 1137(S=O). 
HRMS (ESI): calcd. for C16H15NO3S2Na
+ [M+Na]+ 356.0386, found 356.0381. 
2-(Benzo(d)thiazol-2-ylsulfonyl)-2-methyl-1-phenylpropan-1-ol (7c) 
Synthesis followed the general procedure of the oxidation of sulfide to sulfone from 6c. 
Product was obtained as white solid. Yield: 35%. 1H NMR (CDCl3) δ 8.33 – 8.22 (m, 1H), 8.09 – 
7.99 (m, 1H), 7.72 – 7.56 (m, 2H), 7.39 – 7.27 (m, 5H), 5.54 (s, 1H), 1.54 (s, 3H), 1.22 (s, 3H) 
ppm. 13C NMR (CDCl3) δ 164.9, 152.8, 138.0, 137.3, 128.5, 128.2, 128.1, 128.0, 127.8, 125.7, 
122.2, 74.8, 70.4, 20.8, 14.4 ppm. IR: νmax/cm
-1 3335 (O-H), 1314 (S=O), and 1158 (S=O). 
HRMS (ESI): calcd. for C17H18NO3S2
+ [M+H]+ 348.0723, found 348.0718. 
1-(Benzo(d)thiazol-2-ylsulfonyl)-3-methylbutan-2-ol (7d) 
Synthesis followed the general procedure of the oxidation of sulfide to sulfone from 6d. 
Product was obtained as white solid. Yield: 70%. 1H NMR (CDCl3) δ 8.21 (dd, J = 7.5, 1.3 Hz, 
1H), 8.02 (dd, J = 7.1, 1.1 Hz, 1H), 7.71 – 7.51 (m, 2H), 4.19 (ddd, J = 9.0, 5.1, 2.1 Hz, 1H), 
3.68 (dd, J = 14.7, 2.1 Hz, 1H), 3.61 (dd, J = 14.7, 9.0 Hz, 1H), 1.91 – 1.73 (m, 1H), 0.96 (t, J = 
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6.7 Hz, 6H) ppm. 13C NMR (CDCl3) δ 166.4, 152.4, 136.6, 128.2, 127.8, 125.4, 122.4, 70.5, 
59.5, 33.5, 18.1, 17.1 ppm. IR: νmax/cm
-1 3540 (O-H), 2969 (C-H), 1304 (S=O), and 1126(S=O). 
HRMS (ESI): calcd. for C12H16NO3S2
+ [M+H]+ 286.0566, found 286.0561. 
cis-2-(benzo(d)thiazol-2-ylsulfonyl)cyclohexan-1-ol (7e) 
Synthesis followed the general procedure of the oxidation of sulfide to sulfone from 6e. 
Product was obtained as white solid. Yield: 79%. 1H NMR (CDCl3) δ 8.29 – 8.13 (m, 1H), 
8.09 – 7.93 (m, 1H), 7.72 – 7.51 (m, 2H), 4.59 (s, 1H), 3.59 – 3.43 (m, 1H), 3.29 (s, 1H), 2.20 – 
1.85 (m, 4H), 1.85 – 1.63 (m, 1H), 1.55 – 1.20 (m, 3H). 13C NMR (CDCl3) δ 165.5, 152.7, 136.9, 
128.2, 127.8, 125.5, 122.4, 67.2, 63.8, 32.5, 25.1, 19.5, 18.6 ppm. IR: νmax/cm
-1 3548 (OH) 2925 
(C-H), 1318 (S=O) and 1141 (S=O). HRMS (ESI): calcd. for C13H16NO3S2
+ [M+H]+ 298.0566, 
found 298.0565. 
 
2-(Benzo(d)thiazol-2-ylthio)-1-phenylpropyl acetate (8b) 
A solution of 6b (100 mg, 0.33 mmol) in 2 mL DCM was treated with Ac2O (0.09 mL, 1 
mmol), TEA (0.14 mL, 1 mmol), and N,N-dimethylaminopyridine (DMAP, 4 mg, 0.03 mmol) 
under stirring at room temperature. After 1 hour, the reaction mixture was directly dried under 
reduced pressure and purified by column chromatography (EA/Hex 1:20). Product was obtained 
as clear oil. Yield: 98%. 1H NMR (CDCl3) δ 7.89 (d, J = 8.1 Hz, 1H), 7.75 (dd, J = 7.9, 0.5 Hz, 
1H), 7.42 (dd, J = 11.2, 4.1 Hz, 3H), 7.38 – 7.27 (m, 4H), 5.98 (d, J = 7.1 Hz, 1H), 4.50 (p, J = 
7.1 Hz, 1H), 2.03 (s, 3H), 1.42 (d, J = 7.0 Hz, 3H) ppm. 13C NMR (CDCl3) δ 169.8, 165.6, 
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153.2, 137.5, 135.4, 128.6, 128.4, 127.3, 126.1, 124.4, 121.7, 121.0, 77.8, 48.3, 21.0, 18.1 ppm. 
HRMS (ESI): calcd. for C18H18NO2S2
+ [M+H]+ 344.0773, found 344.0768. 
2-(Benzo(d)thiazol-2-ylthio)-2-methyl-1-phenylpropyl acetate (8c) 
A solution of 6c (63 mg, 0.20 mmol) in 2 mL DCM was treated with Ac2O (0.06 mL, 0.60 
mmol), TEA (0.08 mL, 0.6 mmol), and DMAP (2 mg, 0.02 mmol) under stirring at room 
temperature. After 1 hour, the reaction mixture was directly dried under reduced pressure and 
purified by column chromatography (EA/Hex 1:20). Product was obtained as clear oil. Yield: 
90%. 1H NMR (CDCl3) δ 8.03 (d, J = 7.9 Hz, 1H), 7.80 (dd, J = 8.0, 0.5 Hz, 1H), 7.50 – 7.44 (m, 
1H), 7.44 – 7.27 (m, 6H), 6.36 (s, 1H), 2.08 (s, 3H), 1.60 (s, 3H), 1.51 (s, 3H) ppm. 13C NMR 
(CDCl3) δ 169.6, 162. 6, 153.7, 136.9, 136.4, 128.3, 128.2, 127.9, 126.2, 125.1, 122.8, 120.9, 
79.7, 56.4, 25.7, 24.3, 21.1 ppm. HRMS (ESI): calcd. for C19H19NO2S2Na
+ [M+Na]+ 380.0794, 
found 380.0761. 
2-(Benzo(d)thiazol-2-ylsulfonyl)-1-phenylpropyl acetate (9) 
Synthesis procedure followed the general procedure of the oxidation of sulfide to sulfone 
from 8b. Product obtained as pale white oil. Yield: 83%. 1H NMR (CDCl3) δ 8.27 (dd, J = 8.1, 
0.5 Hz, 1H), 8.03 (dd, J = 8.0, 0.6 Hz, 1H), 7.72 – 7.63 (m, 1H), 7.63 – 7.55 (m, 1H), 7.39 – 7.28 
(m, 5H), 6.05 (d, J = 9.7 Hz, 1H), 4.35 (dq, J = 9.7, 7.3 Hz, 1H), 1.53 (s, 3H), 1.26 (d, J = 7.3 
Hz, 3H) ppm. 13C NMR (CDCl3) δ 168. 7, 166.9, 152. 8, 136.7, 136.6, 129.2, 128.9, 128.1, 
127.8, 127.6, 125.5, 122.27, 74.9, 62.8, 20. 6, 10.6 ppm. IR: νmax/cm
-1 2941 (C-H), 1745 (C=O), 
1317 (S=O), 1221 (C-O), and 1145 (S=O). HRMS (ESI): calcd. for C18H18NO4S2
+ [M+H]+ 
376.0672, found 376.0666. 
2-(Benzo(d)thiazol-2-ylsulfonyl)-2-methyl-1-phenylpropyl acetate (10) 
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Synthesis followed the general procedure of the oxidation of sulfide to sulfone from 8c. 
Product was obtained as white solids. Yield: 85%. 1H NMR (CDCl3) δ 8.27 (d, J = 7.7 Hz, 1H), 
8.02 (d, J = 7.6 Hz, 1H), 7.69 – 7.62 (m, 1H), 7.60 (td, J = 7.7, 1.3 Hz, 1H), 7.36 – 7.24 (m, 5H), 
6.29 (s, 1H), 1.76 (s, 3H), 1.66 (s, 3H), 1.31 (s, 3H) ppm. 13C NMR (CDCl3) δ 168.7, 165.3, 
153.1, 137.3, 135.8, 128.8, 128.4, 128.1, 127.8, 127.7, 125.7, 122.2, 75.7, 69.1, 20.7, 20.3, 16.5 
ppm. IR: νmax/cm
-1 2992 (C-H), 1748 (C=O), 1312 (S=O) 1225 (C-O), 1153 (S=O). HRMS 
(ESI): calcd. for C19H19NO4S2Na
+ [M+Na]+ 412.0648, found 412.0651. 
 
2-(Benzo(d)thiazol-2-ylthio)-2-methyl-1-phenylpropyl propionate (15) 
A solution of 6c (150 mg, 0.48 mmol) was dissolved in 1 mL DCM. To the solution was 
added DMAP (6 mg, 0.05 mmol), TEA (0.13 mL, 0.96 mmol), and propionyl chloride (0.05 mL, 
0.58 mmol) sequentially under stirring. The reaction mixture was heated to 60 °C for 8 hours and 
then stirred at room temperature overnight. The reaction mixture was directly dried over reduced 
pressure and purified by column chromatography (EA/Hex 1:20). Product was obtained as clear 
oil. Yield: 52%. 1H NMR (CDCl3) δ 8.04 (d, J = 7.8 Hz, 1H), 7.80 (dd, J = 8.0, 0.5 Hz, 1H), 7.53 
– 7.27 (m, 7H), 6.38 (s, 1H), 2.48 – 2.27 (m, 2H), 1.61 (s, 3H), 1.52 (s, 3H), 1.15 (t, J = 7.6 Hz, 
3H) ppm. 13C NMR (CDCl3) δ 172.9, 162.6, 153.7, 137.1, 136.4, 128.2, 128.2, 127.9, 126.2, 
125.1, 122.8, 120.9, 79.4, 56.5, 27. 8, 25.6, 24.4, 9.1 ppm. HRMS (ESI): calcd. for 
C20H21NO2S2Na
+ [M+Na]+ 394.0906, found 394.0905. 
2-(Benzo(d)thiazol-2-ylsulfonyl)-2-methyl-1-phenylpropyl propionate (11) 
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Synthesis followed the general procedure of the oxidation of sulfide to sulfone from 11. 
Product was obtained as clear oil. Yield: 81%. 1H NMR (CDCl3) δ 8.26 (d, J = 7.7 Hz, 1H), 8.01 
(d, J = 7.6 Hz, 1H), 7.70 – 7.61 (m, 1H), 7.61 – 7.54 (m, 1H), 7.36 – 7.23 (m, 5H), 6.31 (s, 1H), 
2.02 – 1.79 (m, 2H), 1.76 (s, 3H), 1.30 (s, 3H), 0.89 (t, J = 7.5 Hz, 3H) ppm. 13C NMR (CDCl3) δ 
172.0, 165.3, 153.1, 137.2, 135.9, 128.8, 128.4, 128.1, 127.8, 127.7, 125.7, 122.1, 75.4, 69.1, 
27.3, 20.4, 16.5, 8.5 ppm. IR: νmax/cm
-1 2985 (C-H), 1746 (C=O), 1319 (S=O), 1151 (S=O). 
HRMS (ESI): calcd. for C20H21NO4S2Na
+ [M+Na]+ 426.0804, found 426.0821. 
 
2-(Benzo(d)thiazol-2-ylthio)-2-methyl-1-phenylpropyl pivalate (16) 
Compound 6c (200 mg, 0.63 mmol) and DMAP (7 mg, 0.06 mmol) were dissolved in 2 mL 
DCM. To this solution was added TEA (0.18 mL, 1.26 mmol) and pivaloyl chloride (0.09 mL, 
0.73 mmol) slowly under stirring. The reaction mixture was heated at 60 °C for 8 hours, then 
cooled to room temperature, and stirred overnight. The reaction mixture was diluted with 10 mL 
DCM, and washed with 8 mL water. The aqueous phase was back extracted with DCM (10 mL  
2). Combined organic phase was dried over Na2SO4, concentrated in vacuo, and purified by 
column chromatography (DCM/Hex 1:2 to 1:1 to pure DCM). Product was obtained as clear oil. 
Yield: 63%. 1H NMR (CDCl3) δ 8.03 (d, J = 7.8 Hz, 1H), 7.80 (dd, J = 8.0, 0.5 Hz, 1H), 7.52 – 
7.28 (m, 7H), 6.35 (s, 1H), 1.61 (s, 3H), 1.52 (s, 3H), 1.26 (s, 9H) ppm. 13C NMR (CDCl3) δ 
176.6, 162.6, 153.8, 137.1, 136.3, 128.2, 128.1, 127.8, 126.1, 125.0, 122.8, 120.9, 79.09, 56.7, 
39.0, 27.2, 25.5, 24.4 ppm. HRMS (ESI): calcd. for C22H26NO2S2
+ [M+H]+ 400.1399, found 
400.1384. 
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2-(Benzo(d)thiazol-2-ylsulfonyl)-2-methyl-1-phenylpropyl pivalate (12) 
Synthesis followed the general procedure of the oxidation of sulfide to sulfone from 15. 
Product yielded as white solid. Yield: 86%. 1H NMR (CDCl3) δ 8.32 – 8.20 (m, 1H), 8.09 – 7.93 
(m, 1H), 7.72 – 7.53 (m, 2H), 7.37 – 7.27 (m, 5H), 6.33 (s, 1H), 1.77 (s, 3H), 1.23 (s, 3H), 1.15 
(s, 9H) ppm. 13C NMR (CDCl3) δ 176.1, 164.6, 153.2, 137.3, 136.0, 128.8, 128.4, 128.1, 127.9, 
127.6, 125.8, 122.2, 74.9, 68.6, 38.8, 26.9, 21.6, 16.4 ppm. IR: νmax/cm
-1 2975 (C-H), 1734 
(C=O), 1321 (S=O), 1139 (S=O). HRMS (ESI): calcd. for C22H26NO4S2
+ [M+H]+ 432.1298, 
found 432.1284. 
 
2-(Benzo(d)thiazol-2-ylthio)-2-methyl-1-phenylpropyl 2-chloroacetate (17) 
Compound 6c (140 mg, 0.44 mmol) was dissolved in 5 mL DCM. To this solution was 
added TEA (0.11 mL, 0.80 mmol). The solution was cooled to 0 °C in ice bath. 2-Chloroacetyl 
chloride (0.04 mL, 0.50 mmol) was then added slowly to the solution. The reaction mixture was 
stirred at 0 °C for 90 min. Then 5 mL water was added into the reaction mixture. The aqueous 
layer was extracted with DCM (10 mL  3). Combined organic phase was washed with brine, 
dried over Na2SO4, concentrated, and purified by column chromatography (EA/Hex 1:40 to 
1:20). Product was obtained as clear oil. Yield: 50%. 1H NMR (CDCl3) δ 8.03 (dd, J = 8.1, 0.4 
Hz, 1H), 7.81 (dd, J = 8.0, 0.6 Hz, 1H), 7.53 – 7.45 (m, 1H), 7.45 – 7.28 (m, 6H), 6.54 (s, 1H), 
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4.10 (s, 2H), 1.61 (s, 3H), 1.51 (s, 3H) ppm. 13C NMR (CDCl3) δ 165.8, 162.3, 153.7, 136.2, 
136.1, 128.6, 128.1, 128.0, 126.2, 125.2, 122.8, 121.0, 81.2, 56.1, 41.0, 25.4, 24.1 ppm. HRMS 
(ESI): calcd. for C19H18ClNO2S2Na
+ [M+Na]+ 414.0360, found 414.0383. 
2-(Benzo(d)thiazol-2-ylsulfonyl)-2-methyl-1-phenylpropyl 2-chloroacetate (18) 
Synthesis followed the general procedure of the oxidation of sulfide to sulfone from 16. 
Product was obtained as white solid. Yield: 88%. 1H NMR (CDCl3) δ 8.35 – 8.17 (m, 1H), 8.10 – 
7.91 (m, 1H), 7.76 – 7.56 (m, 2H), 7.42 – 7.27 (m, 5H), 6.41 (s, 1H), 3.88 – 3.68 (m, 2H), 1.73 
(s, 3H), 1.31 (s, 3H) ppm. 13C NMR (CDCl3) δ 165.2, 164.7, 153.0, 137.3, 134.8, 129.2, 128.6, 
128.3, 127.9, 127.8, 125.7, 122.3, 77.1, 69.0, 40.8, 20.4, 16.3 ppm. IR: νmax/cm
-1 2989 (C-H), 
1743 (C=O), 1313 (S=O), 1152 (S=O). HRMS (ESI): calcd. for C19H18ClNO4S2Na
+ [M+Na]+ 
446.0258, found 446.0271. 
2-(Benzo(d)thiazol-2-ylsulfonyl)-2-methyl-1-phenylpropyl dimethylglycinate (13) 
Compound 17 (100 mg, 0.24 mmol) was dissolved in 5 mL acetone and added with K2CO3 
(66 mg, 0.48 mmol). Dimethylamine (2.0 M in methanol, 0.24 mL, 0.48 mmol) was added into 
this solution and then the reaction mixture was stirred overnight. Subsequently, the reaction 
mixture was filtered. The filtrate was concentrated under reduced pressure. Residue was purified 
by column chromatography (EA/Hex 1:4 to 1:1). Product was obtained as yellowish solid. Yield: 
62%. 1H NMR (CDCl3) δ 8.27 (d, J = 7.8 Hz, 1H), 8.01 (d, J = 7.5 Hz, 1H), 7.72 – 7.62 (m, 1H), 
7.62 – 7.50 (m, 1H), 7.36 – 7.26 (m, 5H), 6.33 (s, 1H), 2.86 (d, J = 16.9 Hz, 1H), 2.71 (d, J = 
16.9 Hz, 1H), 2.14 (s, 6H), 1.76 (s, 3H), 1.30 (s, 3H) ppm. 13C NMR (CDCl3) δ 168.5, 165.2, 
153.1, 137.2, 135.6, 128.9 128.4 128.1, 127.85, 127.7 125.8 122.2, 75.5, 69.0, 59.6, 44.9, 20.5, 
16.4 ppm. IR: νmax/cm
-1 2934 (C-H), 1742 (C=O), 1320 (S=O), 1110 (S=O). HRMS (ESI): calcd. 
for C21H25N2O4S2
+ [M+H]+ 433.1250, found 433.1244. 
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1.3.2.3 Confirmation of SO2 release by DTNB test 
DTNB test was adopted from a published method.86 7b and 7c were prepared as 500-μM 
DMSO stock solutions. DTNB was prepared as 15-mM EtOH stock solution. NaHSO3 as 
positive control was prepared as a 1-mM PBS (pH 7.4) stock solution and stored on ice before 
use. 2-OHBT and 2-methyl-1-phenyl-propene as negative controls were prepared as 500-μM 
DMSO stock solutions respectively. 
Each group (200 μL total volume) was prepared by adding 20 μL stock solution into the 
wells of a 96-well plate followed by addition of 180 μL PBS. Each final solution contained 10% 
DMSO. The plate was incubated at 37 °C for 0.5 h with gentle shaking on a Barnstead shaker. 
Then 20 μL DTNB was added into each well. After incubating at room temperature for another 
15 min, the UV absorption was read by a PerkinElmer multiplate reader at 405 nm (n=3). 
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Figure 1-17 DTNB test results. 
 
1.3.2.4 Kinetics study of compound 7a-e by HPLC 
Compounds 7a-d were prepared as 500-μM DMSO stock solution at room temperature. 
Test solution (50 μM) was prepared in 8 mL glass vial by adding 200 μL of a DMSO stock 
solution into 1800 μL PBS and the resulting solution was incubated immediately in a water bath 
at 37 °C. 100 μL of samples for analysis were taken at random time points (n = 10) and were 
mixed with 300 μL ACN in a 1.5-mL eppendorf tube and stored at -80 °C. Frozen samples were 
thawed and centrifuged with benchtop microcentrifuge shortly to allow salt precipitation. 
Supernatant was subjected to HPLC analysis. Standards of 2-OHBT, styrene, and substituted 
styrenes were purchased from commercial vendors. kobs was calculated using 2-OHBT peak 
areas. All kinetic runs were in triplicates. Curve fitting was conducted using the SigmaPlot 10 
software (Figure 1-18).  
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HPLC conditions: 
Binary solvent system: Solvent A: H2O with 0.05% TFA; Solvent B: ACN 
Gradient elution: Solvent B 15% to 60% 
UV detector wavelength: 254 nm 
Injection volume: 20 μL 
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Figure 1-18 Kinetics studies of compounds 7a-e by measuring 2-OHBT peak areas using 
HPLC 
(
A) 
(
B) 
7
a 
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 (A) An example of HPLC chromatogram obtained by HPLC. Chromatogram showing 50 μM 7a 
in 10% DMSO/PBS (pH 7.4) at 37 °C at the 120-min time point. Peak at 3.992 min: 2-OHBT; 
peak at 7.652 min: compound 7a; peak at 9.086 min: styrene. (B) Examples of first-order 
reaction monitored by measuring 2-OHBT peak areas. Upper left: 7a; upper right: 7b; lower 
left: 7c; lower right: 7d.  
 
Compound 7e was prepared as a 20-mM DMSO stock solution at room temperature. Test 
solution (200 μM) was prepared in 1.5 mL eppendorf tube by adding 10 μL of the DMSO stock 
solution into 990 μL PBS followed by incubation in a water bath at 37 °C. Samples for HPLC 
analyses were taken at random time points and subjected to HPLC analysis directly. 2-OHBT 
standard was pretested for retention time (~3.8 min). Kinetic runs were in triplicates (Figure 1-
19). 
HPLC conditions: 
Binary solvent system: Solvent A: H2O with 0.05% TFA; Solvent B: ACN 
Gradient elution: Solvent B 15% to 40% 
UV detector wavelength: 254 nm 
Injection volume: 20 μL 
 
 
 
0 min: 
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196 min: 
 
Overlay (0~196 min): 
 
Figure 1-19 An example of reaction of 7e monitored by HPLC. Peaks at 8.87~8.88 min: 
compound 7e 
 
1.3.2.5 Stability study of compound 9, 10, and 13 by HPLC 
Compound 9 was prepared as a 5-mM DMSO stock solution at room temperature. Test 
solution (50 μM) was prepared in a 1.5 mL eppendorf tube by adding 10 μL of the DMSO stock 
solution into 990 μL PBS followed by incubation at 37 °C in a water bath. Samples for HPLC 
analysis were taken at random time points (n = 10) and subjected to HPLC analysis directly. 
Stability tests were in duplicates (Figure 1-20).  
HPLC conditions: 
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151 min 
Binary solvent system: Solvent A: H2O with 0.05% TFA; Solvent B: ACN 
Gradient elution: Solvent B 15% to 60% 
UV detector wavelength: 254 nm 
Injection volume: 20 μL 
 
Figure 1-20 An example of stability tests of compound 9 monitored by HPLC 
Peaks at 10.07~10.08 min: compound 9; shoulder peaks and peaks at 10.87~10.89 min: 
elimination product. 
 
Compound 10 was prepared as 100-μM DMSO stock solution at room temperature. Test 
solution (10 μM) was prepared in an 8-mL glass vial by adding 500 μL of the DMSO stock 
solution into 4.5 mL PBS followed by incubation at 37 °C in a water bath with stirring. Samples 
for HPLC analysis were taken at random time points (n = 5) and subjected to HPLC analysis 
directly. Stability tests were in duplicates (Figure 1-21).  
HPLC conditions: 
Binary solvent system: Solvent A: H2O with 0.05% TFA; Solvent B: ACN 
Gradient elution: Solvent B 15% to 60% 
0 min 
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UV detector wavelength: 254 nm 
Injection volume: 20 μL 
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0 min: 
 
86 min: 
 
240 min: 
 
Overlay (0~240 min): 
 
Figure 1-21 An example of stability tests of compound 10 monitored by HPLC 
Peaks at 10.60~10.61 min: compound 10 
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A 5-mM stock solution of Compound 13 was prepared at room temperature in DMSO. 
Test solution (50 μM) was prepared in an 8-mL glass vial by adding 20 μL of the DMSO stock 
solution into 1980 μL of PBS followed by incubation at 37 °C in a water bath. Samples for 
HPLC analysis were taken at random time points (n = 5) and subjected to HPLC analysis 
directly. Stability tests were in duplicates (Figure 1-22).  
HPLC conditions: 
Binary solvent system: Solvent A: H2O with 0.05% TFA; Solvent B: ACN 
Gradient elution: Solvent B 15% to 60% 
UV detector wavelength: 254 nm 
Injection volume: 20 μL 
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0 h: 
 
48 h: 
 
97 h: 
 
Figure 1-22 An example of stability studies of compound 13 monitored by HPLC 
Peaks at 3.94~3.95min: 2-OHBT; peaks at 7.07~7.17 min: compound 13; peaks at 11.62~11.63 
min: 2-methyl-1-phenyl-propene. 
 
1.3.2.6 Kinetics study of esterase-triggered SO2 release of compound 10-13 by HPLC 
Stock solutions (500 μM) of compounds 10-13 were prepared in DMSO at room 
temperature. Porcine liver esterase (PLE, 18 unit/mg) was prepared as 0.1 unit/μL PBS stock 
solution. Test solution (50 μM with 5 unit/mL PLE) was prepared in an 8-mL glass vial by first 
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adding 200 μL of the DMSO stock solution into 1700 μL of PBS and thoroughly mixed. Then to 
the solution was added 100 μL of the PLE stock solution followed by incubation at 37 °C in a 
water bath. 100 μL samples for analysis were taken every 10 minutes (n=12) and mixed with 300 
μL ACN in a 1.5-mL eppendorf tube and stored at -80 °C. Frozen samples were thawed and 
centrifuged with benchtop micro-centrifuge at 14.5×103 rpm for 4 min to allow esterase and salt 
to precipitate. Supernatant was subjected to HPLC analysis. 2-OHBT, styrene, and substituted 
styrenes were used as standard and pre-tested for retention time. All kinetic runs were in 
triplicates. Microsoft Excel was used for plotting. Kinetics studies of the esterase-triggered SO2 
release from compound 13 in 1% DMSO/PBS with 1 unit/mL PLE used the same method. Stock 
solutions were prepared accordingly. 
HPLC conditions: 
Binary solvent system: Solvent A: H2O with 0.05% TFA; Solvent B: ACN 
Gradient elution: Solvent B 15% to 60% 
UV detector wavelength: 254 nm 
Injection volume: 20 μL 
1.3.2.7 Kinetics studies of esterase-triggered SO2 release from compound 10-13 as examined 
with fluorescent probe 14 
Standard curve: 
500 μM probe 14 DMSO stock solution was prepared at room temperature. NaHSO3 
solutions of different concentrations were prepared in PBS. The test solution was prepared in a 4 
mL (10 mm×10 mm) quartz cuvette by adding 300 μL probe DMSO stock solution into 2700 μL 
NaHSO3 solution. Final solution contains 50 μM probe 14 and 10% DMSO. The test solution 
was sealed with a cap, thoroughly mixed, and incubated at room temperature for 2 min. 
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Fluorescent emission at 465 nm was then recorded on a Shimadzu RF- 5301PC fluorimeter. 
(λex=400 nm; slit width: ex: 5nm, em: 3 nm) Experiments were conducted in triplicates. Standard 
curves were fitted with Microsoft Excel 2016 (Figure 1-23 (A)). 
Studies of reaction kinetics: 
Stock solutions (1 mM) of compounds 10-13 were prepared in DMSO at room 
temperature. PLE (18 unit/mg) was prepared as 0.1 unit/μL PBS stock solution. Probe 14 was 
prepared as 1 mM DMSO stock solution. Test solution (50 μM prodrug with 50 μM probe and 5 
unit/mL PLE) was prepared by adding 150 μL of the prodrug DMSO stock solution, 150 μL of 
the probe 14 DMSO stock solution, 2550 μL of PBS, and 150 μL PLE stock solution 
sequentially into a 4 mL (10 mm×10 mm) quartz cuvette. The test solution was sealed with a 
cap, and thoroughly mixed; and fluorescent emission at 465 nm was recorded every 10 minutes 
(n=13) (λex=400 nm; slit width: ex: 5nm, em: 3 nm). Fluorescence intensities obtained were 
converted to NaHSO3 concentrations using the standard curve described above. All runs were in 
triplicates (Figure 1-23(B)). 
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              (A) 
 
              (B) 
 
Figure 1-23 Kinetics study of esterase-triggered SO2 release from compound 10-13 by 
fluorescent probe 14. 
(A) Standard curve. (B) Kinetics of esterase-triggered SO2 release from compounds 10-13 
monitored with fluorescent probe 14. 
 
1.3.2.8 Cell imaging study 
Cell culture: 
HeLa cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10 % fetal bovine serum and 1% penicillin-streptomycin at 37 °C with 5 % 
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CO2. The media was changed every other day. Experiment was done within 10 passages of Hela 
cells. 
Cell imaging: 
HeLa cells were pre-seeded onto coverslips in 6-well plate a day before experiment. A 2-
mM DMSO stock solution of probe 14 was prepared. Compound 13 was prepared as 20-mM 
DMSO stock solution. Cells were first treated with compound 13 to make a final concentration 
of 100 μM (0.5% DMSO). 400 μM NaHSO3 was used as a positive control. A mixture 
containing 100 μM 2-OHBT and 100 μM 2-methyl-1-phenyl-propene was used as the negative 
control. Cell only group was also used as negative controls. All final media contained 0.5% 
DMSO. The cells were incubated at 37 °C for 2 hours and washed with PBS once. 2 mL of fresh 
DMEM media was added into each well. The cells were then treated with probe 14 to give a final 
concentration of 10 μM. Cells were incubated for another 0.5 h at 37 °C. After washing twice 
with PBS, the cells were fixed with 4% paraformaldehyde for 30 min at room temperature. The 
cells were then washed once with PBS. Then 25 mM glycine in PBS was added to quench the 
extra formaldehyde. After storing at 4 °C overnight. The glycine solution was discarded. All 
coverslips were immersed in DI water and mounted onto glass slides using DAPI-free mounting 
media (ProLong Live Antifade Reagent; P36974). Fluorescent imaging was performed on a 
Zeiss fluorescent microscope using the DAPI channel (λex: 358 nm, λem: 461 nm). 
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2  DESIGN AND SYNTHESIS OF PRODRUGS OF THIAMINE MONOPHOSPHATE 
MIMICS AS PYRUVATE DEHYDROGENASE KINASE INHIBITORS 
2.1 Introduction 
An increased glucose uptake followed by fermentation to lactate is the most common 
feature of metabolism change of cancer cells. This effect was named as “Warburg effect” after its 
discoverer Otto Warburg.100 Unlike the upregulation of fermentation in normal cells as a 
response to hypoxia environment, excessive fermentation was observed in many cancer cells 
even in the presence of oxygen and was thus termed as “aerobic glycolysis” by Warburg and his 
colleagues.101 Though early thought to result from damaged mitochondrial function, Racker and 
colleagues later revealed that the aerobic glycolysis also exists in presence of fully functional 
mitochondria.100 Despite the recent advances of genetic and pharmacological study, well 
accepted explanation of its origin remains unavailable. Nevertheless, several hypotheses have 
been put forward to give some rationale of this effect.102 Although “uneconomic” in terms of 
glucose consumption, the ATP production rate of glycolysis is 10 to 100 times faster than 
mitochondrial oxidative phosphorylation, affording a comparable rate to compensate the energy 
demand of cancer cell growth.103 This fast consumption of glucose can also provide cancer cells 
advantage to compete for more glucose, providing carbon source for biosynthesis of nucleotides, 
lipids, proteins, and most importantly NADPH, which is in greater need than ATP in cell 
proliferation.104-105 Moreover, the acidification of the microenvironment caused by increase 
production of lactate can facilitate cancer cell metastasis by altering the tumor-stroma interface 
while competition for glucose would suppress the function of tumor-infiltrating lymphocytes 
(TIL), whose function is to kill tumor cells.106-107  
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The alteration of cancer cell energy metabolism has provided potential targets for cancer 
therapy. The decreased activity of thiamine-dependent enzyme - pyruvate dehydrogenase 
complex (PDC, PDH complex) is one of the most critical steps that regulate the enhanced 
glycolytic activity in cancer cells. PDC converses pyruvate into carbon dioxide and acetyl-CoA 
through pyruvate decarboxylation while producing NADH. A reduced activity of PDC will limit 
the carbon flux into the tricarboxylic acid (TCA) cycle and force glucose carbons into lactic acid 
fermentation.108 
2.1.1 PDC structure and function 
Human PDC is a large enzyme consisting of multiple copies of six major components: 
pyruvate dehydrogenase (PDH, E1), dihydrolipoyl transacetylase (E2), dihydrolipoyl 
dehydrogenase (E3), E3 binding protein (E3BP), and two regulatory enzymes: pyruvate 
dehydrogenase kinase (PDK) and pyruvate dehydrogenase phosphatase (PDP).109-110 The 
complex structure is organized around a scaffold of E2 that allows pyruvate to go through 
sequential reactions in the complex to produce CO2 and acetyl-CoA (Figure 2-1). PDH is an α2β2 
heterotetramer with two active sites that catalyze the decarboxylation of pyruvate under the 
assistance of thiamine pyrophosphate (TPP, or vitamin B1) to produce CO2. It also catalyzes the 
reductive acetylation of the lipoyl groups of E2. Sequentially, E2 transfers the acetyl group to 
coenzyme A to form acetyl-CoA. E3 catalyzes the electron transfer from the dihydrolipoyl 
moieties of E2 to FAD+. FADH2 will be oxidized back to FAD
+ while reducing NAD+ to NADH. 
The overall reaction catalyzed by PDC is as follows: 111 
CH3COCOOH + CoASH + NAD
+
 → CH3COSCoA + NADH + H
+ + CO2 
In this process, the decarboxylation step catalyzed by PDH is the rate-limiting step.111-112  
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Figure 2-1 Reactions catalyzed by PDC 
 
2.1.2 PDC regulation by PDK and PDP 
The activity of mammalian PDC is primarily regulated by reversible phosphorylation of 
PDH by PDK and PDP.111-112 PDK attaches to one of the two lipoyl domains (L2) of E2 to reach 
PDH core and inactivates PDH by phosphorylating one or more of its three serine residues (site 
1: Ser-293, site 2: Ser-300, and site 3: Ser-232) on the α subunit of PDH.113 Phosphorylation of 
site 1 is the fastest and most well-known mechanism of deactivating PDC, while reactivation of  
PDC by PDP dephosphorylation are of similar rates at all three sites.114 
Mammalian PDK family consists of four isozymes (PDK1, PDK2, PDK3, and PDK4) 
with varied tissue distribution. PDK1 is mainly expressed in heart; PDK3 is primarily expressed 
in testis; PDK2 is universally expressed in all tissues only with lower level in spleen and lung; 
PDK4 was found in skeletal muscle and heart.115 An elevated level of PDK1 expression has been 
E1 
E2 
E3 
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observed in various cancer cells such as breast, head and neck, and lung cancers.116-117 The 
tissue-specific distribution of PDK isoenzymes would provide potential targets for treating 
diabetes, heart ischemia, and cancer.110, 118 Knock-down of PDK1 will result in restored PDH 
activity and glucose oxidation, as well as reduced lactate production and suppressed tumor 
growth.119 Despite the tissue distribution specificity, PDK isozymes also showed site selective 
phosphorylation on the PDH serine residues. Site 1 and site 2 can be phosphorylated by all four 
isozymes, while site 3 can only be phosphorylated by PDK1.120  
Inhibition of PDC activity by PDK are associated with many physiological and 
pathophysiological processes such as lactic acidosis, diabetes, cerebrovascular and 
cardiovascular diseases, late-onset neurodegenerative diseases, pulmonary arterial hypertension, 
aging, and cancer.121 The activity of PDK isozymes can be stimulated by ATP, NADH, and 
acetyl-CoA with different sensitivity, while pyruvate and ADP can inhibit PDK activity.114 PDK 
family also serves as direct transcriptional target of hypoxia inducible factor 1α (HIF1α), which 
is upregulated in hypoxic tumor cells.122-124 Therefore, the overexpression of PDK is adopted by 
cancer cells to inactivate PDH as an important way to guarantee cancer cells’ survival. 
2.1.3 PDK inhibition for cancer therapy 
The fact that PDK expression and activity can be upregulated by HIF1α and 
downregulated by tumor suppressor protein p53 further supported the important role PDK plays 
in cancer development.125 Inhibition of PDK-mediated phosphorylation of PDH has been 
considered a promising way for reducing cancer cell proliferation.121, 126-127 Restoring PDH 
activity by blocking PDK-regulated deactivation can lead to normalized glycolysis and redirect 
glucose carbons into TCA cycle, forcing the production of ROS by mitochondria, which in turn 
leads to HIF1α downregulation and apoptosis.126 On the other hand, decreased production of 
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lactate through glycolysis may limit the biosynthesis of nucleotides, which may also lead to 
growth inhibition of cancer cells. Moreover, PDK overexpression in cancer cells provides an 
opportunity to target PDK activity selectively to avoid cytotoxicity towards normal tissue.128  
Compounds that can inhibit PDK activity would help to re-establish PDH activity in 
cancer cells and inhibit cell proliferation. It has been demonstrated both in vitro and in vivo that 
inhibiting PDK activity will lead to decreased viability in multiple types of cancer cells.129-130 
Despite substrate-level regulation by pyruvate, NAD+, and CoA, many PDK inhibitors have been 
reported so far targeting four binding sites: pyruvate binding site, lipoamide binding site, and 
allosteric site located in the regulatory N-terminal R domain, and an nucleotide binding site 
(Figure 2-2).114, 121 
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Figure 2-2 Representative PDK inhibitors 
2.1.3.1 Dichloroacetate (DCA) 
Dichloroacetate (DCA) is the first PDK inhibitor developed into clinical use for treatment 
of multiple PDC deficiency diseases including type 2 diabetes, hyperlipoproteinemias, 
myocardial ischemia and failure, and lactic acidosis.121, 131 In recent years, DCA has also shown 
profound effect in inhibiting tumor cell growth in a number of cancer cell lines including breast, 
endometrial, lung, and colorectal by acting as a pyruvate mimic.126-128, 132-133 DCA was shown to 
be able to bind to two sites on PDK: the pyruvate binding pocket, which would adversely affect 
the binding of PDK to PDC;134 and the allosteric site, which would cause conformational 
changes to the nucleotide and lipoamide binding sites.135-136 DCA can be well tolerated by 
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human only with minor reversible effects on the nervous system and liver upon chronical 
administration.137 Upon oral or parenteral administration, DCA can be rapidly absorbed and  can 
penetrate the blood-brain barrier. As a result, DCA was therefore widely investigated on human 
glioblastoma (GBM) cells, which is the most prevalent and malignant form of brain tumor.121 
Besides its stimulating effect on tumor oxygen consumption,  it was reported that DCA can also 
inhibit mitochondrial fatty acid β-oxidation, which would lead to inhibition of endothelial cell 
growth.138  
Despite the great academic interest in its potential as an anti-cancer agent, DCA in its 
original form received little investment from the pharmaceutical industry, since it is no longer 
patentable after its debut in the public more than 30 years ago. Therefore, many DCA prodrugs 
with multi-molar DCA loading and DCA mimics have been reported over the years (Figure 2-2). 
For example, 2-chloroproprionate replaced one chlorine in DCA with a methyl group; Mitaplatin 
contains two molecules of DCA bound to cisplatin; Mito-DCA contains 3 molecules of DCA and 
a mitochondria-targeting triphenylphosphonium moiety. (Figure 2-2) Besides patentability 
interest, such modifications would also provide improved drug properties such as higher potency 
and increased stability.121 
2.1.3.2 Thiamine and analogues as PDK inhibitors  
Thiamine, also known as vitamin B1, is an important dietary supplement that can be 
found in many food sources such as whole grains, meat, and fish. Cellular uptake of thiamine is 
through active transportation by thiamine transporters (THTRs). In mammalian cells, thiamine 
can be di-phosphorylated by thiamine diphosphokinase to produce thiamine pyrophosphate 
(TPP), which is an important coenzyme for several enzymes. Therefore, thiamine is regarded as 
the transport form of TPP to allow transmembrane delivery.139 TPP is also a coenzyme of PDH, 
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whose function is essential for PDH catalyzed trans-acetylation. (Figure 2-1) It has been reported 
that binding of TPP to PDH alters the rate and stoichiometry of phosphorylation of the individual 
sites.120 TPP decreased both the rate and extent of PDH phosphorylation by PDK isoforms. 
Therefore, increased TPP concentration may help restore PDH activity. Previous research from 
Cascante’s group showed that thiamine demonstrated a dichotomous effect that stimulates cancer 
cell growth at low concentration (12.5 to 75 times of recommended daily allowance, 20 μg/kg) 
and inhibits cell growth at high concentration (above 75 times of recommended daily 
allowance).140 Also reported by our collaborator, Dr. Jason Zastre’s group, high-dose thiamine 
decreased proliferation in a mechanism similar to that of DCA by reducing phosphorylation of 
PDH.141 Thiamine showed lower IC50 in both  SK-N-BE (4.9 mM) and Panc-1 (5.4 mM) cell 
lines, when compared with DCA (23.8 for SK-N-BE and 10.3 mM for Panc-1).  Moreover, as a 
dietary supplement, thiamine can be very well tolerated by human that an oral dosage as high as 
1.5g/day showed no adverse effects in healthy patients.142 Therefore, thiamine analogues with 
PDK inhibitory potency would provide a new strategy to target cancer cell metabolism. 
2.2 Results and discussion 
PDK has four isoenzymes: PDK1, PDK2, PDK3, and PDK4. Evaluation of the amino 
acid sequences of the isozymes proved that the ATP binding pockets of the isozymes are 
identical despite minor differences of tertiary structures. PDK1 and PDK4 possess complete ATP 
binding site structure and are therefore suitable for binding modeling assays. Moreover, 
increased expression of PDK1 is observed in multiple types of cancer cells. Therefore, PDK1 
would be the most suitable isozyme for anticancer study.  Previously in our group, four novel 
thiamine analogues (BW-VB-1 to BW-VB-4, Table 2-1) were designed and tested in silico 
against PDK1. Two of the analogues – BW-VB-3 and BW-VB-4 showed good potency in 
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docking studies with docking score of 5.9 and 5.45, respectively, indicating the best binding 
affinity towards PDK1. We further expanded the data base to 19 analogues in collaboration with 
Dr. Bowen Ke’s group (BW-VB-1 to BW-VB-19, Table 2-1). Modifications have been made on 
the pyrimidine ring and ethanolic chain, while the thiazolium ring was replaced by triazole ring. 
The principle of making such modifications is to introduce enough structural difference to allow 
binding optimization. The synthesized analogues were tested against HCT116 cells for inhibitory 
effect. To our disappointment, these thiamine analogues demonstrate only limited inhibitory 
effect on cancer cell proliferation with the lowest IC50 being 0.612 mM (BW-VB-13).  
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Table 2-1 IC50 of first-batch thiamine analogues 
Compound Structure 
IC50 
(mM) 
Compound Structure 
IC50 
(mM) 
Thiamine 
 
>1 BW-VB-10 
 
>1 
BW-VB-1 
 
5.923 BW-VB-11 
 
>1 
BW-VB-2 
 
>10 BW-VB-12 
 
0.725 
BW-VB-3 
 
7.82 BW-VB-13 
 
0.612 
BW-VB-4 
 
6.23 BW-VB-14 
 
0.828 
BW-VB-5 
 
1.09 BW-VB-15 
 
0.875 
BW-VB-6 
 
3.32 BW-VB-16 
 
>1.0 
BW-VB-7 
 
1.026 BW-VB-17 
 
>1.0 
BW-VB-8* 
 
>1 BW-VB-18 
 
0.814 
BW-VB-9* 
 
>1 BW-VB-19 
 
>1.0 
Note:* Compounds were tested against Panc-1 cell line. 
We hypothesize that the low inhibitory effect may be caused by a lack of phosphorylation 
of the analogues. In silico binding assay indicates phosphorylated thiamine analogue would have 
much higher binding affinity to PDK compared with respective non-phosphorylated analogue. 
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Since kinases that can phosphorylate thiamine could be selective towards thiamine structure, the 
analogues may not be able to be phosphorylated inside the cell. In this case, we could either 
screen thiamine analogues that serve as substrate for specific kinases, or we would directly 
deliver phosphorylated thiamine analogues. The first method can be very time and effort 
consuming considering the possibility that the substrates of thiamine diphosphokinase and PDK 
inhibitor may not share the same structure(s). While the second method is also problematic since 
phosphorylated thiamine analogue may not be permeable enough to cross cell membrane due to 
the high polarity introduced by a phosphate group. To address this problem, we turned to 
phosphate prodrug strategy that have been widely applied in delivery of antiviral nucleoside 
phosphates and phosphonates.143 (Figure 2-3)  
 
Figure 2-3 Prodrug strategy to deliver phosphorylated thiamine analogue into the cell 
 
To test this idea, we planned to attach a phosphate moiety on the hydroxyl group of each 
of the thiamine analogues to better mimic the binding mode of thiamine metabolites. To mask 
the charges on phosphate group, the free phosphate groups were attached with prodrug moieties. 
(Figure 2-4) Once the molecule is delivered into the cell, prodrug moiety can be cleaved either 
by enzyme mediated hydrolysis or by spontaneous hydrolysis. Then phosphorylated thiamine 
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analogue would be released. The high polarity of free phosphate would prevent the drug 
molecule from permeating out of the cell, which would allow better interaction with intracellular 
target(s).  
We used several thiamine analogues as the “drug” part and attached different phosphate 
prodrug moieties on the hydroxy group. We picked three phosphate prodrug approaches with 
synthetic ease and proved release efficiency: 1. bis(S-acyl-2-thioethyl), bis(SATE); 2. 
aryloxyphosphoramidate, ProTide; 3. (bis(pivaloyloxymethyl), bis(POM). Besides, we made a 
small modification on the SATE moiety and obtained a carbonothionate structure (2-(t-
butoxycarbonylthio)ethoxyl, BOCTE). We expected this structure to be less stable under 
physiological condition and be more susceptible to hydrolysis compared with SATE prodrugs. 
(Figure 2-4) The phosphate prodrug moieties were attached to the hydroxyl group of the 
respective alkyne following literature reported procedure with necessary modification.144-145 
(Figure 2-4) The prodrugs were then assembled through copper(I)-catalyzed “click” reaction 
with 5-(azidomethyl)-2,4-dimethoxypyrimidine. The resulted prodrugs were subjected to cell 
proliferation assay using HCT116 cells. (Table 2-2) 
 
Figure 2-4 Prodrug structures 
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From cell proliferation assay results, we can see that compared with the thiamine 
analogues without phosphate groups, the phosphate prodrugs demonstrated significantly higher 
inhibitory effects against cancer cell lines that the drug itself. Several compounds have shown 
IC50 lower than 100 μM, indicating a >10 times higher potency than the corresponding thiamine 
analogues. The inhibitory potency demonstrated by the prodrugs seems to have little connection 
with their parental drug. Comparing different prodrug strategies, SATE prodrugs and POM 
prodrugs showed the best inhibitory effects in general. This advantage could be the result from 
the chemical stability of the prodrug moieties that SATE and POM prodrugs are more prone to 
release phosphate drugs under tested conditions. It is also possible that the side products 
associated with these two prodrug moieties have certain cytotoxicity. Different prodrug moieties 
may also cause varied uptake efficiency of the prodrugs by the cells. The results confirmed our 
hypothesis that the phosphate prodrug strategy could increase the potency of thiamine analogues.  
To better understand the inhibitory mechanism, more specific research is going on in Dr. 
Zastre’s lab. Candidate optimization is an iterative process. It is important to build structure-
activity relationship (SAR) to allow better understanding of the binding between phosphorylated 
thiamine analogues and PDK. These problems will be further investigated in the future. 
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Table 2-2 IC50 of phosphate prodrugs of thiamine analogues 
Thiamine 
analogue/IC50 
Structure 
Compound # (BW-VB-#) /IC50 (mM) 
SATE 
prodrug 
BOCTE 
prodrug 
ProTide 
prodrug 
(Type A) 
ProTide 
prodrug 
(Type B) 
POM 
prodrug 
BW-VB-2/ >10 
 
29/0.04 -- 30/0.107 41/0.336 31/0.081 
BW-VB-3/7.82 
 
27/0.085 -- 34/>0.25 40/0.656 28/0.075 
BW-VB-8/ >1 
 
21/0.049 23/0.111 26/0.1 -- -- 
BW-VB-11/ >1 
 
20/0.060 22/0.105 24/0.248 -- 25/0.044 
BW-VB-14/0.828 
 
35/0.088 -- 42/0.624 -- -- 
BW-VB-39/>1 
 
32/0.043 -- -- -- 33/0.045 
BW-VB-43/0.339 
 
44/0.126 45/0.256 46/0.557 47/0.501 -- 
 
2.3 Experimental procedures 
2.3.1 Materials and Methods 
All reagents and chemicals were purchased from commercial suppliers as reagent grade 
or higher and were used without further purification unless otherwise noted. NMR spectra were 
recorded on a Bruker Avance NMR spectrometer at 400 MHz for 1H, 101 MHz for 13C, and 162 
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MHz for 31P at room temperature unless otherwise specified. Solvent peaks were used as 
internal standards. Mass spectral analyses were performed by the GSU Mass Spectrometry 
Facilities. The synthesis of compounds BW-VB-1 to BW-VB-7 were previous reported by Dr. 
Hieu Dinh in his Master thesis.146  Compound BW-VB-12 to BW-VB-19 were provided by Dr. 
Bowen Ke’s lab. Cell proliferation assays were conducted by Dr. Jason Zastre’s lab. 
2.3.2 Synthesis 
 
S-(2-hydroxyethyl) 2,2-dimethylpropanethioate (1)  
Synthesis of S-(2-hydroxyethyl) 2,2-dimethylpropanethioate followed literature 
procedures.145 Briefly, 0.32 mL pivaloyl chloride (2.6 mmol) was added to a stirred solution of 
2-mercaptoethanol (0.18 mL, 2.6 mmol) and trimethylamine (TEA, 0.36 mL, 2.6 mmol) in 5 mL 
dichloromethane (DCM) at -78 oC under argon protection. The reaction mixture was stirred at -
78 oC for 1 h, and then allowed to warm up to room temperature. The reaction was stirred for an 
additional 1 h and quenched by water (3mL). The organic layer was separated. The aqueous 
phase was extracted with DCM (3×10 mL). The combined organic phase was dried over Na2SO4 
and concentrated in vacuo. Column chromatography was used to purify the residue (silica gel, 
hexane/EtOAc 10:1 to 4:1). 410 mg of the title product was obtained as clear oil. Yield: 97%. 
NMR data matched that of the literature report.  
 
O-(tert-butyl) S-(2-hydroxyethyl) carbonothioate (2) 
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718 mg K2CO3 (5.2 mmol) and 568 mg Boc2O (2.6 mmol) were added to a 50-mL round 
bottom flask with 20 mL MeCN. 2-Mercaptoethanol was then added into the solution. The 
solution was stirred at room temperature for 2 days. K2CO3 was filtered off. MeCN was used to 
wash the filter cake. The filtrate was then dried over Na2SO4 and concentrated in vacuo. The oil-
like residue was purified by column chromatography (silica gel, hexane/EtOAc 10:1 to 2:1) to 
give 381 mg product as clear oil. Yield: 82%. NMR data match well with literature report.147   
 
Pent-4-yn-1-yl phosphorodichloridate (3) 
1 mL phosphorus oxychloride (10.7 mmol) was added to a solution of 4-pentyn-1-ol 
(10.7 mmol) in 25 mL DCM at -78 oC under argon protection. TEA (1.64 mL, 11.77 mmol, 1.1 
equiv.) was added dropwise to the solution. The reaction mixture was slowly warmed up to room 
temperature and stirred for another 10 min. Then the solution was quenched by pouring onto ice 
and extracted with DCM (2×30 mL). The combined organic phase was dried over Na2SO4 and 
concentrated in vacuo. The residue was purified by column chromatography (silica gel, 
hexane/EtOAc 10:1). 1.2 g product was obtained as clear oil. Yield: 56%. 1H NMR (CDCl3) δ 
4.59 – 4.40 (m, 2H), 2.41 (t, J = 6.8 Hz, 2H), 2.14 – 1.91 (m, 3H). 13C NMR (CDCl3) δ 81.7, 70.4 
(d, J = 9.2 Hz), 70.0, 28.3 (d, J = 9.3 Hz), 14.6. 31P NMR (162 MHz, CDCl3) δ 7.06.   
Pent-4-yn-1-yl bis(SATE) phosphate (4) 
Pent-4-yn-1-yl phosphorodichloridate (3, 200 mg, 1 mmol) and DMAP (13 mg, 0.1 
mmol, 0.1 equiv.) were dissolved in 15 mL Et2O and cooled to -10 
oC under argon protection. 
Then S-(2-hydroxyethyl) 2,2-dimethylpropanethioate (1, 648 mg, 4 mmol, 4 equiv.) was added 
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to the solution in one portion. TEA (0.29 mL, 2.1 mmol, 2.1 equiv.) was added dropwise to the 
solution with stirring. The reaction mixture was allowed to warm up to room temperature and 
heated up to reflux overnight. Then the reaction mixture was mixed with 10 mL of water and 
extracted with EtOAc (3×30 mL). The combined organic phase was dried over Na2SO4, 
concentrated in vacuo and purified by column chromatography (silica gel, hexane/EtOAc 20:1 to 
5:1). 164 mg product was obtained as clear oil. Yield: 36%. 1H NMR (CDCl3) δ 4.18 (dd, J = 
13.1, 6.2 Hz, 2H), 4.14 – 4.03 (m, 4H), 3.14 (q, J = 6.4 Hz, 4H), 2.33 (td, J = 7.0, 2.7 Hz, 2H), 
1.97 (t, J = 2.7 Hz, 1H), 1.90 (dd, J = 7.0, 6.1 Hz, 2H), 1.24 (s, 18H). 13C NMR (CDCl3) δ 205.7, 
82.7, 69., 66.4 (d, J = 6.0 Hz), 66.1 (d, J = 5.7 Hz), 50.7, 46.5, 29.0 (d, J = 7.2 Hz), 28.6 (d, J = 
7.5 Hz), 27.3, 14.7. 31P NMR (CDCl3) δ -1.82 (dt, J = 14.9, 7.4 Hz). HRMS (ESI): calcd for 
C19H33NaO6PS2 [M+Na]
+ 475.1348, found 475.1335. 
Pent-4-yn-1-yl bis(2-((tert-butoxycarbonyl)thio)ethanyl) phosphate (5) 
The synthesis of 5 follows similar procedure with the synthesis of 4. Pent-4-yn-1-yl 
phosphorodichloridate (3, 200 mg, 1 mmol) and DMAP (13 mg, 0.1 mmol, 0.1 equiv.) were 
dissolved in 15 mL Et2O and cooled to -10 
oC under argon protection. Then O-(tert-butyl) S-(2-
hydroxyethyl) carbonothioate (2, 380 mg, 2.13 mmol, 2.13 equiv.) was added to the solution in 
one portion. TEA (0.29 mL, 2.1 mmol, 2.1 equiv.) was added dropwise to the stirring solution. 
The reaction mixture was allowed to warm up to room temperature and heated up to reflux 
overnight. Then to the reaction mixture was added 10 mL of water and resulting solution was 
extracted with EtOAc (3×30 mL). The combined organic phase was dried over Na2SO4, 
concentrated in vacuo and purified by column chromatography (silica gel, hexane/EtOAc 20:1 to 
5:1). 173 mg product was obtained as clear oil. Yield: 36%. 1H NMR (CDCl3) δ 4.25 – 4.08 (m, 
6H), 3.07 (t, J = 6.6 Hz, 4H), 2.32 (td, J = 7.0, 2.6 Hz, 2H), 1.96 (t, J = 2.7 Hz, 1H), 1.92 – 1.81 
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(m, 2H), 1.48 (s, 18H). 13C NMR (CDCl3) δ 168.2, 85.4, 82.7, 69.3, 66.3 (dd, J = 21.2, 5.8 Hz), 
30.9 (d, J = 7.4 Hz), 29.0 (d, J = 7.3 Hz), 28.2, 14.7. 31P NMR (CDCl3) δ -1.42 – -2.16 (m). 
HRMS (ESI): calcd for C19H33NaO8PS2 [M+Na]
+ 507.1247, found 507.1258. 
 
 
Pent-4-yn-2-yl phosphorodichloridate (6) 
1 mL phosphorus oxychloride (10.7 mmol) was added to a solution of 4-pentyn-2-ol 
(10.7 mmol) in 25 mL DCM at -78 oC under argon protection. TEA (1.64 mL, 11.77 mmol, 1.1 
equiv.) was added dropwise to the solution. The reaction mixture was slowly warmed up to room 
temperature and stirred for another 10 min. Then the solution was quenched by pouring onto ice 
and extracted with DCM (2×30 mL). The combined organic phase was dried over Na2SO4 and 
concentrated in vacuo. The residue was purified by column chromatography (silica gel, 
hexane/EtOAc 10:1). 1.0 g product was obtained as clear oil. Yield: 47%.  1H NMR (CDCl3) δ 
5.11 – 4.83 (m, 1H), 2.82 – 2.55 (m, 2H), 2.12 (t, J = 2.4 Hz, 1H), 1.59 (d, J = 6.2 Hz, 3H).13C 
NMR (CDCl3) δ 79.2 (d, J = 9.1 Hz), 77.7, 72.0, 27.0 (d, J = 7.1 Hz), 20.5 (d, J = 4.4 Hz). 
31P 
NMR (162 MHz, CDCl3) δ 6.61 (d, J = 11.1 Hz). 
Pent-4-yn-2-yl bis(SATE) phosphate (7) 
Pent-4-yn-2-yl phosphorodichloridate (6, 200 mg, 1 mmol) and DMAP (13 mg, 0.1 
mmol, 0.1 equiv.) were dissolved in 15 mL Et2O and cooled to -10 
oC under argon protection. 
Then S-(2-hydroxyethyl) 2,2-dimethylpropanethioate (1, 366 mg, 2.2 mmol, 2.2 equiv.) was 
added to the solution in one portion. TEA (0.29 mL, 2.1 mmol, 2.1 equiv.) was added dropwise 
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to the solution with stirring. The reaction mixture was allowed to warm up to room temperature 
and then heated at reflux overnight. Then to the reaction mixture was added 10 mL of water and 
the resulting mixture was extracted with EtOAc (3×30 mL). The combined organic phase was 
dried over Na2SO4, concentrated in vacuo and purified by column chromatography (silica gel, 
hexane/EtOAc 20:1 to 5:1). 163 mg racemic product was obtained as clear oil. Yield: 36%. 1H 
NMR (CDCl3) δ 4.62 (dp, J = 12.8, 6.3 Hz, 1H), 4.22 – 3.99 (m, 4H), 3.15 (td, J = 6.6, 1.6 Hz, 
4H), 2.66 – 2.42 (m, 2H), 2.04 (t, J = 2.7 Hz, 1H), 1.45 (d, J = 6.2 Hz, 3H), 1.24 (s, 18H). 13C 
NMR (CDCl3) δ 177.9, 78.8, 74.4 (d, J = 8.4 Hz), 71.4, 62.7 (dd, J = 4.8, 2.7 Hz), 38.8, 30.8 – 
30.5 (m), 27.5 (d, J = 5.6 Hz), 27.1, 21.1 (d, J = 3.9 Hz). 31P NMR (CDCl3) δ 54.30 (pd, J = 
16.5, 10.5 Hz).  HRMS (ESI): calcd for C19H33NaO6PS2 [M+Na]
+ 475.1348, found 475.1348. 
 
Pent-4-yn-2-yl bis(2-((tert-butoxycarbonyl)thio)ethanyl) phosphate (8)  
Pent-4-yn-2-yl phosphorodichloridate (6, 200 mg, 1 mmol) and DMAP (13 mg, 0.1 
mmol, 0.1 equiv.) were dissolved in 15 mL Et2O and cooled to -5 
oC under argon protection. 
Then O-(tert-butyl) S-(2-hydroxyethyl) carbonothioate (2, 375 mg, 2.1 mmol, 2.1 equiv.) was 
added to the solution in one portion. TEA (0.29 mL, 2.1 mmol, 2.1 equiv.) was added dropwise 
to the solution stirring. The reaction mixture was allowed to warm up to room temperature and 
heated up at reflux overnight. Then to the reaction mixture was added 10 mL of water and the 
resulting mixture was extracted with EtOAc (3×30 mL). The combined organic phase was dried 
over Na2SO4, concentrated in vacuo and purified by column chromatography (silica gel, 
hexane/EtOAc 20:1 to 5:1). 288 mg racemic product was obtained as clear oil. Yield: 60%.1H 
NMR (CDCl3) δ 4.62 (dp, J = 12.5, 6.2 Hz, 1H), 4.25 – 4.09 (m, 4H), 3.08 (td, J = 6.7, 2.0 Hz, 
3H), 2.64 – 2.45 (m, 2H), 2.04 (t, J = 2.7 Hz, 1H), 1.49 (s, 18H), 1.45 (d, J = 6.2 Hz, 3H). 13C 
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NMR (CDCl3) δ 168.2, 85.4, 79.3, 73.7 (d, J = 5.9 Hz), 71.1, 66.2 (dd, J = 5.8, 2.4 Hz), 30.9 (d, 
J = 7.6 Hz), 28.2, 27.2 (d, J = 6.2 Hz), 20.8 (d, J = 4.1 Hz). 31P NMR (CDCl3) δ -2.93 (h, J = 7.6 
Hz). HRMS (ESI): calcd for C19H34O8PS2 [M+H]
+ 485.1427, found 485.1140. 
 
Using the same method described above, compound 9, 10, and 11 were prepared accordingly. 
But-3-yn-1-yl phosphorodichloridate (9) 
Yield 40%. 1H NMR (CDCl3) δ 4.43 (dt, J = 10.4, 6.8 Hz, 2H), 2.74 (tdd, J = 6.8, 2.6, 0.4 
Hz, 2H), 2.12 (t, J = 2.7 Hz, 1H).  13C NMR (CDCl3) δ 77.8, 71.5, 68.9 (d, J = 9.0 Hz), 20.2 (d, J 
= 10.0 Hz). 31P NMR (CDCl3) δ 7.29 (t, J = 9.6 Hz). 
But-3-yn-1-yl bis(SATE) phosphate (10) 
Yield: 59%. 1H NMR (CDCl3) δ 4.31 (dd, J = 14.0, 7.6 Hz, 4H), 4.28 – 4.19 (m, 2H), 
3.17 (dt, J = 16.5, 6.4 Hz, 4H), 2.64 (t, J = 6.6 Hz, 2H), 2.03 (s, 1H), 1.21 (s, 18H). 31P NMR 
(CDCl3) δ 55.99 (ddd, J = 26.0, 16.8, 9.4 Hz). HRMS (ESI): calcd for C18H31NaO6PS2 [M+Na]
+ 
461.1192, found 461.1179.   
But-3-yn-1-yl bis(2-((tert-butoxycarbonyl)thio)ethanyl) phosphate (11) 
Yield: 46%. 1H NMR (CDCl3) δ 4.28 – 3.96 (m, 6H), 3.06 (t, J = 6.7 Hz, 4H), 2.58 (td, J 
= 6.8, 2.6 Hz, 2H), 2.01 (t, J = 2.6 Hz, 1H), 1.47 (s, 18H). 13C NMR (CDCl3) δ 168.2, 85.4, 79.3, 
70.5, 66.3 (d, J = 5.7 Hz), 65.5 (d, J = 5.8 Hz), 30.9 (d, J = 7.4 Hz), 28.2, 20.6 (d, J = 7.3 Hz). 
31P NMR (CDCl3) δ -2.15 (hept, J = 7.9 Hz). HRMS (ESI): calcd for C18H32O8PS2 [M+H]
+ 
471.1271, found 471.1260.   
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Phenyl phosphorodichloridate (12) 
To a solution of phosphorus oxychloride (1 mL, 10.7 mmol) in 25 mL of anhydrous 
diethyl ether was added dropwise a solution of phenol (1.01 g, 10.7 mmol) and TEA (1.5 mL, 
10.7 mmol) in 25 mL of anhydrous diethyl ether at -78 oC under argon atmosphere over 1 h. The 
solution was allowed to slowly warm up to room temperature and stirred overnight. Then the 
solution was filtered using Celite®. The filtrate was immediately dried over vacuum and kept 
under high vacuum for 3 h. The crude product was directly used for the next step without further 
purification.  
 
General procedure of preparing compound 13 and 14 
The crude product of phenyl phosphorodichloridate (12) described above was dissolved 
in 10 mL DCM together with L-alanine alkyl ester hydrogen chloride (10.7 mmol) and cooled to 
- 78 oC under argon protection. 3 mL TEA (21.4 mmol) dissolved in 10 mL DCM was slowly 
added to the reaction solution. The reaction solution was allowed to slowly warm up to room 
temperature and reacted overnight under stirring. Then the reaction was filtered over Celite® 
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(wash with DCM). The filtrate was concentrated and purified by column (silica gel, 
hexane/EtOAc 20:1 to 2:1). 
Ethyl (chloro(phenoxy)phosphoryl)-L-alaninate (13) 
Total yield of two steps: 17%. Spectra data correspond well with literature report.148  
Methyl (chloro(phenoxy)phosphoryl)-L-alaninate (14) 
Total yield of two steps: 13%. Spectra data correspond well with literature report.149 
General procedure of preparing compound 15, 16, 17, 18, and 19 
Alkyl (chloro(phenoxy)phosphoryl)-L-alaninate (13 or 14) was prepared as 1 M stock 
solution in THF. To a solution of alkynyl alcohol (1.19 mmol) and N-methylimidazole in 1 mL 
THF at 0 oC was added dropwise 1.19 mL stock solution of compound 13 or 14. The resulting 
mixture was stirred at room temperature for 3 days. Then the reaction mixture was dried over 
rotavap, premixed with silica gel, and purified by column (silica gel, hexane/EtOAc 20:1 to 2:1) 
to yield the product. 
Ethyl ((pent-4-yn-1-yloxy)(phenoxy)phosphoryl)-L-alaninate (15) 
Product (mixture of two diasteromers) was obtained as clear oil. Yield: 46%. 1H NMR 
(CDCl3) δ 7.37 – 7.23 (m, 2H), 7.19 (t, J = 7.6 Hz, 2H), 7.11 (t, J = 7.3 Hz, 1H), 4.26 – 4.07 (m, 
4H), 4.04 – 3.89 (m, 1H), 3.78 (m, J = 16.0, 10.5 Hz, 1H), 2.25 (m, 2H), 1.95 (m, 1H), 1.90 – 
1.77 (m, 2H), 1.34 (m, 3H), 1.22 (m, 3H). 13C NMR (CDCl3) δ 173.5 (m), 150.8 (m), 129.6 (d, J 
= 2.8 Hz), 124.7, 120.2 (m), 82.9, 69.2 (d, J = 4.3 Hz), 65.5 (m), 61.4, 50.4 – 50.1 (m), 29.0 (d, J 
= 7.3 Hz), 21.0 (m), 14.7 (d, J = 3.1 Hz), 14.1 (d, J = 3.7 Hz). 31P NMR (CDCl3) δ 2.98 – 1.68 
(m).  HRMS (ESI): calcd for C16H23NO5P [M+H]
+ 340.1308, found 340.1299.   
Methyl ((pent-4-yn-1-yloxy)(phenoxy)phosphoryl)-L-alaninate (16) 
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Product (mixture of two diasteromers) was obtained as clear oil. Yield: 24 %. 1H NMR 
(CDCl3) δ 7.41 – 7.24 (m, 2H), 7.23 – 7.15 (m, 2H), 7.15 – 7.05 (m, 1H), 4.27 – 4.13 (m, 2H), 
4.00 (dt, J = 9.2, 1.7 Hz, 1H), 3.73 – 3.57 (m, 4H), 2.26 (qd, J = 7.1, 2.6 Hz, 2H), 1.94 (q, J = 2.7 
Hz, 1H), 1.86 (dd, J = 14.2, 6.9 Hz, 2H), 1.35 (dd, J = 7.0, 5.0 Hz, 3H). 13C NMR (CDCl3) δ 
174.1 – 173.8 (m), 150.8 (dd, J = 6.7, 3.7 Hz), 129.6 (d, J = 2.1 Hz), 124.8, 120.2 (dd, J = 4.9, 
3.3 Hz), 82.9, 69.2 (d, J = 3.7 Hz), 65.5 (t, J = 5.9 Hz), 52.4 (d, J = 2.4 Hz), 50.3 – 50.1 (m), 29.0 
(d, J = 7.1 Hz), 21.1 – 20.8 (m), 14.7 (d, J = 3.7 Hz). 31P NMR (162 MHz, CDCl3) δ 2.55 – 1.82 
(m). HRMS (ESI): calcd for C15H21NO5P [M+H]
+ 326.1152, found 326.1145.   
Ethyl ((but-3-yn-1-yloxy)(phenoxy)phosphoryl)-L-alaninate (17) 
Yield: 21%. 1H NMR (CDCl3) δ 7.36 – 7.24 (m, 2H), 7.24 – 7.15 (m, 2H), 7.15 – 7.05 
(m, 1H), 4.17 (ddq, J = 21.5, 12.6, 7.0 Hz, 4H), 4.02 (ddd, J = 23.0, 8.3, 7.4 Hz, 1H), 3.79 (dt, J 
= 17.4, 10.5 Hz, 1H), 2.57 (dtd, J = 9.4, 6.9, 2.6 Hz, 2H), 2.01 (dt, J = 5.4, 2.7 Hz, 1H), 1.37 (dd, 
J = 7.0, 3.2 Hz, 3H), 1.24 (dt, J = 10.8, 7.1 Hz, 3H). 13C NMR (CDCl3) δ 173.4 (d, J = 7.9 Hz), 
150.9 – 150.6 (m), 129.6 (d, J = 2.1 Hz), 124.8, 120.2 (t, J = 4.7 Hz), 79.6 (d, J = 2.5 Hz), 70.3 
(d, J = 3.1 Hz), 64.8 – 64.4 (m), 61.5 (d, J = 2.2 Hz), 50.2 (d, J = 6.8 Hz), 21.0 (t, J = 4.8 Hz), 
20.6 (dd, J = 7.5, 4.7 Hz), 14.1 (d, J = 3.4 Hz). 31P NMR (CDCl3) δ 2.63 – 1.85 (m). HRMS 
(ESI): calcd for C15H21NO5P [M+H]
+ 326.1152, found 326.1151. 
 Methyl ((but-3-yn-1-yloxy)(phenoxy)phosphoryl)-L-alaninate (18) 
Yield: 39%. 1H NMR (CDCl3) δ 7.41 – 7.23 (m, 2H), 7.19 (ddd, J = 7.7, 6.9, 1.0 Hz, 2H), 
7.15 – 7.01 (m, 1H), 4.27 – 4.08 (m, 2H), 4.02 (d, J = 6.8 Hz, 1H), 3.83 (s, 1H), 3.72 – 3.53 (m, 
3H), 2.67 – 2.41 (m, 2H), 1.99 (dt, J = 5.4, 2.6 Hz, 1H), 1.36 (dd, J = 7.1, 3.4 Hz, 3H). 13C NMR 
(CDCl3) δ 173.9 (d, J = 7.7 Hz), 150.7 (dd, J = 6.8, 3.5 Hz), 129.6 (d, J = 2.1 Hz), 124.9, 120.2 
(dd, J = 4.8, 3.2 Hz), 79.6 (d, J = 1.6 Hz), 70.4 (d, J = 4.2 Hz), 64.9 – 64.5 (m), 52.5 (d, J = 3.6 
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Hz), 50.2 (d, J = 6.5 Hz), 20.9 (t, J = 5.5 Hz), 20.6 (dd, J = 7.6, 5.1 Hz). 31P NMR (CDCl3) δ 
2.10. HRMS (ESI): calcd for C14H19NO5P [M+H]
+ 312.0995, found 312.0984. 
Ethyl ((pent-4-yn-2-yloxy)(phenoxy)phosphoryl)-L-alaninate (19) 
Yield: 21%. 1H NMR (CDCl3) δ 7.38 – 7.24 (m, 2H), 7.24 – 7.16 (m, 2H), 7.12 (t, J = 7.3 
Hz, 1H), 4.78 – 4.54 (m, 1H), 4.24 – 4.08 (m, 2H), 4.09 – 3.92 (m, 1H), 3.70 – 3.46 (m, 1H), 
2.62 – 2.38 (m, 2H), 2.07 – 1.96 (m, 1H), 1.44 (dd, J = 14.5, 6.2 Hz, 1H), 1.40 – 1.30 (m, 5H), 
1.30 – 1.14 (m, 3H). 13C NMR (CDCl3) δ 173.5 (d, J = 8.2 Hz), 150.9, 129.6, 124.8, 120.3 (dd, J 
= 9.1, 4.7 Hz), 79.6, 79.4, 72.9 (dd, J = 10.7, 5.4 Hz), 70.9 (d, J = 3.0 Hz), 61.5, 50.3 (d, J = 6.4 
Hz), 27.5 – 27.1 (m), 21.0 (t, J = 15.6 Hz), 20.8 – 20.3 (m), 14.1 (d, J = 2.2 Hz). 31P NMR 
(CDCl3) δ 1.67 – 0.74 (m). calcd for C16H22NaNO5P [M+Na]
+ 362.1128, found 362.1137. 
 
Chlorophosphoryl-bisPOM (20) 
Synthesis of chlorophosphoryl-bisPOM (20) starting from trimethyl phosphate followed 
literature reported procedure.15 However, we found the products in the sequential four steps are 
hard to visualize on TLC using commonly used staining reagents. None of previous literature 
recorded method for this problem. So, we tried a series of staining reagents and found acidic α-
naphthol stain can efficiently visualize compounds contains POM moiety in these four reactions.  
Pent-4-yn-2-yl bisPOM phosphate (21) 
To a stirred solution of 4-pentyn-1-ol (21 μL, 0.22 mmol) and chlorophosphoryl-bisPOM 
(20, 380 mg, 1.10 mmol, 5 equiv.) in 2 mL Et2O was added TEA (0.3 mL, 2.20mol, 10 equiv.) 
dropwise at room temperature. The solution was stirred under room temperature overnight. Then 
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the reaction was quenched with saturated ammonium chloride solution and extracted with EtOAc 
(3×10 mL). The organic phase was dried over Na2SO4 and purified by column (silica gel, 
hexane/EtOAc 10:1). 47 mg product was obtained. Yield: 55%. 1H NMR (CDCl3) δ 5.63 (d, J = 
13.6 Hz, 4H), 4.19 (dd, J = 13.4, 6.2 Hz, 2H), 2.30 (td, J = 7.0, 2.7 Hz, 2H), 1.95 (t, J = 2.7 Hz, 
1H), 1.92 – 1.81 (m, 2H), 1.26 – 1.14 (m, 18H). 13C NMR (CDCl3) δ 176.7, 82.8 (d, J = 5.1 Hz), 
82.5, 69.4, 67.0 (d, J = 6.1 Hz), 38.8, 28.9 (d, J = 7.4 Hz), 26.9, 14.7. 31P NMR (CDCl3) δ -3.82 
(ddd, J = 20.6, 13.8, 7.1 Hz). HRMS (ESI): calcd for C17H29NaO8P [M+Na]
+ 415.1492, found 
415.1495. 
But-3-yn-1-yl bisPOM phosphate (22) 
The synthesis of compound 22 followed the same procedure with compound 21 using  
but-3-yn-1-ol. Yield: 58%. 1H NMR (CDCl3) δ 5.75 – 5.51 (m, 4H), 4.13 (q, J = 7.3 Hz, 2H), 
2.55 (t, J = 6.9 Hz, 2H), 1.98 (s, 1H), 1.19 (s, 18H). 13C NMR (CDCl3) δ 176.7, 82.8 (d, J = 5.1 
Hz), 78.8, 70.7, 65.8 (d, J = 5.7 Hz), 38.8, 26.8, 20.5 (d, J = 7.7 Hz). 31P NMR (CDCl3) δ -3.94 – 
-4.62 (m). HRMS (ESI): calcd for C16H27NaO8P [M+Na]
+ 401.1336, found 401.1322. 
  
5-(Azidomethyl)-2,4-dimethoxypyrimidine (23) 
Compound 23 was prepared using literature reported procedure from 2,4-dimethoxypyrimidine-
5-carbaldehyde.150-151 1H NMR (CDCl3) δ 8.16 (s, 1H), 4.27 (s, 2H), 4.06 (s, 3H), 4.03 (s, 3H). 
13C NMR (CDCl3) δ 169.6, 165.6, 158.1, 109.7, 55.0, 54.3, 47.1. HRMS (ESI): calcd for 
C7H9N5NaO2 [M+Na]
+ 218.0648, found 218.0661. 
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5-(Azidomethyl)-2-methylpyrimidin-4-amine (24) 
Compound 24 was prepared using reported procedure.146 Spectra data correspond well 
with literature report. 
 
5-(Azidomethyl)pyrimidine (25) 
Pyrimidin-5-ylmethanol (266 mg, 2.42 mmol) and DPPA (0.73 mL, 3.39 mmol) were 
dissolved in 15 mL dry toluene and cooled to 0 ℃ in an ice bath under N2 protection. Then DBU 
(0.51 mL, 3.39 mmol) was slowly added to the solution with a syringe. The reaction mixture was 
allowed to slowly warm up to room temperature and stirred overnight. The reaction mixture was 
then diluted with EtOAc and washed with 1N HCl solution. The organic phase was dried over 
Na2SO4, concentrated, and purified with Al2O3 column. Product was obtained as yellowish oil 
with a 75% yield. 1H NMR (CDCl3) δ 9.21 (s, 1H), 8.72 (s, 2H), 4.44 (s, 2H). 
13C NMR (CDCl3) 
δ 158.7, 156.4, 129.3, 49.8. HRMS (ESI): calcd for C5H6N5 [M+Na]
+ 136.0618, found 136.0623. 
General procedure for “click” reaction 
Azide was prepared as 50 mg/mL stock solution in MeOH beforehand. 1 mL of this 
solution was added into a 20-mL glass vial. 1 equiv. of the respective alkyne was added into the 
solution. 0.63 mL (0.05 equiv.) freshly made 20 mM CuSO4/sodium ascorbate stock solution (50 
mg CuSO4·5H2O, 40 mg sodium ascorbate dissolved in 10 mL water) was slowly added to the 
reaction solution. The reaction mixture was stirred at room temperature overnight. Then solvent 
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was removed with vacuum. The residue was premixed with silica gel and purified by column 
chromatography (silica, pure EtOAc to EtOAc/MeOH 20:1).  
 
1-(1-((2,4-Dimethoxypyrimidin-5-yl)methyl)-1H-1,2,3-triazol-4-yl)propan-2-ol (BW-VB-8) 
Yield: 73%. 1H NMR (CDCl3) δ 8.14 (s, 1H), 7.38 (s, 1H), 5.34 (s, 2H), 4.07 (s, 1H), 
3.96 (dd, J = 16.1, 5.1 Hz, 6H), 3.21 (s, 1H), 2.80 (dd, J = 14.9, 3.8 Hz, 1H), 2.70 (dd, J = 14.9, 
8.0 Hz, 1H), 1.19 (d, J = 6.2 Hz, 3H). 13C NMR (CDCl3) δ 169.3, 165.9, 159.2, 145.7, 122.1, 
109.3, 67.2, 55.3, 54.6, 46.2, 35.1, 23.1. HRMS (ESI): calcd for C12H17N5NaO3
+ [M+Na]+ 
302.1224, found 302.1243. 
 
2-(1-((2,4-Dimethoxypyrimidin-5-yl)methyl)-1H-1,2,3-triazol-4-yl)butan-2-ol (BW-VB-9) 
Yield: 98%.1H NMR (CDCl3) δ 8.13 (s, 1H), 7.41 (s, 1H), 5.33 (s, 2H), 3.93 (d, J = 12.5 
Hz, 6H), 3.00 (s, 1H), 1.80 (d, J = 6.4 Hz, 2H), 1.49 (s, 3H), 0.75 (t, J = 7.0 Hz, 3H). 13C NMR 
(CDCl3) δ 169.2, 165.8, 159.0, 155.1, 120.3, 109.3, 71.4, 55.6, 54.5, 46.2, 36.0, 28.2, 8.4. HRMS 
(ESI): calcd for C13H19N5NaO3
+ [M+Na]+ 316.1380, found 316.1389. 
 
1-(1-((2,4-Dimethoxypyrimidin-5-yl)methyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol (BW-VB-10) 
Yield: 67%. 1H NMR (CDCl3) δ 8.18 (s, 1H), 7.48 (s, 1H), 5.37 (s, 2H), 5.04 (d, J = 4.0 
Hz, 1H), 3.98 (d, J = 15.6 Hz, 6H), 3.18 (s, 1H), 1.53 (d, J = 6.2 Hz, 3H). 13C NMR (CDCl3) δ 
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169.4 166.0, 159.3, 153.1, 120.4, 109.2, 63.3, 55.4, 54.7, 46.4, 23.495. HRMS (ESI): calcd for 
C11H15N5NaO3
+ [M+Na]+ 288.1067, found 288.1078. 
 
3-(1-((2,4-Dimethoxypyrimidin-5-yl)methyl)-1H-1,2,3-triazol-4-yl)propan-1-ol (BW-VB-11) 
Yield: 52%. 1H NMR (CDCl3) δ 8.17 (s, 1H), 7.31 (s, 1H), 5.36 (s, 2H), 3.99 (d, J = 16.1 
Hz, 6H), 3.67 (s, 2H), 2.78 (t, J = 7.3 Hz, 2H), 2.64 (s, 1H), 2.01 – 1.79 (m, 2H). 13C NMR 
(CDCl3) δ 169.4, 166.0, 159.2, 148.1, 121.2, 109.4, 62.1, 55.4, 54.7, 46.3, 32.3, 22.4. HRMS 
(ESI): calcd for C12H17N5NaO3
+ [M+Na]+ 302.1224, found 302.1237. 
 
 
3-(1-((2,4-dimethoxypyrimidin-5-yl)methyl)-1H-1,2,3-triazol-4-yl)propyl bis-SATE 
phosphate (BW-VB-20) 
Yield: 64%. 1H NMR (CDCl3) δ 8.18 (s, 1H), 7.39 (s, 1H), 5.37 (s, 2H), 4.15 – 4.04 (m, 
6H), 4.00 (d, J = 19.2 Hz, 6H), 3.12 (t, J = 6.7 Hz, 4H), 2.81 (t, J = 7.5 Hz, 2H), 2.13 – 1.97 (m, 
2H), 1.76 (s, 2H), 1.22 (s, 18H). 13C NMR (CDCl3) δ 205.7, 165.71, 158.9, 146.8, 121.6, 109.2, 
67.1, 66.1 (d, J = 5.7 Hz), 55.1, 54.4, 46.5, 46.0, 29.8, 28.6 (d, J = 7.5 Hz), 27.3, 21.6. 31P NMR 
(CDCl3) δ -1.67 (dq, J = 15.1, 7.5 Hz). HRMS (ESI): calcd for C26H42N5O8NaPS2 [M+Na]
+ 
670.2105, found 670.2133. 
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1-(1-((2,4-dimethoxypyrimidin-5-yl)methyl)-1H-1,2,3-triazol-4-yl)propan-2-yl bisSATE 
phosphate (BW-VB-21) 
Product was obtained as racemic mixture. Yield: 53%. 1H NMR (CDCl3) δ 8.20 (s, 1H), 
7.55 (s, 1H), 5.42 (s, 2H), 4.87 – 4.68 (m, 2H), 4.15 – 3.91 (m, 10H), 3.18 – 2.97 (m, 6H), 1.39 
(d, J = 6.2 Hz, 3H), 1.24 (d, J = 1.8 Hz, 18H). 13C NMR (CDCl3) δ 205.7, 169.0, 165.7, 158.8, 
143.3, 122.5, 109.2, 75.3, 65.9, 55.1, 54.4, 46.5, 46.1, 33.7, 28.5, 27.3, 21.1. 31P NMR (CDCl3) δ 
-2.8 (h, J = 7.4 Hz). HRMS (ESI): calcd for C26H42N5O8NaPS2 [M+Na]
+ 670.2105, found 
670.2123. 
3-(1-((2,4-dimethoxypyrimidin-5-yl)methyl)-1H-1,2,3-triazol-4-yl)propyl bis(2-((tert-
butoxycarbonyl)thio)ethanyl) phosphate (BW-VB-22) 
Yield: 37%. 1H NMR (CDCl3) δ 8.19 (s, 1H), 7.39 (s, 1H), 5.37 (s, 2H), 4.17 (q, J = 7.0 
Hz, 4H), 4.09 (q, J = 6.4 Hz, 2H), 4.03 (s, 3H), 3.98 (s, 3H), 3.06 (t, J = 6.6 Hz, 4H), 2.81 (t, J = 
7.4 Hz, 2H), 2.06 (p, J = 6.6 Hz, 2H), 1.47 (s, 18H). 13C NMR (CDCl3) δ 169.1, 168.2, 165.7, 
158.9, 146.8, 121.3, 109.2, 85.4, 67.1 (d, J = 6.1 Hz), 66.2 (d, J = 5.7 Hz), 55.1, 54.4, 46.0, 30.9 
(d, J = 7.4 Hz), 29.8 (d, J = 7.1 Hz), 28.2, 21.6. 31P NMR (CDCl3) δ -1.64 (dt, J = 15.2, 7.5 Hz). 
HRMS (ESI): calcd for C26H42N5O10NaPS2 [M+Na]
+ 702.2003, found 702.2041. 
1-(1-((2,4-dimethoxypyrimidin-5-yl)methyl)-1H-1,2,3-triazol-4-yl)propan-2-yl bis(2-((tert-
butoxycarbonyl)thio)ethanyl) phosphate (BW-VB-23) 
Product was obtained as racemic mixture. Yield: 92%. 1H NMR (CDCl3) δ 8.19 (s, 1H), 
7.53 (s, 1H), 5.39 (s, 2H), 4.82 – 4.62 (m, 1H), 4.10 (ddd, J = 7.7, 5.2, 3.9 Hz, 4H), 4.04 (dd, J = 
21.9, 10.7 Hz, 7H), 3.08 – 2.95 (m, 6H), 1.65 (s, 4H), 1.48 (d, J = 1.9 Hz, 18H), 1.37 (d, J = 6.2 
Hz, 3H). 13C NMR (CDCl3) δ 169.0, 168.1, 165.7, 158.8 , 143.2, 122.5, 109.2, 85.4 , 75.4 (d, J = 
6.2 Hz), 66.0 (dd, J = 5.6, 4.2 Hz), 55.1 , 54.4 , 46.0 , 33.7 (d, J = 6.2 Hz), 30.8 (d, J = 7.5 Hz), 
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28.1 , 21.1 (d, J = 3.4 Hz). 31P NMR (CDCl3) δ -2.78 (dd, J = 15.1, 7.5 Hz). HRMS (ESI): calcd 
for C26H42N5O10NaPS2 [M+Na]
+ 702.2003, found 702.2032. 
 
Ethyl ((3-(1-((2,4-dimethoxypyrimidin-5-yl)methyl)-1H-1,2,3-triazol-4-
yl)propoxy)(phenoxy)phosphoryl)-L-alaninate (BW-VB-24) 
Product was obtained as mixture of two diastereomers. Yield: 94%. 1H NMR (CDCl3) δ 
8.18 (s, 1H), 7.34 (s, 1H), 7.30 (m, 2H), 7.19 (t, J = 7.8 Hz, 2H), 7.13 (t, J = 7.3 Hz, 1H), 5.36 (s, 
2H), 4.22 – 4.05 (m, 4H), 4.02 (s, 3H), 3.98 (s, 3H), 3.75 – 3.61 (m, 1H), 2.86 – 2.69 (m, 2H), 
2.04 (m, 2H), 1.36 (m, 3H), 1.23 (q, J = 7.2 Hz, 3H). 13C NMR (CDCl3) δ 173.5 (d, J = 7.8 Hz), 
169.0, 165.7, 158.8, 150.8 (d, J = 6.8 Hz), 129.6 (d, J = 2.1 Hz), 124.8, 121.3, 120.4 – 120.1 (m), 
109.2, 66.3 – 65.8 (m), 61.5 (d, J = 2.3 Hz), 55.1, 54.4, 50.3 (d, J = 3.8 Hz), 46.0, 29.9 – 29.7 
(m), 21.5 (d, J = 4.8 Hz), 21.0 (t, J = 4.6 Hz), 14.1 (d, J = 3.0 Hz). 31P NMR (CDCl3) δ 2.44 (dd, 
J = 17.1, 8.8 Hz). HRMS (ESI): calcd for C23H31N6O7NaP [M+Na]
+ 557.1884, found 557.1871. 
 
3-(1-((2,4-dimethoxypyrimidin-5-yl)methyl)-1H-1,2,3-triazol-4-yl)propyl bisPOM 
phosphate (BW-VB-25) 
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Yield: 63%. 1H NMR (CDCl3) δ 8.18 (s, 1H), 7.37 (s, 1H), 5.62 (d, J = 13.4 Hz, 4H), 
5.37 (s, 2H), 4.14 – 4.05 (m, 2H), 4.02 (s, 3H), 3.97 (s, 3H), 2.78 (t, J = 7.4 Hz, 2H), 2.15 – 1.98 
(m, 2H), 1.21 (d, J = 5.9 Hz, 18H). 13C NMR (CDCl3) δ 176.7, 165.7, 158.9, 146.6, 121.3, 109.2, 
82.7 (d, J = 5.1 Hz), 67.5 (d, J = 6.0 Hz), 55.1, 54.4, 46.0, 38.7, 29.6 (d, J = 7.2 Hz), 26.8, 21.4 
(s). 31P NMR (CDCl3) δ -3.87 (dtt, J = 20.5, 13.4, 6.7 Hz). HRMS (ESI): calcd for C24H39N5O10P 
[M+H]+ 588.2429, found 588.2414. 
 
Ethyl (((1-(1-((2,4-dimethoxypyrimidin-5-yl)methyl)-1H-1,2,3-triazol-4-yl)propan-2-
yl)oxy)(phenoxy)phosphoryl)-L-alaninate (BW-VB-26) 
Product was obtained as mixture of two diastereomers. Yield: 34%. 1H NMR (CDCl3) δ 
8.15 (d, J = 26.2 Hz, 1H), 7.48 (d, J = 13.0 Hz, 1H), 7.37 – 7.17 (m, 5H), 7.17 – 7.06 (m, 4H), 
5.37 (d, J = 2.0 Hz, 2H), 5.28 (s, 1H), 4.87 (ddd, J = 18.5, 12.1, 5.9 Hz, 2H), 4.20 – 4.06 (m, 
3H), 3.96 (dt, J = 15.8, 10.3 Hz, 11H), 3.74 – 3.40 (m, 2H), 3.04 (dd, J = 14.4, 5.3 Hz, 3H), 1.42 
– 1.10 (m, 15H). 13C NMR (CDCl3) δ 173.6, 169.0 (d, J = 8.3 Hz), 165.7, 150.9, 129.5 (d, J = 
3.0 Hz), 124.7, 122.4, 120.3 (dd, J = 8.9, 4.2 Hz), 109.2, 74.3, 61.6 – 61.3 (m), 55.1, 54.4 (d, J = 
4.7 Hz), 50.3, 46.0 (d, J = 9.5 Hz), 21.2, 21.0, 14.1. 31P NMR (CDCl3) δ 1.52, 1.19. HRMS 
(ESI): calcd for C23H31N6O7P [M+H]
+ 535.2065, found 535.2065. 
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2-(1-((4-amino-2-methylpyrimidin-5-yl)methyl)-1H-1,2,3-triazol-4-yl)ethyl bisSATE 
phosphate (BW-VB-27) 
Yield: 64%. 1H NMR (CDCl3) δ 8.20 (s, 1H), 7.52 (s, 1H), 5.73 (s, 2H), 5.35 (s, 2H), 
4.40 (dd, J = 15.2, 6.4 Hz, 2H), 4.24 (t, J = 6.4 Hz, 4H), 3.10 (dt, J = 14.8, 6.2 Hz, 6H), 2.47 (s, 
3H), 1.19 (s, 18H). 13C NMR (CDCl3) δ 178.1, 156.0, 144.2, 122.3, 108.1, 66.5 (d, J = 8.2 Hz), 
62.8 (d, J = 4.4 Hz), 48.6, 38.8, 30.4 (d, J = 3.4 Hz), 27.1, 25.6. 31P NMR (CDCl3) δ 56.32 – 
55.58 (m). HRMS (ESI): calcd for C24H39N6O6PS2 [M+H]
+ 603.2183, found 603.2184. 
 
2-(1-((4-amino-2-methylpyrimidin-5-yl)methyl)-1H-1,2,3-triazol-4-yl)ethyl bisPOM 
phosphate (BW-VB-28) 
Yield: 44%. 1H NMR (CDCl3) δ 8.19 (s, 1H), 7.53 (s, 1H), 5.70 (s, 2H), 5.58 (d, J = 13.2 
Hz, 4H), 5.33 (s, 2H), 4.31 (q, J = 6.6 Hz, 2H), 3.08 (t, J = 6.1 Hz, 2H), 2.46 (s, 3H), 1.19 (s, 
18H). 13C NMR (CDCl3) δ 176.8, 168.9, 162.0, 156.2, 144.3, 122.3, 108.1, 82.7 (d, J = 5.0 Hz), 
67.0 (d, J = 5.8 Hz), 48.7, 38.7, 27.4 – 26.9(m), 27.1 – 26.7 (m), 25.6. 31P NMR (CDCl3) δ -4.44 
(qd, J = 13.3, 6.5 Hz). HRMS (ESI): calcd for C22H35N6O8P [M+H]
+ 543.2327, found 543.2326. 
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3-(1-((4-amino-2-methylpyrimidin-5-yl)methyl)-1H-1,2,3-triazol-4-yl)propyl bisSATE 
phosphate (BW-VB-29) 
Yield: 42%. 1H NMR (CDCl3) δ 8.14 (s, 1H), 7.41 (s, 1H), 5.83 (s, 2H), 5.29 (s, 2H), 
4.24 (t, J = 6.4 Hz, 4H), 4.14 (dd, J = 14.7, 6.2 Hz, 2H), 3.08 (dt, J = 16.6, 6.5 Hz, 4H), 2.76 (t, J 
= 7.3 Hz, 2H), 2.42 (s, 3H), 2.10 – 2.00 (m, 2H), 1.14 (s, 18H). 13C NMR (CDCl3) δ 178.0, 
168.8, 162.0, 156.0, 147.3, 121.5, 108.2, 66.9 (d, J = 8.3 Hz), 62.7 (d, J = 4.6 Hz), 48.6, 38.8, 
30.4 (d, J = 3.3 Hz), 29.5 (d, J = 7.0 Hz), 27.1, 25.5, 21.5. 31P NMR (CDCl3) δ 56.10 – 55.33 
(m). HRMS (ESI): calcd for C25H41N6O6PS2 [M+H]
+ 617.2339, found 617.2341. 
 
Ethyl ((3-(1-((4-amino-2-methylpyrimidin-5-yl)methyl)-1H-1,2,3-triazol-4-
yl)propoxy)(phenoxy)phosphoryl)-L-alaninate (BW-VB-30) 
Yield: 34%. 1H NMR (CDCl3) δ 8.16 (s, 1H), 7.29 (dd, J = 16.3, 8.7 Hz, 3H), 7.15 (dt, J 
= 14.8, 7.1 Hz, 3H), 5.75 (s, 2H), 5.29 (s, 2H), 4.21 – 3.89 (m, 5H), 3.75 (dd, J = 24.1, 10.6 Hz, 
1H), 2.75 (q, J = 7.5 Hz, 2H), 2.47 (s, 3H), 2.01 (dd, J = 13.8, 6.3 Hz, 3H), 1.35 (dd, J = 6.9, 2.8 
Hz, 3H), 1.22 (q, J = 6.7 Hz, 4H). 13C NMR (CDCl3) δ 173.6, 162.0, 156.0, 150.8, 147.7, 129.7 
(d, J = 2.2 Hz), 124.9 121.5, 120.2 (t, J = 5.3 Hz), 100.0, 65.8, 61.5, 50.3 (d, J = 8.1 Hz), 48.7, 
29.5, 25.6, 21. 5 (d, J = 3.3 Hz), 21.0, 14.1 (d, J = 3.1 Hz). 31P NMR (CDCl3) δ 3.14 – 1.78 (m). 
HRMS (ESI): calcd for C22H30N7O5P [M+H]
+ 504.2119, found 504.2113. 
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3-(1-((4-amino-2-methylpyrimidin-5-yl)methyl)-1H-1,2,3-triazol-4-yl)propyl bisPOM 
phosphate (BW-VB-31) 
Yield: 48%. 1H NMR (CDCl3) δ 8.20 (s, 1H), 7.41 (s, 1H), 5.66 (s, 2H), 5.61 (d, J = 13.4 
Hz, 4H), 5.33 (s, 2H), 4.07 (q, J = 6.2 Hz, 2H), 2.79 (t, J = 7.2 Hz, 2H), 2.47 (s, 3H), 2.03 (dt, J 
= 13.1, 6.6 Hz, 3H), 1.20 (s, 18H). 13C NMR (CDCl3) δ 176.8, 168.8, 162.1, 156.0, 147.3, 121.6, 
108.2, 82.7 (d, J = 5.1 Hz), 67.3 (d, J = 6.1 Hz), 48.6, 38.7, 30.9, 29.3 (d, J = 7.3 Hz), 26.8, 25.6, 
21.3. 31P NMR (CDCl3) δ -3.59 – -4.40 (m). HRMS (ESI): calcd for C23H38N6O8P [M+H]
+ 
557.2483, found 557.2482. 
 
2-(1-((2,4-dimethoxypyrimidin-5-yl)methyl)-1H-1,2,3-triazol-4-yl)ethyl bisSATE phosphate 
(BW-VB-32) 
Yield: 56%. 1H NMR (CDCl3) δ 8.20 (s, 1H), 7.49 (s, 1H), 5.39 (s, 2H), 4.41 (dd, J = 
14.5, 6.2 Hz, 2H), 4.26 (t, J = 6.4 Hz, 4H), 4.00 (d, J = 18.9 Hz, 6H), 3.32 – 3.01 (m, 6H), 1.18 
(s, 18H). 13C NMR (CDCl3) δ 178.0, 169.0, 66.6 (d, J = 8.2 Hz), 62.7 (d, J = 4.6 Hz), 55.1, 54.4, 
46.1, 38.7, 30.4 (d, J = 3.3 Hz), 27.0 (d, J = 5.6 Hz). 31P NMR (CDCl3) δ 56.23 – 55.35 (m). 
HRMS (ESI): calcd for C25H40N5O8PS2 [M+H]
+ 634.2129, found 634.2130. 
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2-(1-((2,4-dimethoxypyrimidin-5-yl)methyl)-1H-1,2,3-triazol-4-yl)ethyl bisPOM phosphate 
(BW-VB-33) 
Yield: 33%. 1H NMR (CDCl3) δ 8.20 (s, 1H), 7.49 (s, 1H), 5.60 (d, J = 13.4 Hz, 4H), 
5.38 (s, 2H), 4.32 (q, J = 6.8 Hz, 2H), 4.00 (d, J = 18.9 Hz, 6H), 3.09 (t, J = 6.4 Hz, 2H), 1.21 (d, 
J = 12.1 Hz, 18H). 13C NMR (CDCl3) δ 176.7, 169.1 165.7, 158.9, 143.3, 122.2, 109.1, 100.0, 
82.7 (d, J = 5.0 Hz), 67.1 (d, J = 6.1 Hz), 55.1, 54.4, 46.1, 38.7, 27.1 – 26.7 (m). 31P NMR 
(CDCl3) δ -3.91 – -4.49 (m). HRMS (ESI): calcd for C23H36N5O10NaP [M+Na]
+ 596.2092, found 
596.2073. 
 
Ethyl ((2-(1-((4-amino-2-methylpyrimidin-5-yl)methyl)-1H-1,2,3-triazol-4-
yl)ethoxy)(phenoxy)phosphoryl)-L-alaninate (BW-VB-34) 
Yield: 72%. 1H NMR (CDCl3) δ 8.14 (s, 1H), 7.34 (d, J = 8.4 Hz, 1H), 7.27 (t, J = 7.0 
Hz, 2H), 7.14 (t, J = 7.3 Hz, 3H), 5.92 (s, 2H), 5.26 (s, 2H), 4.41 – 4.23 (m, 2H), 4.17 – 4.05 (m, 
2H), 4.08 – 3.82 (m, 2H), 3.06 (q, J = 6.4 Hz, 2H), 2.45 (s, 3H), 1.32 (t, J = 7.7 Hz, 3H), 1.21 (t, 
J = 6.9 Hz, 3H). 13C NMR (CDCl3) δ 173.6 (t, J = 7.5 Hz), 168.7, 162.0, 156.1, 150.7 (d, J = 6.8 
Hz), 144.7 (d, J = 4.7 Hz), 129.6 (d, J = 3.0 Hz), 124.9, 122.2, 120.3 – 120.0 (m), 108.1, 65.5, 
61.5, 50.3 (d, J = 4.7 Hz), 48.5, 27.1 (d, J = 7.3 Hz), 25.5, 21.0 – 20.6 (m), 14.1 (d, J = 2.3 Hz). 
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31P NMR (CDCl3) δ 2.79 – 1.97 (m). HRMS (ESI): calcd for C21H29N7O5P [M+H]
+ 490.1962, 
found 490.1946. 
 
2-(1-((4-amino-2-methylpyrimidin-5-yl)methyl)-1H-1,2,3-triazol-4-yl)-1-methyl-ethyl 
bisSATE phosphate (BW-VB-35) 
Yield: 42%. 1H NMR (CDCl3) δ 8.21 (s, 1H), 7.53 (s, 1H), 5.67 (s, 2H), 5.36 (s, 2H), 
5.11 – 4.74 (m, 1H), 4.25 (dt, J = 12.6, 6.5 Hz, 4H), 3.19 – 2.85 (m, 6H), 2.48 (s, 3H), 1.42 (d, J 
= 6.2 Hz, 3H), 1.20 (s, 18H). 13C NMR (CDCl3) δ 178.1, 162.0, 143.8, 122.8, 76.36 (d, J = 8.7 
Hz), 62.9 – 62.6 (m), 48.7, 38.8, 33.9 (d, J = 5.7 Hz), 30.7 (d, J = 3.4 Hz), 30.4 (d, J = 3.2 Hz), 
27.2, 25.6, 21.7 (d, J = 3.2 Hz). 31P NMR (CDCl3) δ 54.15 (td, J = 16.9, 10.6 Hz). HRMS (ESI): 
calcd for C25H41N6O6PS2 [M+H]
+ 617.2339, found 617.2340. 
 
3-(1-((6-methylpyridin-3-yl)methyl)-1H-1,2,3-triazol-4-yl)propyl bisSATE phosphate (BW-
VB-36) 
Yield: 62%. 1H NMR (CDCl3) δ 8.43 (s, 1H), 7.45 (d, J = 7.9 Hz, 1H), 7.33 (s, 1H), 7.11 
(d, J = 8.0 Hz, 1H), 5.44 (s, 2H), 4.25 (t, J = 6.4 Hz, 4H), 4.15 (dd, J = 14.7, 6.3 Hz, 2H), 3.09 
(dt, J = 16.5, 6.4 Hz, 4H), 2.77 (t, J = 7.4 Hz, 2H), 2.50 (s, 3H), 2.06 (p, J = 6.6 Hz, 2H), 1.15 (s, 
19H). 13C NMR (CDCl3) δ 178.0, 159.2, 148.5, 147.0, 136.1, 127.6, 123.6, 121.2, 67.0 (d, J = 
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8.2 Hz), 62.7 (d, J = 4.6 Hz), 51.2, 38.8, 30.4 (d, J = 3.3 Hz), 29.7 (d, J = 7.0 Hz), 27.1, 24.2, 
21.6. 31P NMR (CDCl3) δ 56.13 – 55.36 (m). HRMS (ESI): calcd for C26H42N4O6PS2 [M+H]
+ 
601.2278, found 601.2259. 
 
Ethyl ((3-(1-((6-methylpyridin-3-yl)methyl)-1H-1,2,3-triazol-4-
yl)propoxy)(phenoxy)phosphoryl)-L-alaninate (BW-VB-37) 
Yield: 44%. 1H NMR (CDCl3) δ 8.49 (s, 1H), 7.49 (d, J = 7.9 Hz, 1H), 7.34 – 7.24 (m, 
3H), 7.17 (dt, J = 23.9, 7.3 Hz, 4H), 5.47 (s, 2H), 4.25 – 4.05 (m, 4H), 4.01 (dt, J = 15.9, 7.9 Hz, 
1H), 3.69 (td, J = 10.3, 4.5 Hz, 1H), 2.78 (dd, J = 15.3, 7.6 Hz, 2H), 2.56 (s, 3H), 2.06 (dt, J = 
14.0, 6.8 Hz, 2H), 1.37 (t, J = 5.9 Hz, 3H), 1.25 (q, J = 6.9 Hz, 3H). 13C NMR (CDCl3) δ 173.5 
(d, J = 7.7 Hz), 159.1, 151.0 – 150.7 (m), 148.4, 147.3, 136.1, 129.6 (d, J = 2.2 Hz), 127.7, 
124.8, 123.6, 121.1, 120.2 (t, J = 5.1 Hz), 66.1 – 65.8 (m), 61.5 (d, J = 2.2 Hz), 51.2, 50.3 (d, J = 
6.0 Hz), 29.7 (dd, J = 7.2, 3.0 Hz), 24.2, 21.5 (d, J = 4.9 Hz), 21.0 (t, J = 4.8 Hz), 14.1 (d, J = 2.9 
Hz). 31P NMR (CDCl3) δ 2.45 (dd, J = 16.9, 7.8 Hz). HRMS (ESI): calcd for C23H31N5O5P 
[M+H]+ 488.2057, found 488.2038.  
 
2-(1-((4-amino-2-methylpyrimidin-5-yl)methyl)-1H-1,2,3-triazol-4-yl)ethyl dibenzyl 
phosphate (26) 
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Yield: 40%. 1H NMR (CDCl3) δ 8.11 (s, 1H), 7.36 – 7.28 (m, 10H), 5.78 (s, 2H), 5.22 (s, 
2H), 5.04 – 4.90 (m, 4H), 4.22 (dd, J = 13.7, 6.5 Hz, 2H), 3.00 (t, J = 6.3 Hz, 2H), 2.46 (s, 3H). 
13C NMR (CDCl3) δ 168.9, 162.0, 156.0, 144.6, 135.7 (d, J = 6.6 Hz), 128.6 (d, J = 1.8 Hz), 
128.0, 122.1, 108.0, 69.4 (d, J = 5.6 Hz), 66.2 (d, J = 5.9 Hz), 48.6, 27.0 (d, J = 7.1 Hz), 25.6. 31P 
NMR (CDCl3) δ -0.82 – -1.44 (m). HRMS (ESI): calcd for C24H28N6O4P [M+H]
+ 495.1904, 
found 495.1933.  
 
 2-(1-((4-amino-2-methylpyrimidin-5-yl)methyl)-1H-1,2,3-triazol-4-yl)ethyl dihydrogen 
phosphate (BW-VB-38) 
70 mg compound 26 was dissolved in 5 mL MeOH in a round-bottom flask equipped 
with a 3-way switch. 8.8 mg Pd/C was added to the solution carefully. The round bottom flask 
was flushed with N2 and then equipped with a H2 balloon. The solution was stirred under room 
temperature overnight. Then the reaction mixture was filtered through a Celite® pad. The filtrate 
was concentrated and dried over high vacuum. Yield: 56%. 1H NMR (D2O) δ 7.86 (d, J = 9.9 Hz, 
2H), 5.48 (s, 2H), 3.99 (q, J = 6.2 Hz, 2H), 2.94 (t, J = 6.0 Hz, 2H), 2.47 (s, 3H). 13C NMR 
(D2O) δ 163.2, 162.6, 145.6, 143.2, 124.5, 109.7, 64.0 (d, J = 5.2 Hz), 46.6, 26.4 (d, J = 7.4 Hz), 
20.8. 31P NMR (D2O) δ 0.26. HRMS (ESI): calcd for C10H16N6O4P [M+H]
+ 315.0965, found 
315.0968.  
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2-(1-((2,4-Dimethoxypyrimidin-5-yl)methyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol (BW-VB-39) 
Yield: 32%. 1H NMR (MeOD) δ 8.29 (s, 1H), 7.84 (s, 1H), 5.45 (s, 2H), 4.00 (d, J = 15.5 
Hz, 6H), 3.31 (s, 1H), 2.86 (s, 2H). 13C NMR (CDCl3) δ 169.1, 165.7, 158.9, 109.1, 61.5, 55.1, 
54.4, 46.1, 28.7. HRMS (ESI): calcd for C11H16N5O3 [M+H]
+ 266.1248, found 266.1239.  
 
Methyl ((2-(1-((4-amino-2-methylpyrimidin-5-yl)methyl)-1H-1,2,3-triazol-4-
yl)ethoxy)(phenoxy)phosphoryl)-L-alaninate (BW-VB-40) 
Yield: 84%. 1H NMR (CDCl3) δ 8.13 (s, 1H), 7.32 (d, J = 11.8 Hz, 1H), 7.29 – 7.20 (m, 
2H), 7.12 (t, J = 7.3 Hz, 3H), 5.82 (s, 2H), 5.25 (s, 2H), 4.29 (tt, J = 6.4, 4.5 Hz, 2H), 4.05 – 3.78 
(m, 2H), 3.65 (d, J = 1.3 Hz, 3H), 3.42 (s, 1H), 3.04 (dd, J = 14.4, 6.4 Hz, 2H), 2.44 (s, 3H), 1.30 
(dd, J = 9.5, 6.6 Hz, 3H). 13C NMR (CDCl3) δ 174.2 – 173.8 (m), 168.8, 162.0, 156.1 (d, J = 1.9 
Hz), 150.7 (d, J = 6.9 Hz), 144.7 (d, J = 4.9 Hz), 129.6 (d, J = 2.5 Hz), 124. 9, 122.2, 120.2 (dd, 
J = 4.8, 3.1 Hz), 108.1, 65.6 (d, J = 5.1 Hz), 52.5 (d, J = 1.8 Hz), 50.2 (d, J = 5.5 Hz), 48.6, 27.1 
(d, J = 7.1 Hz), 25.6, 21.0 – 20.7 (m). 31P NMR (CDCl3) δ 2.63 – 1.87 (m). HRMS (ESI): calcd 
for C20H27N7O5P [M+H]
+ 476.1806, found 476.1786. 
 
Methyl ((3-(1-((4-amino-2-methylpyrimidin-5-yl)methyl)-1H-1,2,3-triazol-4-
yl)propoxy)(phenoxy)phosphoryl)-L-alaninate (BW-VB-41) 
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Yield: 75%. 1H NMR (CDCl3) δ 8.12 (s, 1H), 7.31 (d, J = 3.4 Hz, 1H), 7.26 (dd, J = 7.9, 
6.8 Hz, 2H), 7.20 – 7.11 (m, 2H), 7.09 (t, J = 7.3 Hz, 1H), 5.84 (s, 2H), 5.26 (s, 2H), 4.13 – 3.88 
(m, 4H), 3.65 (d, J = 8.4 Hz, 3H), 2.72 (dd, J = 14.7, 7.5 Hz, 2H), 2.43 (s, 3H), 1.99 (dt, J = 17.7, 
6.7 Hz, 2H), 1.32 (dd, J = 6.4, 3.4 Hz, 3H). 13C NMR (CDCl3) δ 174.3 – 173.9 (m), 168.7, 162.0, 
156.0, 150.8 (d, J = 9.2 Hz), 147.5, 129.6 (d, J = 1.8 Hz), 124.8, 121.4, 120.2 (t, J = 4.5 Hz), 
108.1, 66.0 – 65.5 (m), 52.4 (d, J = 3.3 Hz), 50.2 (d, J = 8.6 Hz), 48.5, 29.5 (d, J = 7.3 Hz), 25.5, 
21.4 (d, J = 2.8 Hz), 21.3 – 20.7 (m). 31P NMR (CDCl3) δ 2.42 (ddd, J = 32.8, 17.0, 8.3 Hz). 
HRMS (ESI): calcd for C21H29N7O5P [M+H]
+ 490.1962, found 490.1943.  
 
Ethyl (((1-(1-((4-amino-2-methylpyrimidin-5-yl)methyl)-1H-1,2,3-triazol-4-yl)propan-2-
yl)oxy)(phenoxy)phosphoryl)-L-alaninate (BW-VB-42) 
Product is a mixture of two diastereomers. Yield: 37%. 1H NMR (CDCl3) δ 8.14 (d, J = 
29.2 Hz, 1H), 7.53 (d, J = 20.7 Hz, 1H), 7.28 (t, J = 7.6 Hz, 2H), 7.13 (dd, J = 15.5, 7.7 Hz, 3H), 
5.86 (d, J = 10.8 Hz, 2H), 5.31 (d, J = 3.3 Hz, 1H), 5.18 (t, J = 10.1 Hz, 1H), 4.83 (dt, J = 18.4, 
6.1 Hz, 1H), 4.27 – 4.02 (m, 2H), 4.01 – 3.72 (m, 2H), 3.16 – 2.83 (m, 2H), 2.46 (s, 3H), 1.39 – 
1.17 (m, 9H). 13C NMR (CDCl3) δ 173.7, 168.7, 162.0, 156.1 (d, J = 17.4 Hz), 150.8 (d, J = 7.0 
Hz), 144.6 – 144.0 (m), 129.6 (d, J = 3.9 Hz), 124.8 (d, J = 3.9 Hz), 122.8 – 122.4 (m), 120.2 
(dd, J = 11.2, 6.0 Hz), 108.1, 74.3, 74.0, 61.5, 50.5 – 50.0 (m), 48.5, 34.0 – 33.5 (m), 25.5, 21.1 
(dd, J = 42.2, 9.0 Hz), 14.1. 31P NMR (CDCl3) δ 1.79 – 0.89 (m). HRMS (ESI): calcd for 
C22H31N7O5P [M+H]
+ 504.2119, found 504.2111.  
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2-(1-(Pyrimidin-5-ylmethyl)-1H-1,2,3-triazol-4-yl)ethan-1-ol (BW-VB-43) 
Yield: 35%. 1H NMR (CDCl3) δ 9.16 (s, 1H), 8.68 (s, 2H), 7.48 (s, 1H), 5.53 (s, 2H), 
3.88 (t, J = 6.0 Hz, 2H), 2.91 (t, J = 6.0 Hz, 3H). 13C NMR (CDCl3) δ 158.9, 156.5, 146.6, 128.8, 
121.9, 61.2, 49.1, 28.8. HRMS (ESI): calcd for C9H12N5O [M+H]
+ 206.1039, found 206.1029.  
 
2-(1-((Pyrimidin-5-ylmethyl)-1H-1,2,3-triazol-4-yl)ethyl bisSATE phosphate (BW-VB-44) 
Yield: 26%. 1H NMR (CDCl3) δ 9.18 (s, 1H), 8.70 (s, 2H), 7.58 (s, 1H), 5.56 (s, 2H), 
4.30 (dd, J = 13.9, 6.3 Hz, 2H), 4.02 (dd, J = 14.5, 6.8 Hz, 4H), 3.15 – 3.02 (m, 6H), 1.19 (s, 
18H). 13C NMR (CDCl3) δ 205.8, 158.9, 156.4, 144.6, 128.8, 122.3, 66.5 (d, J = 5.9 Hz), 66.1 (d, 
J = 5.7 Hz), 49.1, 46.5, 28.5 (d, J = 7.4 Hz), 27.4 – 26.9 (m). 31P NMR (CDCl3) δ -1.98 (dt, J = 
15.5, 7.7 Hz). HRMS (ESI): calcd for C23H37N5O6PS2 [M+H]
+ 574.1917, found 574.1906.  
 
2-(1-((Pyrimidin-5-ylmethyl)-1H-1,2,3-triazol-4-yl)ethyl bis(2-((tert-
butoxycarbonyl)thio)ethanyl) phosphate (BW-VB-45) 
Yield: 23%. 1H NMR (CDCl3) δ 9.19 (s, 1H), 8.70 (s, 2H), 7.56 (s, 1H), 5.55 (s, 2H), 
4.30 (dd, J = 13.8, 6.3 Hz, 2H), 4.12 (dt, J = 7.8, 6.6 Hz, 4H), 3.11 (t, J = 6.2 Hz, 2H), 3.01 (t, J 
= 6.6 Hz, 4H), 1.45 (s, 18H). 13C NMR (CDCl3) δ 168.1, 159.0, 156.4, 144.6, 128.8, 122.3, 85.5, 
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66.6 (d, J = 5.9 Hz), 66.3 (d, J = 5.7 Hz), 49.1, 30.9 (d, J = 7.4 Hz), 28.2, 27.1 (d, J = 7.0 Hz). 
31P NMR (CDCl3) δ -1.96 (dt, J = 15.5, 7.7 Hz). HRMS (ESI): calcd for C23H37N5O8PS2 [M+H]
+ 
606.1816, found 606.1815.  
 
Ethyl (phenoxy(2-(1-(pyrimidin-5-ylmethyl)-1H-1,2,3-triazol-4-yl)ethoxy)phosphoryl)-L-
alaninate (BW-VB-46) 
Yield: 36%. 1H NMR (CDCl3) δ 9.17 (s, 1H), 8.66 (d, J = 1.7 Hz, 2H), 7.37 (d, J = 10.0 
Hz, 1H), 7.25 (ddd, J = 9.1, 6.9, 2.3 Hz, 2H), 7.12 (dd, J = 16.2, 8.3 Hz, 3H), 5.46 (s, 2H), 4.43 – 
4.21 (m, 2H), 4.18 – 4.02 (m, 2H), 3.97 – 3.71 (m, 2H), 3.08 (dd, J = 14.8, 6.3 Hz, 2H), 1.30 (dd, 
J = 8.8, 7.1 Hz, 3H), 1.20 (td, J = 7.1, 2.8 Hz, 3H). 13C NMR (CDCl3) δ 173.5 (t, J = 7.1 Hz), 
158.9, 156.4 (d, J = 1.8 Hz), 150.7 (d, J = 4.3 Hz), 144.7 (d, J = 4.6 Hz), 129.6 (d, J = 2.8 Hz), 
128.8, 124.9, 122.2, 120.2 (t, J = 4.7 Hz), 65.7 – 65.3 (m), 61.5, 50.3 (d, J = 3.8 Hz), 49.0, 27.1 
(d, J = 6.9 Hz), 21.0 – 20.6 (m), 14.1 (d, J = 2.0 Hz). 31P NMR (CDCl3) δ 2.68 – 1.85 (m). 
HRMS (ESI): calcd for C20H26N6O5P [M+H]
+ 461.1697, found 461.0942.  
 
Methyl (phenoxy(2-(1-(pyrimidin-5-ylmethyl)-1H-1,2,3-triazol-4-yl)ethoxy)phosphoryl)-L-
alaninate (BW-VB-47) 
Yield: 37%. 1H NMR (CDCl3) δ 9.15 (s, 1H), 8.65 (s, 2H), 7.37 (d, J = 13.2 Hz, 1H), 
7.24 (dt, J = 7.5, 1.7 Hz, 2H), 7.11 (dt, J = 15.3, 4.2 Hz, 3H), 5.45 (s, 2H), 4.36 – 4.19 (m, 2H), 
119 
4.01 – 3.79 (m, 2H), 3.63 (d, J = 0.8 Hz, 3H), 3.06 (dt, J = 9.1, 6.2 Hz, 2H), 1.29 (dd, J = 9.1, 6.7 
Hz, 3H). 13C NMR (CDCl3) δ 174.0 (dd, J = 8.9, 6.9 Hz), 158.8, 156.4 (d, J = 1.0 Hz), 150.8 – 
150.6 (m), 144.7 (d, J = 4.4 Hz), 129.6 (d, J = 2.7 Hz), 128.8, 124.9, 122.3, 120.4 – 120.1 (m), 
65.5 (t, J = 5.3 Hz), 52.5 (d, J = 2.3 Hz), 50.2 (d, J = 5.1 Hz), 49.0, 27.1 (d, J = 7.1 Hz), 20.8 (t, J 
= 4.9 Hz). 31P NMR (CDCl3) δ 3.03 – 1.49 (m). HRMS (ESI): calcd for C19H24N6O5P [M+H]
+ 
461.1697, found 461.0942. 
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